name,filter_object,graphql_object,llm_result
Skin Metastasis Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Skin""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who have metastatic tumors. Specifically, these tumors are classified as absent and are located on the skin."
NODAL bulky no agg,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulky_nodal_aggregate"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulky_nodal_aggregate"": [""No""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants who are part of the NODAL consortium and do not have bulky nodal aggregates as a disease characteristic.
Male99,"{""sex"": {""selectedValues"": [""Male""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}}",{},The cohort consists of male participants who are part of the INSTRuCT consortium.
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}}",{},The cohort consists of male participants who are part of the INSTRuCT consortium.
Female metastatic,"{""sex"": {""selectedValues"": [""Female""]}, ""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}",{},The cohort consists of female individuals with metastatic tumor classification.
Male metastatic,"{""sex"": {""selectedValues"": [""Male""]}, ""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}",{},The cohort consists of male individuals with metastatic tumor classifications.
s,"{""sex"": {""selectedValues"": [""Male""]}}",{},The cohort consists of individuals who are male.
alivetest,"{""race"": {""selectedValues"": [""Asian""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""survival_characteristics.lkss"": {""selectedValues"": [""Alive""]}}",{},"The cohort consists of individuals who are of Asian race, are part of the INSTRuCT consortium, and are currently alive."
mets,"{""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}",{},"The cohort consists of individuals whose tumor assessments have been classified as ""Metastatic."""
ERMS,"{""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",{},The cohort consists of individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
Instruct multiple filters,"{""sex"": {""selectedValues"": [""Female"", ""Male""]}, ""molecular_analysis.anaplasia"": {""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}",{},"The cohort consists of individuals who are either female or male, have an absence of anaplasia in their molecular analysis, and have tumors classified as metastatic."
All - wide open,{},{},"The JSON files provided are empty, indicating that there are no selection criteria or filters specified for the cohort."
"ARMS, Alive, FOXO1/PAX7","{""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.gene1"": {""selectedValues"": [""FOXO1""]}, ""molecular_analysis.gene2"": {""selectedValues"": [""PAX7""]}, ""survival_characteristics.lkss"": {""selectedValues"": [""Alive""]}}",{},"The cohort consists of individuals who are part of the INSTRuCT consortium and have been diagnosed with alveolar rhabdomyosarcoma (ARMS). These individuals have a molecular analysis showing the presence of the FOXO1 and PAX7 genes. Additionally, all individuals in this cohort are currently alive."
Ex01,"{""sex"": {""selectedValues"": [""Female""]}, ""histologies.histology"": {""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)""]}, ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX7 fusion""]}}",{},The cohort consists of female individuals diagnosed with Botryoid rhabdomyosarcoma (BRMS) who have a molecular abnormality characterized by the FOXO1-PAX7 fusion.
AA / Asian Males,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Black or African American"", ""Asian""]}}",{},The cohort consists of male individuals who are either Black or African American or Asian.
Alive M1 at Dx with event,"{""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND"", ""censor_status"": {""selectedValues"": [""Subject has had one or more events""]}, ""survival_characteristics.lkss"": {""selectedValues"": [""Alive""]}, ""disease_phase:Initial Diagnosis"": {""filter"": {""stagings.tnm_finding"": {""selectedValues"": [""Metastases, M1""]}}}}",{},"The cohort consists of subjects from the INSTRuCT consortium who have experienced one or more events. These subjects are alive and were initially diagnosed with a disease phase characterized by TNM staging of Metastases, M1."
All black female,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Black or African American""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and identify as Black or African American.
Age less than on eyear,"{""disease_phase:Initial Diagnosis"": {""filter"": {""tumor_assessments.age_at_tumor_assessment"": {""lowerBound"": 0, ""upperBound"": 364}}}}",{},The cohort consists of individuals who are in the initial diagnosis phase of their disease. The selection criteria include those who had a tumor assessment conducted when they were between 0 and 364 days old.
Age less than one year,"{""disease_phase:Initial Diagnosis"": {""filter"": {""tumor_assessments.age_at_tumor_assessment"": {""lowerBound"": 0, ""upperBound"": 364}}}}",{},The cohort consists of individuals who are at the initial diagnosis phase of their disease. The selection criteria include those who have had a tumor assessment conducted when they were between 0 and 364 days old.
Less than one year ,"{""disease_phase:Initial Diagnosis"": {""filter"": {""tumor_assessments.age_at_tumor_assessment"": {""lowerBound"": 0, ""upperBound"": 364}}}}",{},The cohort consists of individuals who are at the initial diagnosis phase of their disease. The selection criteria include those who have had a tumor assessment conducted when they were between 0 and 364 days old.
Test 1,"{""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}",{},The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) whose tumors are classified as metastatic.
Female99,"{""sex"": {""selectedValues"": [""Female""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}}",{},The cohort consists of female participants who are part of the INSTRuCT consortium.
Female,"{""sex"": {""selectedValues"": [""Female""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}}",{},The cohort consists of female participants who are part of the INSTRuCT consortium.
"Instruct M, F all","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female"", ""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female"", ""Male""]}}, {""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of individuals who are either female or male and are part of the INSTRuCT consortium.
"Female,Asian","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are both female and Asian.
male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria use an ""AND"" combination mode, but no additional criteria are specified."
male asian,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, although no additional criteria are specified."
male asian and black,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
ARMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}",{},The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS).
FemaleAsian,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and Asian.
MaleAsian,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both male and Asian.
male asian 2,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both male and Asian.
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
Male Asian,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria use an ""AND"" combination mode, but no additional filters are specified."
Male Asian Black,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
male and asian,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and identify as Asian.
AgeAtCStatusMaleOnly,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND"", ""age_at_censor_status"": {""lowerBound"": 6479, ""upperBound"": 10268}}",{},The cohort consists of male participants whose age at the time of censoring is between 17.75 and 28.14 years.
male and (asian or black),"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both male and Asian.
male,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both male and Asian.
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, although no additional criteria are specified."
Male Asian,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
Male Asian Black,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
All female,"{""sex"": {""selectedValues"": [""Female""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are female. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
All Asian female,"{""sex"": {""selectedValues"": [""Female""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are female. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male.
All Asian female 2,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and Asian.
Male Asian Black,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
All black female,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Black or African American""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and identify as Black or African American.
All asian female,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Black or African American""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and Black or African American.
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
Male Asian,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
INTERACT - Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
M All with Save As,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",,The cohort consists of individuals who are male.
"All asian, black, native female","{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Black or African American""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and identify as Black or African American.
BRMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}",{},The cohort includes individuals diagnosed with Botryoid rhabdomyosarcoma (BRMS).
Female,"{""sex"": {""selectedValues"": [""Female""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are female.
Male Asian Not Reported,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Not Reported""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and are either Asian or have not reported their race.
Male Asian Not Reported Black,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Not Reported""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and are either Asian or have not reported their race.
ERMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",{},The cohort consists of individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
asian,"{""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are identified as Asian. The selection criteria are combined using an ""AND"" logic, although no additional criteria are specified."
asian not hispanic,"{""race"": {""selectedValues"": [""Asian""]}, ""ethnicity"": {""selectedValues"": [""Not Hispanic or Latino""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are Asian and are not Hispanic or Latino.
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
AgeAtCStatusMaleOnlyNHISP,"{""sex"": {""selectedValues"": [""Male""]}, ""ethnicity"": {""selectedValues"": [""Not Hispanic or Latino""]}, ""__combineMode"": ""AND"", ""age_at_censor_status"": {""lowerBound"": 6479, ""upperBound"": 10268}}",{},"The cohort consists of male participants who are not Hispanic or Latino. Additionally, their age at the time of censoring is between 17.75 and 28.14 years. All these criteria must be met for inclusion in the study."
Male Asian,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and identify as Asian.
Male Asian Black,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Black or African American""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and belong to either the Asian or Black or African American racial groups.
AgeAtCStatusMaleOnlyAEDIT1,"{""sex"": {""selectedValues"": [""Male"", ""Female""]}, ""race"": {""selectedValues"": [""Asian"", ""Black or African American""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND"", ""censor_status"": {""selectedValues"": [""Subject is censored (i.e. has had no event(s))""]}, ""age_at_censor_status"": {""lowerBound"": 6479, ""upperBound"": 10268}}",{},"The cohort consists of individuals who are either male or female and identify as either Asian or Black or African American. All participants are part of the INSTRuCT consortium. The individuals included in the study have been censored, meaning they have not experienced any events of interest. Additionally, their age at the time of censoring falls between 17.75 and 28.14 years."
Male Asian Black Not Reported,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Black or African American"", ""Not Reported""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of male participants who are either Asian, Black or African American, or have not reported their race. All specified criteria must be met for inclusion in the cohort."
Alveolar rhabdo,"{""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}",{},The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with alveolar rhabdomyosarcoma (ARMS).
Embryonal rhabdo,"{""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",{},The cohort consists of participants who are part of the INSTRuCT consortium and have been diagnosed with embryonal rhabdomyosarcoma (ERMS).
hispanic female,"{""sex"": {""selectedValues"": [""Female""]}, ""ethnicity"": {""selectedValues"": [""Hispanic or Latino""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and Hispanic or Latino.
hispanic male,"{""sex"": {""selectedValues"": [""Male""]}, ""ethnicity"": {""selectedValues"": [""Hispanic or Latino""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and identify as Hispanic or Latino. Both criteria must be met for inclusion in the cohort.
eyelid,"{""__combineMode"": ""AND"", ""tumor_assessments.tumor_site"": {""selectedValues"": [""Eyelid""]}}",{},The cohort consists of individuals who have tumor assessments indicating the tumor site is specifically located on the eyelid.
ARMS ORBIT,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""selectedValues"": [""Eyelid"", ""Orbit""]}}",{},The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have tumors located in either the eyelid or the orbit.
MF All with Save As,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both male and Asian.
AgeAtCStatusFemaleOnly,"{""sex"": {""selectedValues"": [""Female""]}, ""__combineMode"": ""AND"", ""age_at_censor_status"": {""lowerBound"": 6479, ""upperBound"": 10268}}",{},The cohort consists of female participants whose age at the time of censoring is between 17.75 and 28.14 years.
Male,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
Male Asian,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
Male Asian Black,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
All asian and black female,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Black or African American""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both female and identify as Black or African American.
NODAL HL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, not otherwise specified (NOS). Both criteria must be met for inclusion in the cohort."
"ARMS - Male, Fem, white","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male"", ""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""White""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male"", ""Female""]}}, {""IN"": {""race"": [""White""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are either male or female, identify as White, and have been diagnosed with alveolar rhabdomyosarcoma (ARMS). All these criteria must be met for inclusion in the study."
DaSH - INRG MYCN Not Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
ERMS ORBIT,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)""]}, ""tumor_assessments.tumor_site"": {""selectedValues"": [""Eyelid"", ""Orbit""]}}",{},"The cohort consists of individuals diagnosed with either Botryoid rhabdomyosarcoma (BRMS) or Embryonal rhabdomyosarcoma (ERMS), with tumors located in the eyelid or orbit."
orbit anaplasia,"{""__combineMode"": ""AND"", ""molecular_analysis.anaplasia"": {""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_site"": {""selectedValues"": [""Eyelid"", ""Orbit""]}}",{},The cohort consists of individuals who have anaplasia present in their molecular analysis and have tumors located in either the eyelid or the orbit.
INstructMale,"{""sex"": {""selectedValues"": [""Male""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND""}",{},The cohort consists of male participants who are part of the INSTRuCT consortium. Both criteria must be met for inclusion in the cohort.
ERMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",{},The cohort consists of individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
ERMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",{},The cohort consists of individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
pleo,"{""__combineMode"": ""AND"", ""disease_phase:Initial Diagnosis"": {""filter"": {""histologies.histology"": {""selectedValues"": [""Pleomorphic rhabdomyosarcoma (PRMS)""]}}}}",{},The cohort consists of individuals who were initially diagnosed with pleomorphic rhabdomyosarcoma (PRMS).
test2,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Rhabdomyosarcoma (RMS), not classifiable"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Botryoid rhabdomyosarcoma (BRMS)""]}, ""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}",{},"The cohort consists of individuals diagnosed with specific types of rhabdomyosarcoma, including ""Rhabdomyosarcoma (RMS), not classifiable,"" ""Pleomorphic rhabdomyosarcoma (PRMS),"" and ""Botryoid rhabdomyosarcoma (BRMS)."" Additionally, these individuals have tumors classified as ""Metastatic."""
Instruct Male,"{""sex"": {""selectedValues"": [""Male""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND""}",{},The cohort consists of male participants who are part of the INSTRuCT consortium. Both criteria must be met for inclusion in the cohort.
InstructFemale,"{""sex"": {""selectedValues"": [""Female""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND""}",{},The cohort consists of female participants who are part of the INSTRuCT consortium. Both criteria must be met for inclusion in the cohort.
InstructFemaleYear,"{""sex"": {""selectedValues"": [""Female""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND"", ""year_at_disease_phase"": {""lowerBound"": 2010, ""upperBound"": 2016}}",{},The cohort consists of female participants who are part of the INSTRuCT consortium. These participants were in a specific disease phase between the years 2010 and 2016.
test,"{""race"": {""selectedValues"": [""Black or African American""]}, ""data_contributor_id"": {""selectedValues"": [""COG""]}}",{},The cohort consists of individuals who are identified as Black or African American and whose data was contributed by the Children's Oncology Group (COG).
ljkl,"{""sex"": {""selectedValues"": [""Female""]}, ""__combineMode"": ""OR""}",{},"The cohort includes individuals who are female. The selection criteria use an ""OR"" combination mode, but no additional criteria are specified."
lj,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""OR""}",{},"The cohort includes individuals who are male. The selection criteria use an ""OR"" combination mode, but no additional criteria are specified."
both,"{""sex"": {""selectedValues"": [""Male"", ""Female""]}, ""__combineMode"": ""OR""}",{},"The cohort includes individuals who are either male or female. The selection criteria use an ""OR"" logic, meaning that individuals of either sex are included."
positive,"{""__combineMode"": ""AND"", ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Present""]}}",{},"The cohort consists of individuals who have a molecular abnormality characterized by the presence of a FOXO1 fusion. Specifically, the fusion must be one of the following types: FOXO1-PAX3 fusion, FOXO1-PAX7 fusion, or FOXO1-Other fusion. Additionally, the result of the molecular abnormality analysis must indicate that the fusion is present."
1990-2002,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}","The cohort consists of participants who are part of the INRG consortium. Additionally, these participants were involved in a disease phase that occurred between the years 1991 and 2002, inclusive."
ARMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""selectedValues"": [""Eyelid"", ""Orbit""]}}",{},The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have tumors located in either the eyelid or the orbit.
orbital,"{""__combineMode"": ""AND"", ""tumor_assessments.tumor_site"": {""selectedValues"": [""Orbit""]}}",{},The cohort consists of individuals who have tumor assessments specifically indicating the tumor site as the orbit.
INSTRuCT Addendum 3,,"{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals are at the initial diagnosis phase of their disease and have a TNM finding of metastases, specifically classified as M1."
INSTRuCT Addendum 2,,"{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 5}}, {""LTE"": {""age_at_tumor_assessment"": 9131}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals were at the initial diagnosis phase of their disease and had metastases classified as M1. Additionally, at the time of tumor assessment, they were between 5 days and 25 years old."
INSTRuCT Addendum 1,,"{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort includes participants who are part of the INSTRuCT consortium.
test,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""American Indian or Alaska Native""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and identify as American Indian or Alaska Native. Both criteria must be met for inclusion in the cohort.
InstructMaleAlive,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""survival_characteristics.lkss"": {""__type"": ""OPTION"", ""selectedValues"": [""Alive""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""lkss"": [""Alive""]}}], ""path"": ""survival_characteristics""}}]}",The cohort consists of male participants who are part of the INSTRuCT consortium and are currently alive.
InstructSensorEvent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""censor_status"": {""__type"": ""OPTION"", ""selectedValues"": [""Subject has had one or more events""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}]}",The cohort consists of subjects who are part of the INSTRuCT consortium and have experienced one or more events.
BRMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Botryoid rhabdomyosarcoma (BRMS) as their histology type.
INSS Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer according to the INSS staging system.
INSS Stage 1-3,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort includes individuals who are in Stage 1, Stage 2a, Stage 2b, or Stage 3 of a specified condition, as determined by their staging information."
No 17q gain,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants do not exhibit the 17q gain molecular abnormality, as the result for this abnormality is absent."
Yes - 17q gain,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have a molecular abnormality characterized by a 17q gain, and this abnormality is confirmed to be present in their molecular analysis results."
Stage IV INSS,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are classified as having Stage 4 according to the INSS staging system.
test,"{""sex"": {""selectedValues"": [""Male""]}, ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are male. The selection criteria are combined using an ""AND"" logic, but no additional criteria are specified."
INRG High MKI,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_characteristics.mki"": {""__type"": ""OPTION"", ""selectedValues"": [""High (>4% or >200/5,000 cells)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""mki"": [""High (>4% or >200/5,000 cells)""]}}], ""path"": ""disease_characteristics""}}]}","The cohort consists of participants who are part of the INRG consortium and have a disease characteristic where the MKI (mitosis-karyorrhexis index) is high, specifically greater than 4% or more than 200 out of 5,000 cells."
arms,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of male individuals diagnosed with either Alveolar rhabdomyosarcoma (ARMS) or Botryoid rhabdomyosarcoma (BRMS).
INRG and INSTRUCT,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}]}",The cohort consists of participants who are part of either the INRG consortium or the INSTRuCT consortium. Participants are included if they belong to at least one of these two consortia.
INRG MALE,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
NODAL clHL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Classical, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Classical, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Classical Hodgkin Lymphoma, not otherwise specified (NOS)."
test4,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are not Hispanic or Latino and are part of the INSTRuCT consortium.
COMPOSED1,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of participants who are part of either the INRG or INSTRuCT consortiums. Additionally, the cohort includes male participants specifically from the INRG consortium."
test3,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}]}",The cohort consists of male participants who are not Hispanic or Latino and are part of the INSTRuCT consortium.
xyz,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INRG consortium.
MYCN-yes,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis indicating the presence of MYCN amplification.
INRG Ganglioneuroblastoma all,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with either ""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"" or ""Ganglioneuroblastoma, Nodular (Composite)"" histologies."
Composed2,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with specific types of neuroblastoma. The selection criteria include individuals with ""Neuroblastoma (Schwannian Stroma-Poor)"" as well as those with ""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"" or ""Ganglioneuroblastoma, Nodular (Composite)"" histologies."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."""
DaSH - INRG MYCN Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium and have a molecular analysis showing the presence of MYCN Amplification.
Kirk-NBL-Histology,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."""
Kirk-11q-deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
NODAL mixed cell,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Mixed Cellularity, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Mixed Cellularity, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Hodgkin Lymphoma, specifically the Mixed Cellularity, NOS subtype."
INRG Neuroblastoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Neuroblastoma (Schwannian Stroma-Poor).
NBL 11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of an 11q deletion.
INRG Neuroblastoma and Ganglioneuroblastoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)"", ""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)"", ""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with specific types of histologies. These histologies include Neuroblastoma (Schwannian Stroma-Poor), Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich), and Ganglioneuroblastoma, Nodular (Composite)."
NBL 1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
11p or 1q deletion,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion. The selection criteria require both the histological diagnosis and the molecular abnormality to be present, and this combination is applied consistently across the cohort."
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
Stage 4 Lung Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer, and their tumor assessments indicate the presence of a tumor located in the lung."
Stage 4 Skin Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, they have tumors that are located on the skin, and the tumors are currently present."
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor).
MYCN Amplified,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit the presence of MYCN amplification as a molecular abnormality.
R2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}], ""path"": ""studies""}}]}","The cohort consists of participants who are part of the INRG consortium and are enrolled in studies with the treatment arm labeled ""R2"". Both criteria must be met for inclusion in the cohort."
ARST0332,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ARST0332""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ARST0332""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INSTRuCT consortium and are involved in the study identified by the study ID ARST0332. Both criteria must be met for inclusion in the cohort.
NBL 1p or 11q deletion,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit a molecular abnormality characterized by the presence of an 11q deletion.
11q del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also have a molecular analysis showing the presence of an 11q deletion.
1p del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular abnormality characterized by a 1p deletion, and this deletion is confirmed to be present."
11q,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present"", ""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present"", ""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, the analysis focuses on the presence or absence of the 11q deletion molecular abnormality."
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of a 1p deletion molecular abnormality.
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit an 11q deletion, and the result of this molecular abnormality is absent."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) histology.
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."""
NODAL LR,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Lymphocyte-Rich""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Lymphocyte-Rich""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Hodgkin Lymphoma, specifically the Lymphocyte-Rich subtype. Both criteria must be met for inclusion in the study."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) histology.
11q or 1p deletion,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular abnormalities. The selection criteria include patients with either an 11q deletion or a 1p deletion, both of which must be present. The presence of either molecular abnormality, in conjunction with the specified histology, qualifies a patient for inclusion in the study."
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of an 11q deletion.
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."""
PAX7,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""molecular_analysis.gene2"": {""__type"": ""OPTION"", ""selectedValues"": [""PAX7""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""gene2"": [""PAX7""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INSTRuCT consortium who have undergone molecular analysis. Specifically, these participants have been identified with the presence of the PAX7 gene abnormality."
1p,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis for the 1p deletion abnormality. The results of this analysis include both ""Absent"" and ""Present"" outcomes for the 1p deletion."
MYCN Nonamplified,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit MYCN Amplification as a molecular abnormality, but the result of this molecular abnormality is recorded as absent."
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular abnormality characterized by a 1p deletion, and this deletion is confirmed to be present."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."""
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular abnormality characterized by a 1p deletion, and this deletion is confirmed to be present."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor).
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also have a molecular abnormality characterized by the presence of an 11q deletion.
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with the presence of this abnormality confirmed."
DASH-Nmyc amp,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants who are part of the INRG consortium and have a molecular abnormality characterized by MYCN amplification.
17q gain,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, the analysis focused on the presence of the 17q gain molecular abnormality. The results for this abnormality were either ""Absent"" or ""Present."""
INRG 4 >18 mo,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer according to the INSS staging system. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 10,983 days."
INRG M >18mo,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage M cancer. Additionally, their age at the time of tumor assessment is between 547 days and 10,983 days."
PAX3 ,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""molecular_analysis.gene2"": {""__type"": ""OPTION"", ""selectedValues"": [""PAX3""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""gene2"": [""PAX3""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have undergone molecular analysis, specifically focusing on the gene PAX3, and have been found to have a molecular abnormality result that is present."
INRG Stage 4 Stage M,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4"", ""Stage M""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were at the initial diagnosis phase of their disease. Specifically, these individuals were diagnosed with either Stage 4 or Stage M of the disease."
ANBL0931,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID ANBL0931. Both criteria must be met for inclusion in the cohort.
MYCN Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
1p absent,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit a specific molecular abnormality. Specifically, these individuals have a ""1p deletion"" abnormality, and the result of this molecular abnormality is ""Absent."" Both criteria must be met for inclusion in the cohort."
joe,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present"", ""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present"", ""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present"", ""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present"", ""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}]}]}]}","The cohort consists of patients from the INRG consortium who meet specific molecular and clinical criteria. These patients have either an 11q deletion, 1p deletion, or MYCN amplification, with the presence or absence of these abnormalities being considered. Additionally, patients are included if they are classified as Stage 4 according to the INSS staging system or Stage M, with an age at tumor assessment between 547 and 10,983 days."
grp1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been staged using the INRGSS system and are classified as Stage L1. Additionally, they exhibit a molecular abnormality characterized by MYCN amplification, which is confirmed to be present."
Kirk-MYCN-Present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit the presence of MYCN amplification as a molecular abnormality.
Kirk-MYCN-Absent,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit MYCN Amplification, but the result of this molecular abnormality is recorded as absent."
Kirk-All NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor).
Kirk-11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also have a molecular abnormality characterized by the presence of an 11q deletion.
11_absent_HR,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. At the initial diagnosis, these patients were classified as Stage 4 and had a molecular abnormality of 11q deletion, with the result of this abnormality being absent. The age of the patients at the time of tumor assessment ranged from 547 days to 10,610 days."
Kirk-1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
MYCN_absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with the disease between the years 2001 and 2014. These patients were at Stage 4 at the time of initial diagnosis and had MYCN amplification present, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these patients ranged from 1.5 years (547 days) to approximately 29 years (10,610 days)."
11_present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with the disease between the years 2001 and 2014. These patients were at Stage 4 at the time of initial diagnosis and had a molecular abnormality of 11q deletion, which was confirmed to be present. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 29 years (10,610 days)."
1p_present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. These patients were at the initial diagnosis phase of their disease and were classified as Stage 4. They exhibited a molecular abnormality characterized by a 1p deletion, which was confirmed to be present. Additionally, the age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 29 years (10,610 days)."
MYCN_present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. These patients have a molecular abnormality of MYCN amplification, which is present in their molecular analysis. Additionally, the age at tumor assessment for these patients ranges from 547 days to 10,610 days."
Composed ARMS metastatic OR ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of patients with either Alveolar rhabdomyosarcoma (ARMS) that is classified as metastatic, or patients with Embryonal rhabdomyosarcoma (ERMS)."
1p-absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. At the initial diagnosis, these patients were classified as Stage 4 and had a molecular abnormality of 1p deletion, with the result of this abnormality being absent. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 29 years (10,610 days)."
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular abnormality characterized by a 1p deletion, and this deletion is confirmed to be present."
Kirk -q^p,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular abnormalities. The selection criteria include patients with either an 11q deletion or a 1p deletion, both of which must be present. The presence of either molecular abnormality, in conjunction with the specified histology, qualifies a patient for inclusion in the study."
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with this abnormality confirmed as present."
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit an 11q deletion molecular abnormality. Both criteria must be met for inclusion in the study.
SCA_present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. These patients must have a molecular abnormality that is present, specifically either MYCN Amplification, 1p deletion, or 11q deletion. Additionally, the age at tumor assessment for these patients ranges from 547 days to 10,610 days."
SCA_absent,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2001 and 2014. At the initial diagnosis, these patients were in Stage 4 of the disease. The cohort is divided into two groups based on molecular abnormalities. The first group includes patients with an 11q deletion, while the second group includes those with a 1p deletion. In both groups, the molecular abnormality result was absent. Additionally, the age at tumor assessment for all patients ranged from 547 to 10,610 days."
SCA negative,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion"", ""MYCN Amplification"", ""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion"", ""MYCN Amplification"", ""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. These patients had a tumor assessment age ranging from 547 to 10,610 days. Additionally, they exhibited molecular abnormalities such as 11q deletion, MYCN amplification, or 1p deletion, with the molecular abnormality result being absent."
11q present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. These patients were at the initial diagnosis phase of their disease and were classified as Stage 4. They exhibited a molecular abnormality characterized by an 11q deletion, which was confirmed to be present. Additionally, the age of these patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 29 years (10,610 days)."
Ganglio,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with the histology type ""Ganglioneuroblastoma, Nodular (Composite)."""
Ganglio2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Ganglioneuroma (Schwannian Stroma-Dominant), specifically the Maturing Subtype."
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
ARMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) as their histology type.
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with the presence of this abnormality confirmed."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor).
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
Kirk-1p-deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with the abnormality confirmed as present."
Kirk-q+p,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular abnormalities. Specifically, the patients must have a present 11q deletion and a present 1p deletion. Both conditions must be met for inclusion in the study."
ARMS Metastatic Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of male patients diagnosed with alveolar rhabdomyosarcoma (ARMS) who have metastatic tumors.
toddler_11q_present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients were diagnosed with Stage 4 disease according to the INSS staging system. They exhibited a molecular abnormality characterized by the presence of an 11q deletion. Additionally, the age of these patients at the time of tumor assessment ranged from 365 to 546 days."
toddler_1p_present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 cancer according to the INSS staging system. They have a molecular abnormality characterized by a 1p deletion, which is present. Additionally, the age of these patients at the time of tumor assessment was between 365 and 546 days."
4_Old,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2014}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 541, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 541}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease. The diagnosis occurred between the years 2000 and 2014. Additionally, the age at tumor assessment for these individuals ranges from 541 days to 10,983 days."
Surgery,"{""molecular_analysis.gene1"": {""selectedValues"": [""FOXO1""]}, ""tumor_assessments.nodal_pathology"": {""selectedValues"": [""N0 Stage Finding""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Absent""]}}",{},"The cohort consists of individuals whose molecular analysis shows the presence of the gene FOXO1. Additionally, these individuals have a nodal pathology assessment indicating an N0 stage finding, meaning there is no regional lymph node metastasis. Furthermore, their molecular analysis results show the absence of any molecular abnormalities."
Alveolar Alive Fox+,"{""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""survival_characteristics.lkss"": {""selectedValues"": [""Alive""]}, ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Present""]}}",{},The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who are currently alive. These individuals have a molecular abnormality characterized by the presence of the FOXO1-PAX3 fusion.
toddler_mycn_present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were classified as Stage 4 according to the INSS staging system. They exhibited MYCN amplification, which was present as a molecular abnormality. Additionally, the age of the patients at the time of tumor assessment ranged from 365 to 546 days."
toddler_hypodiploid,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were classified as Stage 4 according to the INSS staging system. Their DNA index was less than or equal to 1, indicating hypodiploid or diploid status. Additionally, the age of these patients at the time of tumor assessment was between 365 and 546 days."
INRG - Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
toddler_hist_unfavorable,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""selectedValues"": [""Unfavorable""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients were diagnosed with Stage 4 disease according to the INSS staging system. Their histology was classified as unfavorable, and their age at tumor assessment was between 365 and 546 days."
neg,"{""__combineMode"": ""AND"", ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Absent""]}}",{},"The cohort consists of individuals who have molecular analyses indicating the presence of FOXO1-PAX3 fusion, FOXO1-PAX7 fusion, or FOXO1-Other fusion abnormalities. Additionally, these individuals have results showing the absence of these molecular abnormalities."
unk,"{""__combineMode"": ""AND"", ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Unknown""]}}",{},"The cohort consists of individuals who have a molecular abnormality involving a fusion with FOXO1, specifically FOXO1-PAX3 fusion, FOXO1-PAX7 fusion, or FOXO1-Other fusion. Additionally, the result of the molecular abnormality analysis for these individuals is recorded as ""Unknown."""
Fusion Positive ORMS,"{""__combineMode"": ""AND"", ""tumor_assessments.tumor_site"": {""selectedValues"": [""Eyelid"", ""Orbit""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Present""]}}",{},"The cohort consists of individuals who have tumor assessments indicating the tumor site is either the eyelid or the orbit, and who have a molecular analysis showing the presence of a molecular abnormality."
jj,"{""__combineMode"": ""OR"", ""disease_phase:Initial Diagnosis"": {""filter"": {""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Present""]}}}}",{},"The cohort includes individuals at the initial diagnosis phase who have a molecular abnormality of either FOXO1-PAX7 fusion, FOXO1-PAX3 fusion, or FOXO1-Other fusion, with the result of the molecular abnormality being present. The selection criteria are combined using an OR logic."
1990-2002 Stage 4 Bone Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as having Stage 4 disease. Their tumors were metastatic, with the tumor site being the bone. The tumor state was recorded as either absent or present."
1990-2002 Stage 4 Liver Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with their disease between the years 1990 and 2002. At the initial diagnosis phase, these patients were classified as Stage 4 and had metastatic tumors. The tumor assessments indicated that the tumor site was the liver, and the tumor state was either absent or present."
ARMS Metastatic Femal,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of female patients diagnosed with alveolar rhabdomyosarcoma (ARMS) who have metastatic tumors.
toddler_unfavorable,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""selectedValues"": [""Unfavorable""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase with Stage 4 disease according to the INSS staging system. The patients were between 1 and 1.5 years old at the time of tumor assessment. The cohort includes subgroups based on specific molecular and histological characteristics: those with a 1p deletion, 11q deletion, MYCN amplification, unfavorable histology, or a DNA index of less than or equal to 1 (hypodiploid or diploid), with all molecular abnormalities confirmed as present."
HR paients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. At the time of tumor assessment, these patients were aged between 1.5 years (547 days) and approximately 29 years (10,610 days)."
toddler_11q_absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients were diagnosed with Stage 4 disease according to the INSS staging system. They exhibited a 1p deletion molecular abnormality, but the result of this molecular abnormality was absent. Additionally, the age of the patients at the time of tumor assessment was between 365 and 546 days."
INRG and INSTRuCT Female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
INRG Female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
INRG 12-18 months,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 548}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 548}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were at the initial diagnosis phase of their disease. Specifically, these individuals had their age at tumor assessment between 365 and 548 days."
HR patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 540, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 540}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were at the initial diagnosis phase of their disease. These individuals were assessed using the INRGSS staging system and were classified as Stage M. Additionally, their age at the time of tumor assessment ranged from 540 days to 10,983 days."
INRG Copy Number Alteration Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion"", ""1p deletion"", ""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion"", ""1p deletion"", ""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals from the INRG consortium who were at the initial diagnosis phase of their disease. These individuals have a molecular abnormality that is either an 11q deletion, 1p deletion, or MYCN amplification, and the result of this molecular abnormality is present."
initial diagnosis,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2004, ""upperBound"": 2022}, ""survival_characteristics.lkss"": {""__type"": ""OPTION"", ""selectedValues"": [""Alive""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2004}}, {""LTE"": {""year_at_disease_phase"": 2022}}]}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""lkss"": [""Alive""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of female individuals who were diagnosed with the disease between the years 2004 and 2022. Additionally, these individuals are currently alive according to their survival characteristics."
Florida INSTRuCT Addendum 5,,"{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
"composed INTERACT M, F","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}]}",The cohort consists of individuals who are part of the INTERACT consortium. It includes both male and female participants.
11q normal HR patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. At the initial diagnosis, these patients were classified as Stage 4. They exhibited a molecular abnormality of 11q deletion, which was absent in the molecular abnormality result. Additionally, the age at tumor assessment for these patients ranged from 547 days to 10,610 days."
1p normal HR patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. At the initial diagnosis, these patients were classified as Stage 4 and had a molecular abnormality of 1p deletion, which was absent in the molecular analysis results. Additionally, the age at tumor assessment for these patients ranged from 547 days to 10,610 days."
1p normal HR patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. These patients were at the initial diagnosis phase of their disease and were classified as Stage 4. They had a molecular abnormality of 1p deletion, but the result of this molecular abnormality was absent. Additionally, the age at tumor assessment for these patients ranged from 547 days to 10,610 days."
FOXO1-PAX3 Fusion Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals from the INSTRuCT consortium who were at the initial diagnosis phase of their disease. These individuals were specifically selected based on the absence of the FOXO1-PAX3 fusion molecular abnormality in their molecular analysis results.
MYCN normal HR patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed between the years 2001 and 2014. These patients were at Stage 4 at the time of initial diagnosis and had MYCN amplification as a molecular abnormality, with the result of this abnormality being absent. Additionally, the age of the patients at the time of tumor assessment ranged from 547 days to 10,610 days."
FOXO1-PAX7,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who have undergone molecular analysis and exhibit the FOXO1-PAX7 fusion molecular abnormality.
1P Deletion present,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who have a molecular analysis showing the presence of a 1p deletion abnormality.
SCA negative HR patients,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. The patients included in the study were assessed for tumors at ages ranging from 1.5 years to approximately 29 years. The cohort is divided into three groups based on molecular abnormalities: those with 11q deletion, 1p deletion, and MYCN amplification. In all cases, the molecular abnormality result was absent."
SCA negative HR patients,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. The patients included in the study had a tumor assessment age ranging from 547 to 10,610 days. The cohort is divided into three groups based on molecular abnormalities: those with 11q deletion, 1p deletion, and MYCN amplification. In all cases, the molecular abnormality result was absent."
SCA negative HR,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. The patients included in the study were assessed for tumors at ages ranging from 547 days to 10,610 days. The cohort is divided into three groups based on molecular abnormalities: those with 11q deletion, 1p deletion, and MYCN amplification. In all cases, the molecular abnormality result was absent."
StJude,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SJCRH""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""SJCRH""]}}]}",The cohort consists of participants whose data was contributed by the St. Jude Children's Research Hospital (SJCRH).
ARMS <50% necrosis,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.necrosis"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""<50% Necrosis""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""!="": {""histology"": ""Alveolar rhabdomyosarcoma (ARMS)""}}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""necrosis"": [""<50% Necrosis""]}}], ""path"": ""tumor_assessments""}}]}",The cohort includes patients whose tumors exhibit less than 50% necrosis. Patients with a histological diagnosis of Alveolar rhabdomyosarcoma (ARMS) are excluded from the cohort.
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
11q present HR,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. These patients have a molecular abnormality of 11q deletion, which is confirmed to be present. Additionally, the age at tumor assessment for these patients ranges from 547 days to 10,610 days."
1p present HR patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2001 and 2014. These patients were at the initial diagnosis phase of their disease and were classified as Stage 4. They exhibited a molecular abnormality characterized by a 1p deletion, which was confirmed to be present. Additionally, the age of the patients at the time of tumor assessment ranged from 547 days to 10,610 days."
MYCN present HR,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with the disease between the years 2001 and 2014. These patients were at Stage 4 at the time of initial diagnosis and had a MYCN amplification molecular abnormality that was present. Additionally, the age of the patients at the time of tumor assessment ranged from 547 days to 10,610 days."
SCA postive HR,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2001, ""upperBound"": 2014}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2001}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2001 and 2014. The patients included in the study must have been between 1.5 and 29 years old at the time of tumor assessment. The cohort is divided into three groups based on specific molecular abnormalities present at diagnosis: those with 11q deletion, those with 1p deletion, and those with MYCN amplification. Each of these molecular abnormalities must be confirmed as present for inclusion in the respective group."
1p,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis indicating the presence of a 1p deletion abnormality.
ARMS Metastatic,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a tumor classification of metastatic. Both criteria must be met for inclusion in the study.
FOXO1-PAX3 Fusion Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals from the INSTRuCT consortium who were at the initial diagnosis phase of their disease. These individuals have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
<5cm,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Spindle cell""]}, ""tumor_assessments.longest_diam_dim1"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 4.9}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""longest_diam_dim1"": 0}}, {""LTE"": {""longest_diam_dim1"": 4.9}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals with tumors classified as ""Spindle cell"" histology. Additionally, the longest diameter of the tumor, as measured in dimension 1, ranges from 0 to 4.9 units. Both criteria must be met for inclusion in the study."
Test 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2016}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Lymph Nodes"", ""Lung""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes"", ""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INSTRuCT consortium and were diagnosed with Alveolar rhabdomyosarcoma (ARMS) between the years 2000 and 2016. At the initial diagnosis, these patients had metastatic tumors located in either the lymph nodes or the lungs."
Test 2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2016}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Forearm""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Forearm""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INSTRuCT consortium and were diagnosed between the years 2000 and 2016. These patients were at the initial diagnosis phase of their disease, specifically diagnosed with alveolar rhabdomyosarcoma (ARMS). The tumor was classified as primary and located in the forearm."
1990-2002 Stage 4 Marrow Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor assessments indicated that the tumor site was the bone marrow, and the tumor state could be either absent or present."
FOXO1-PAX3 Fusion Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals from the INSTRuCT consortium who were at the initial diagnosis phase of their disease. These individuals were specifically selected based on the absence of the FOXO1-PAX3 fusion molecular abnormality in their molecular analysis results.
Female and iNRG,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of female participants who are part of the INRG consortium.
Test Arm,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2016}, ""survival_characteristics.lkss"": {""__type"": ""OPTION"", ""selectedValues"": [""Dead"", ""Alive""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Forearm"", ""Hand""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}, {""nested"": {""AND"": [{""IN"": {""lkss"": [""Dead"", ""Alive""]}}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Forearm"", ""Hand""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and were diagnosed with their disease between the years 2000 and 2016. The participants have survival statuses of either ""Dead"" or ""Alive."" At the initial diagnosis phase, these individuals were diagnosed with alveolar rhabdomyosarcoma (ARMS), with the tumor classified as ""Primary"" and located in either the forearm or hand."
Test Lung,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2016}, ""survival_characteristics.lkss"": {""__type"": ""OPTION"", ""selectedValues"": [""Dead"", ""Alive""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""lkss"": [""Dead"", ""Alive""]}}], ""path"": ""survival_characteristics""}}]}",The cohort consists of patients from the INSTRuCT consortium who were initially diagnosed with alveolar rhabdomyosarcoma (ARMS) between the years 2000 and 2016. These patients had metastatic tumors located in the lung at the time of initial diagnosis. The survival status of the patients in this cohort includes both those who are alive and those who are deceased.
ARMS 2000-present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2016}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}]}",The cohort consists of individuals who are part of the INSTRuCT consortium and were diagnosed with Alveolar rhabdomyosarcoma (ARMS) at the initial diagnosis phase. The diagnosis occurred between the years 2000 and 2016.
ERMS 2000-present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2016}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}]}]}], ""path"": ""histologies""}}]}",The cohort consists of patients who are part of the INSTRuCT consortium and were initially diagnosed with embryonal rhabdomyosarcoma (ERMS) between the years 2000 and 2016.
Neuroblastoma Schwannian stroma poor,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Both criteria must be met for inclusion in the study.
ARMS of arm,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Forearm"", ""Hand""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Forearm"", ""Hand""]}}]}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of patients from the INSTRuCT consortium who were at the initial diagnosis phase. These patients have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and have primary tumors located in the forearm or hand.
ARMS mets bone,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Bone or Bone Marrow""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Bone or Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INSTRuCT consortium who were at the initial diagnosis phase. These patients have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and have metastatic tumors located in the bone, bone marrow, or both."
Baseline,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were specifically at Stage 4 of their condition. Additionally, the age of the patients at the time of tumor assessment was between 365 and 547 days."
Toddler cohort,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present"", ""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present"", ""Unknown""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 disease. At the time of tumor assessment, they were between 1 and 1.5 years old (365 to 547 days). Additionally, their molecular analysis results showed either the presence of a molecular abnormality or the result was unknown."
FOXO1 fusion type,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-Other fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-Other fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who also exhibit one of the following molecular abnormalities: FOXO1-Other fusion, FOXO1-PAX3 fusion, or FOXO1-PAX7 fusion."
11q deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit an 11q deletion molecular abnormality. Both criteria must be met for inclusion in the study.
Common characteristics,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were classified as Stage 4 according to the INSS staging system. Additionally, the age of the patients at the time of tumor assessment was between 365 and 547 days."
FOXO1 fusion,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-Other fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""OR""}","{""OR"": [{""nested"": {""OR"": [{""IN"": {""molecular_abnormality"": [""FOXO1-Other fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort includes individuals who have undergone molecular analysis and exhibit one of the following molecular abnormalities: FOXO1-Other fusion, FOXO1-PAX3 fusion, or FOXO1-PAX7 fusion."
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
Stage 4 11q+ Toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were specifically at Stage 4 and had a molecular abnormality characterized by the presence of an 11q deletion. Additionally, the age of the patients at the time of tumor assessment ranged from 365 to 547 days."
Stage 4 nymc-na Toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 cancer and exhibited MYCN amplification as a molecular abnormality, but the result of this molecular abnormality was absent. Additionally, the age of the patients at the time of tumor assessment ranged from 365 to 547 days."
Primary Abdomen,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Abdomen""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Abdomen""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Primary""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are at the initial diagnosis phase of their disease. These individuals have tumors located in the abdomen, and the tumors are currently present and classified as primary."
Stage 4 nymc-na UH Toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""selectedValues"": [""Unfavorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 cancer and had an unfavorable histology according to the INPC classification. They exhibited MYCN amplification as a molecular abnormality, but the result of this molecular abnormality was absent. Additionally, the age of the patients at the time of tumor assessment was between 365 and 547 days."
Stage 4 nymc-na 1p+ Toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients were diagnosed with Stage 4 disease and had a molecular abnormality of 1p deletion, which was confirmed to be present. Additionally, the age of the patients at the time of tumor assessment was between 365 and 547 days."
Stage 4 toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}",The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 disease and were between 1 and 1.5 years old at the time of their tumor assessment.
"Stage 4 toddlers, 11q-","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 disease and had a molecular abnormality characterized by the presence of an 11q deletion. Additionally, the age of the patients at the time of tumor assessment was between 365 and 547 days."
Stage 4 nmyc-amp toddlers,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who were at the initial diagnosis phase of their disease. These patients were specifically diagnosed with Stage 4 cancer. Additionally, they exhibited a molecular abnormality characterized by MYCN amplification, which was confirmed to be present. The age of the patients at the time of tumor assessment ranged from 1 year (365 days) to just under 1.5 years (547 days)."
Stage 4 17q+ Toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""17q gain""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were specifically at Stage 4 and exhibited a molecular abnormality characterized by a 17q gain, which was confirmed to be present. Additionally, the age of the patients at the time of tumor assessment ranged from 365 to 547 days."
"Stage 4 toddlers, mycn-NA, diploid","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. The selection criteria include two groups: 

1. The first group includes patients with Stage 4 disease, a DNA index of less than or equal to 1 (indicating hypodiploid or diploid status), and an age at tumor assessment between 365 and 547 days.

2. The second group includes patients with Stage 4 disease, MYCN amplification, an absence of molecular abnormality results, and an age at tumor assessment between 365 and 547 days. 

Both groups are combined using an ""AND"" logic, meaning patients must meet all criteria within their respective group to be included in the cohort."
Stage 4 diploid Toddlers,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were specifically at Stage 4 of their condition. Additionally, their DNA index was less than or equal to 1, indicating they were either hypodiploid or diploid. The age of the patients at the time of tumor assessment was between 365 and 547 days."
Stage 4 nymc-na 1p+ toddlers,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase with Stage 4 disease. The patients were between 1 and 1.5 years old at the time of tumor assessment. Two specific groups were identified: one group had MYCN amplification with the molecular abnormality result being absent, and the other group had a 1p deletion with the molecular abnormality result being present."
"Stage 4 toddlers, mycn-NA","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 cancer and had MYCN amplification as a molecular abnormality, but the result of this molecular abnormality was absent. Additionally, the age of the patients at the time of tumor assessment was between 365 and 547 days."
"Stage 4 toddlers, mycn-NA, UH","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""selectedValues"": [""Unfavorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients were diagnosed with Stage 4 disease and had an unfavorable histology according to the INPC classification. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these patients ranged from 365 to 547 days."
"Stage 4 toddlers, 17q+","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""17q gain""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were diagnosed with Stage 4 cancer and exhibited a molecular abnormality characterized by a 17q gain, which was confirmed to be present. Additionally, the age of the patients at the time of tumor assessment ranged from 365 to 547 days."
"Stage 4 toddlers, mycn-NA, 11q=","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase with Stage 4 disease. The patients were between 1 and 1.5 years old at the time of tumor assessment. Two groups were identified: one group had MYCN amplification without the molecular abnormality result being present, and the other group had an 11q deletion with the molecular abnormality result being present."
"Stage 4 toddlers, mycn-NA, 1p-","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase with Stage 4 disease. The patients were between 1 and 1.5 years old at the time of tumor assessment. Two groups were identified: one group had MYCN amplification without the molecular abnormality result being present, and the other group had a 1p deletion with the molecular abnormality result being present."
"Final Cohort, Mixed Phenotype Toddlers","{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""selectedValues"": [""Unfavorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase with Stage 4 disease. The patients were between 1 and 1.5 years old at the time of tumor assessment. The cohort includes several subgroups based on molecular abnormalities: 

1. Patients with MYCN amplification and absent molecular abnormality result.
2. Patients with 1p deletion and present molecular abnormality result.
3. Patients with 17q gain and present molecular abnormality result.
4. Patients with 11q deletion and present molecular abnormality result.
5. Patients with a DNA index of less than or equal to 1 (hypodiploid or diploid).
6. Patients with unfavorable histology and MYCN amplification with absent molecular abnormality result.

Each subgroup is defined by the presence or absence of specific molecular abnormalities, and all patients meet the age and stage criteria."
INTERACT - femme,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
No bulk,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""No""]}}], ""path"": ""disease_characteristics""}}]}","The cohort consists of individuals who are part of the NODAL consortium and do not have bulk disease, as indicated by the disease characteristics."
"Stage 4 toddlers, 1p-","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients were diagnosed with Stage 4 disease and had a molecular abnormality of 1p deletion, which was confirmed to be present. Additionally, the age of the patients at the time of tumor assessment ranged from 365 to 547 days."
PAX3.FOXO1 +,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit the FOXO1-PAX3 fusion abnormality, with the result of this abnormality being present."
PAX7.FOXO1+,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit the FOXO1-PAX7 fusion abnormality, with the result of this abnormality being present."
"Stage 4 toddlers, diploid","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease. These patients were specifically at Stage 4 of their condition. Additionally, their DNA index was less than or equal to 1, indicating a hypodiploid or diploid status. The age of the patients at the time of tumor assessment was between 365 and 547 days."
"Stage 4 toddlers, mycn-NA, 17q-","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""17q gain""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase with Stage 4 disease. The patients were between 1 and 1.5 years old at the time of tumor assessment. Two groups were identified: one group had MYCN amplification with the molecular abnormality result absent, and the other group had a 17q gain with the molecular abnormality result present."
INRG FEMALE,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INRG consortium.
"INRG white, male","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""White""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""race"": [""White""]}}]}","The cohort consists of individuals who are male, identify as White, and are part of the INRG consortium. All these criteria must be met for inclusion in the study."
"Metastatic bone marrow, present","{""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who have been assessed for tumors located in the bone marrow. These tumors are classified as metastatic and are currently present.
"Primary, Adrenal gland, present","{""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Adrenal Gland""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Adrenal Gland""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who have a primary tumor located in the adrenal gland, and the tumor is currently present."
11q deletion absence,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit an 11q deletion, but the result of this molecular abnormality is absent."
pme,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.parameningeal_extension"": {""__type"": ""OPTION"", ""selectedValues"": [""Yes""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""parameningeal_extension"": [""Yes""]}}]}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are at the initial diagnosis phase of their disease and have a tumor assessment indicating the presence of parameningeal extension.
ARMSn,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with alveolar rhabdomyosarcoma (ARMS). Additionally, these participants do not exhibit any molecular abnormalities, as indicated by the absence of molecular abnormality results."
Relapse Primary Abdomen,"{""value"": {""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Abdomen""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Abdomen""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals in the relapse phase of their disease. These individuals have primary tumors located in the abdomen, and the tumors are currently present."
INRG Stage 4 Neuroblastoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have been diagnosed with Stage 4 Neuroblastoma, specifically the Schwannian Stroma-Poor subtype, and their tumors are classified as metastatic."
females,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
Spindle Cell >=5 cm,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Spindle cell""]}, ""tumor_assessments.longest_diam_dim1"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 4.9}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""longest_diam_dim1"": 0}}, {""LTE"": {""longest_diam_dim1"": 4.9}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals with tumors classified as ""Spindle cell"" histology. Additionally, the longest diameter of these tumors, as measured in one dimension, ranges from 0 to 4.9 units. Both criteria must be met for inclusion in the cohort."
Spindle Cell >5 cm,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Spindle cell""]}, ""tumor_assessments.longest_diam_dim1"": {""__type"": ""RANGE"", ""lowerBound"": 5, ""upperBound"": 20}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""longest_diam_dim1"": 5}}, {""LTE"": {""longest_diam_dim1"": 20}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals with tumors classified as ""Spindle cell"" histology. Additionally, the longest diameter of the tumor, as measured in dimension 1, must be between 5 and 20 units. Both criteria must be met for inclusion in the study."
MYCN Negative,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN amplification as a molecular abnormality."
MYCN Positive,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis indicating the presence of MYCN amplification.
male and (asian or black),"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",,The cohort consists of individuals who are male and identify as Asian. Both criteria must be met for inclusion in the cohort.
male and (asian or black),"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",,The cohort consists of individuals who are both male and Asian.
Male Asian Not Reported Black,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Not Reported""]}, ""__combineMode"": ""AND""}",,The cohort consists of individuals who are male and are either Asian or have not reported their race.
ERMS - female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of female individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
>=5cm,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Spindle cell""]}, ""tumor_assessments.longest_diam_dim1"": {""__type"": ""RANGE"", ""lowerBound"": 5, ""upperBound"": 20}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""longest_diam_dim1"": 5}}, {""LTE"": {""longest_diam_dim1"": 20}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals with tumors classified as ""Spindle cell"" histology. Additionally, the longest diameter of the tumor, as measured in dimension 1, must be between 5 and 20 units. Both criteria must be met for inclusion in the study."
NODAL M NB HiA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Albumin""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 4, ""upperBound"": 161}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""No""]}}], ""path"": ""disease_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""Albumin""]}}, {""AND"": [{""GTE"": {""lab_result_numeric"": 4}}, {""LTE"": {""lab_result_numeric"": 161}}]}], ""path"": ""labs""}}]}","The cohort consists of male participants who are part of the NODAL consortium. These individuals do not have bulk disease. Additionally, they have undergone lab tests for Albumin, with their lab results falling within the numeric range of 4 to 161."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."""
"Neuroblastoma, Initial=y, male","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of male patients who are part of the INRG consortium. These patients were at the initial diagnosis phase and had Stage 4 neuroblastoma, specifically the Schwannian Stroma-Poor histology type."
MYCN Positive,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis indicating the presence of MYCN amplification.
botryoid,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the INSTRuCT consortium and have been diagnosed with Botryoid rhabdomyosarcoma (BRMS).
botryoid,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Botryoid rhabdomyosarcoma (BRMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the INSTRuCT consortium and have been diagnosed with Botryoid rhabdomyosarcoma (BRMS).
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)""."
Neuroblastoma,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor).
"Neuroblastoma, Initial=y, male","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of male patients who are part of the INRG consortium. These patients were at the initial diagnosis phase and had Stage 4 Neuroblastoma, specifically the Schwannian Stroma-Poor histology type."
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
INTERACT all subjects,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
"1p present, 11q absent","{""value"": [{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}]}",The cohort consists of individuals who have a molecular analysis showing the presence of a 1p deletion and the absence of an 11q deletion.
ARMS Met,"{""value"": {""stagings.tnm_finding"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastases, M1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who also have a TNM staging finding of Metastases, M1. Both criteria must be met for inclusion in the study."
2003-2020 Stage 4 CNS Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients who are part of the INRG consortium. These patients have been diagnosed with Stage 4 cancer, specifically with tumors present in the Central Nervous System. Additionally, the data for these patients spans from the year 2003 to 2020."
2003-2020,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}","The cohort consists of participants who are part of the INRG consortium. Additionally, these participants have a year at disease phase that falls between 2003 and 2020, inclusive."
1990-2002 Stage 4 Lung Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were initially diagnosed with their disease between the years 1990 and 2002. At the time of initial diagnosis, these patients were classified as having Stage 4 disease. Additionally, their tumors were metastatic, and the tumor site was the lung. The tumor state could be either absent or present."
"1p present, 11q absent","{""value"": [{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}]}",The cohort consists of individuals who have a molecular analysis showing the presence of a 1p deletion and the absence of an 11q deletion.
ALK,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ALK rearranged""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""ALK rearranged""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who have undergone molecular analysis and exhibit an ALK rearrangement that is present.
MYCN Nonamplified,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit MYCN Amplification, but the result of this molecular abnormality is recorded as absent."
MYCN Nonamplified,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit MYCN Amplification as a molecular abnormality, but the result of this molecular abnormality is recorded as absent."
MYCN Nonamplified,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit MYCN Amplification as a molecular abnormality, but the result of this molecular abnormality is recorded as absent."
MYCN Nonamplified,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit MYCN Amplification as a molecular abnormality, but the result of this molecular abnormality is recorded as absent."
NODAL F B LA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Albumin""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 3}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}], ""path"": ""disease_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""Albumin""]}}, {""AND"": [{""GTE"": {""lab_result_numeric"": 0}}, {""LTE"": {""lab_result_numeric"": 3}}]}], ""path"": ""labs""}}]}","The cohort consists of female participants who are part of the NODAL consortium. These participants have been tested for Albumin, with their lab results falling within the range of 0 to 3. Additionally, they have been identified as having bulk disease."
FOXO1-PAX7 fusion,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit the FOXO1-PAX7 fusion abnormality, with the result of this abnormality being present."
FOXO1-PAX7 fusion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX7 fusion abnormality.
INSTRuCT,,"{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
FOXO1-PAX3,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
Stage 4 CNS Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have tumors located in the Central Nervous System, and the tumors are currently present. Additionally, all individuals are classified as having Stage 4 cancer."
Stage 4 bone marrow absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the bone marrow, and the tumor state is absent."
"4N, HR","{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 574, ""upperBound"": 18534}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""GTE"": {""age_at_censor_status"": 574}}, {""LTE"": {""age_at_censor_status"": 18534}}]}]}]}","The cohort consists of individuals from the INRG consortium who are at Stage 4 of their condition. The selection criteria include those with tumors present in the lymph nodes. Additionally, individuals with tumors absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone are included. The age at censor status for participants ranges from 574 to 18,534 days."
NODAL F NB HiA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Albumin""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 4, ""upperBound"": 150}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""No""]}}], ""path"": ""disease_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""Albumin""]}}, {""AND"": [{""GTE"": {""lab_result_numeric"": 4}}, {""LTE"": {""lab_result_numeric"": 150}}]}], ""path"": ""labs""}}]}","The cohort consists of female participants who are part of the NODAL consortium. These participants do not have bulk disease. Additionally, they have undergone a lab test for Albumin, with their lab results falling within the numeric range of 4 to 150."
MS,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage MS""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage MS""]}}], ""path"": ""stagings""}}]}",The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under the INRGSS staging system and are specifically at Stage MS.
"Composed INTERACT male, female","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of individuals who are part of the INTERACT consortium. The selection includes both female and male participants, ensuring that all members are from the INTERACT consortium."
FOXO1-PAX7,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX7 fusion abnormality.
FOXO1-PAX3,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
Treatment Data for INRG Proposal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""3881"", ""3891"", ""3951"", ""8741"", ""8742"", ""8743"", ""9243"", ""9244"", ""9340"", ""9341"", ""9640"", ""A3961"", ""A3973"", ""321P2"", ""321P3"", ""321P4"", ""P9641"", ""ANBL0032"", ""ANBL00P1"", ""ANBL00P2"", ""ANBL02P1"", ""ANBL0531"", ""ANBL0532"", ""ANBL0931"", ""ANBL1232"", ""ANBL1531"", ""SIOPEN HR-NBL1"", ""SIOPEN-EUNB"", ""ANBL12P1"", ""ANBL09P1"", ""ANBL17P1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""3881"", ""3891"", ""3951"", ""8741"", ""8742"", ""8743"", ""9243"", ""9244"", ""9340"", ""9341"", ""9640"", ""A3961"", ""A3973"", ""321P2"", ""321P3"", ""321P4"", ""P9641"", ""ANBL0032"", ""ANBL00P1"", ""ANBL00P2"", ""ANBL02P1"", ""ANBL0531"", ""ANBL0532"", ""ANBL0931"", ""ANBL1232"", ""ANBL1531"", ""SIOPEN HR-NBL1"", ""SIOPEN-EUNB"", ""ANBL12P1"", ""ANBL09P1"", ""ANBL17P1""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium. The study includes individuals from specific studies with the following study IDs: 3881, 3891, 3951, 8741, 8742, 8743, 9243, 9244, 9340, 9341, 9640, A3961, A3973, 321P2, 321P3, 321P4, P9641, ANBL0032, ANBL00P1, ANBL00P2, ANBL02P1, ANBL0531, ANBL0532, ANBL0931, ANBL1232, ANBL1531, SIOPEN HR-NBL1, SIOPEN-EUNB, ANBL12P1, ANBL09P1, and ANBL17P1."
1990-2002 Stage 4 Skin Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as having Stage 4 disease. Their tumors were metastatic, with the tumor site being the skin. The tumor state was recorded as either absent or present."
ARMS Metastatic M/F,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of individuals diagnosed with metastatic alveolar rhabdomyosarcoma (ARMS). The selection includes both male and female participants, each meeting the criteria of having a metastatic classification of their tumor."
FOXO1-PAX3 or PAX7,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who exhibit either the FOXO1-PAX3 fusion or the FOXO1-PAX7 fusion, with the presence of these molecular abnormalities confirmed."
Fem AA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Black or African American""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are both female and identify as Black or African American.
ARMS metastatic OR ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of patients with either Alveolar rhabdomyosarcoma (ARMS) that is classified as metastatic, or patients with Embryonal rhabdomyosarcoma (ERMS)."
testnov,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
"GDC - Ganglioneuroblastoma, Intermixed","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""selectedValues"": [""TARGET - GDC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""TARGET - GDC""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INRG consortium who have been referenced in the TARGET - GDC external resource. These participants have a histology diagnosis of Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)."
Script-FOXO1-PAX3,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit the FOXO1-PAX3 fusion abnormality, with the result of this abnormality being present."
ARMS Metastatic race N/R,"{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Not Reported""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Not Reported""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals whose race is not reported, have a histology of alveolar rhabdomyosarcoma (ARMS), and have a tumor classification of metastatic. All these criteria must be met for inclusion in the study."
ARMS Metastatic Femal,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of female patients diagnosed with alveolar rhabdomyosarcoma (ARMS) who have metastatic tumors.
ARMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals with a histological diagnosis of Alveolar rhabdomyosarcoma (ARMS).
"GDC - Ganglioneuroblastoma, Intermixed","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""selectedValues"": [""TARGET - GDC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""TARGET - GDC""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium. These participants have a histological diagnosis of Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich). Additionally, their data is referenced in the TARGET - GDC external resource. All these criteria must be met for inclusion in the cohort."
abdomen,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Abdomen""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Abdomen""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are at the initial diagnosis phase of their disease. Specifically, these individuals have tumor assessments indicating that the tumor site is located in the abdomen."
bladder,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Bladder""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bladder""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are at the initial diagnosis phase of their disease, specifically with tumors located in the bladder."
Script-FOXO1-PAX3+ARMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
Script-1p_deletion+NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of a 1p deletion molecular abnormality.
Kirk-1p deletion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
Script-1p_deletion+NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with the result of this abnormality being present."
"GDC Small - Ganglioneuroblastoma, Intermixed","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""selectedValues"": [""TARGET - GDC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""TARGET - GDC""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium. These participants have a histological diagnosis of Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich). Additionally, their data is referenced in the TARGET - GDC external resource. All these criteria must be met for inclusion in the cohort."
s,"{""sex"": {""selectedValues"": [""Male""]}}",,The cohort consists of individuals who are male.
INRG Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease.
Script-FOXO1-PAX7,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX7 fusion abnormality.
Script-FOXO1-PAX7+ARMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
Script-11qDEL+NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
AllAML,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
AML FLT3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
AML inv`6,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
AML t8-21,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, identified as the translocation t(8;21)(q22;q22) RUNX1/ETO, which is confirmed to be present in their molecular analysis results."
INTERACT fem,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
P3F,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion"", ""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort includes individuals who have a molecular abnormality characterized by either a ""FOXO1-PAX3 fusion"" or a ""FOXO1-PAX7 fusion"" as identified through molecular analysis."
Script-1p_deletion+NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of a 1p deletion molecular abnormality.
All RMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) that is not classifiable, and Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features."
MYCN amplification,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). Additionally, these individuals have undergone molecular analysis, which shows the presence of MYCN Amplification, but the result of this molecular abnormality is recorded as absent."
primary present,"{""value"": {""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who have a tumor classified as ""Primary"" and the tumor is currently ""Present,"" as assessed in their tumor evaluations."
Group B,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Black or African American""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of male individuals who are Black or African American and have been diagnosed with alveolar rhabdomyosarcoma (ARMS).
Group A,"{""value"": {""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Asian""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals who are of Asian race and have been diagnosed with Alveolar rhabdomyosarcoma (ARMS). Both criteria must be met for inclusion in the study.
INSTRuCT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
MYCN non-amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium. These patients have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and are classified under Stage M according to the INRGSS staging system. Additionally, they have undergone molecular analysis which shows MYCN Amplification, but the result of this molecular abnormality is absent."
M,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}",The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under the INRGSS staging system as Stage M.
met unknown,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of patients who are part of the INRG consortium. These patients have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and have a tumor classification of metastatic. Additionally, the tumor state for these patients is recorded as unknown."
MYCN absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants do not exhibit MYCN amplification, as the molecular abnormality result for MYCN amplification is absent."
FOXO1-PAX3 <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a FOXO1-PAX3 fusion molecular abnormality that is present. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years).
FOXO1-PAX3 <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a FOXO1-PAX3 fusion molecular abnormality present. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years).
>10y at Censor Neuroblastoma from COG,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 3650, ""upperBound"": 18534}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""COG""]}}, {""AND"": [{""GTE"": {""age_at_censor_status"": 3650}}, {""LTE"": {""age_at_censor_status"": 18534}}]}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals whose data was contributed by the Children's Oncology Group (COG). Participants were between the ages of 10 and 50 years at the time of censoring. They were diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and their disease phase occurred between the years 2003 and 2023.
NBL Biology only,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""9047"", ""ANBL00B1"", ""APEC14B1""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""9047""}}, {""!="": {""study_id"": ""ANBL00B1""}}, {""!="": {""study_id"": ""APEC14B1""}}]}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, with data contributed by COG. The cohort excludes participants from studies with the IDs 9047, ANBL00B1, and APEC14B1."
NBL Biology only,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""9047"", ""ANBL00B1"", ""APEC14B1""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""9047""}}, {""!="": {""study_id"": ""ANBL00B1""}}, {""!="": {""study_id"": ""APEC14B1""}}]}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, with data contributed by COG. The cohort excludes participants from studies with the IDs 9047, ANBL00B1, and APEC14B1."
FOXO1-PAX7 fusion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX7 fusion abnormality.
11q deletion <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
FOXO1-PAX7 <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a FOXO1-PAX7 fusion molecular abnormality present. The age at tumor assessment for these individuals ranges from 92 days to 1824 days.
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are staged using the INRGSS system and are classified as Stage M. Additionally, they exhibit MYCN Amplification, which is confirmed to be present through molecular analysis."
FOXO1-PAX7 <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a confirmed presence of the FOXO1-PAX7 fusion molecular abnormality. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
1p deletion <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a 1p deletion molecular abnormality that is present. The age at tumor assessment for these individuals ranges from 1 day to 1824 days (approximately 5 years).
MYCN AMp,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort includes individuals who have a molecular abnormality characterized by MYCN Amplification, as determined through molecular analysis."
FOXO1-PAX7 <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a FOXO1-PAX7 fusion molecular abnormality that is present. The age at tumor assessment for these individuals ranges from 92 days to 1824 days.
11q deletion <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
Neuroblastoma Stage M,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Stage M neuroblastoma, specifically the Schwannian Stroma-Poor subtype, according to the INRGSS staging system. The cohort is divided into two groups based on the presence or absence of MYCN amplification. One group includes patients with MYCN amplification present, while the other includes those without this molecular abnormality."
L1,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage L1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}]}",The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under the INRGSS staging system and are specifically at Stage L1.
L2,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage L2""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under the INRGSS staging system and are specifically at Stage L2.
"INSTRuCT M,F AA","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female"", ""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""IN"": {""race"": [""Black or African American""]}}]}",The cohort consists of individuals who are part of the INSTRuCT consortium. The selection includes both female and male participants who identify as Black or African American.
DSH-PAX7-FOXO1-ARMS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and exhibit the FOXO1-PAX7 fusion molecular abnormality, which is confirmed to be present."
1p del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular abnormality characterized by a 1p deletion, and this deletion is confirmed to be present."
1p absent,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit a 1p deletion molecular abnormality, but the result of this abnormality is absent."
1990-2020 Stage 4 Node Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were initially diagnosed with their disease between the years 1990 and 2002. At the time of initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor assessments indicated that the tumor site was the lymph nodes, and the tumor state was either absent or present."
"RMS (excluding ""Other"" histology)","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with specific types of rhabdomyosarcoma. These types include Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) that is not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, and Spindle cell rhabdomyosarcoma."
11q del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of an 11q deletion.
NB all adults,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 6570, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 6570}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. Additionally, these individuals have had tumor assessments conducted when they were between the ages of 18 and 30 years."
11q absent,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit an 11q deletion, but the result of this molecular abnormality is absent."
1p and 11q absent,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular characteristics. Specifically, the patients either have an 11q deletion that is absent or a 1p deletion that is absent. Both conditions must be met for inclusion in the study."
>10y at Censor Neuroblastoma from COG,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 3650, ""upperBound"": 18534}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""COG""]}}, {""AND"": [{""GTE"": {""age_at_censor_status"": 3650}}, {""LTE"": {""age_at_censor_status"": 18534}}]}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals whose data was contributed by the Children's Oncology Group (COG). Participants were between 10 and 50.75 years old at the time of censoring. They were diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and their disease phase occurred between the years 2003 and 2023.
NBL Biology only,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""9047"", ""ANBL00B1"", ""APEC14B1""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""9047""}}, {""!="": {""study_id"": ""ANBL00B1""}}, {""!="": {""study_id"": ""APEC14B1""}}]}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, with data contributed by COG. The cohort excludes participants from studies with the IDs 9047, ANBL00B1, and APEC14B1."
Temp9-delete,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian"", ""Native Hawaiian or Other Pacific Islander"", ""Black or African American""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian"", ""Native Hawaiian or Other Pacific Islander"", ""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}","The cohort consists of female participants who identify as either Asian, Native Hawaiian or Other Pacific Islander, or Black or African American."
Temp9-delete,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian"", ""Native Hawaiian or Other Pacific Islander""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""race"": [""Asian"", ""Native Hawaiian or Other Pacific Islander""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of female individuals who are either Asian or Native Hawaiian or Other Pacific Islander. Additionally, these individuals have been diagnosed with embryonal rhabdomyosarcoma (ERMS)."
ERMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",,"The cohort consists of individuals with the histology type ""Embryonal rhabdomyosarcoma (ERMS)."" All selected participants meet this specific criterion."
RER,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rapid Early Response (adequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Rapid Early Response (adequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have demonstrated a ""Rapid Early Response (adequate)"" in their interim responses."
11q deletion <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
All NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)""."
1p or 11q del,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular abnormalities. The selection criteria include patients with either a 1p deletion or an 11q deletion, both of which must be present. The presence of these deletions is confirmed through molecular analysis."
All INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
123,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2014, ""upperBound"": 2024}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2014}}, {""LTE"": {""year_at_disease_phase"": 2024}}]}]}","The cohort includes individuals whose year at the disease phase falls between 2014 and 2024, inclusive."
BlackMaleNonHisp,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Not Hispanic or Latino""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}]}","The cohort consists of individuals who are male, identify as Black or African American, and are not Hispanic or Latino."
SER,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Slow Early Response (inadequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Slow Early Response (inadequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have shown a ""Slow Early Response (inadequate)"" in their interim responses. Both criteria must be met for inclusion in the study."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit the MYCN Amplification molecular abnormality, which is confirmed to be present."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit the presence of MYCN Amplification as a molecular abnormality."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit the presence of MYCN Amplification as a molecular abnormality."
2003-2020 Stage 4 all other not bone or marrow,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection includes three specific groups based on tumor assessments: those with absent tumors in the bone marrow, those with absent tumors in the bone, and those with present tumors in the central nervous system, liver, lung, other sites, or skin. Additionally, all patients were diagnosed between the years 2003 and 2020."
No_MYCN,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
M,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under Stage M according to the INRGSS staging system.
ERMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Embryonal Rhabdomyosarcoma (ERMS).
1990-2002 Stage 4 all other not bone or marrow,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection includes three specific groups based on tumor assessments: those with absent tumors in the bone marrow, those with absent tumors in the bone, and those with present tumors in the central nervous system, liver, lung, other sites, or skin. Additionally, all patients were diagnosed between the years 1991 and 2002."
Group B,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone or Bone Marrow""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone or Bone Marrow""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and have been diagnosed with embryonal rhabdomyosarcoma (ERMS). Additionally, these individuals have tumor assessments indicating the presence of tumors in the bone or bone marrow. All these criteria must be met for inclusion in the cohort."
No_MYCN,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of male participants who are part of the INRG consortium. These participants have undergone molecular analysis, specifically for MYCN amplification, and the results of this analysis indicate that MYCN amplification is absent."
TARGET Quality Check,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TARGET - GDC""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""TARGET - GDC""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of female individuals who are Black or African American and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These individuals exhibit MYCN Amplification, which is confirmed to be present. The data for this cohort is sourced from the TARGET - GDC database."
Saved Filter,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
MYCN non-amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These individuals are staged using the INRGSS system and are classified as Stage M. Additionally, they have undergone molecular analysis which shows MYCN Amplification, but the result of this molecular abnormality is absent."
INRG and Sec,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
TARGET Quality Check,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TARGET - GDC""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""TARGET - GDC""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of female individuals who are Black or African American and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These individuals exhibit MYCN Amplification, with the molecular abnormality confirmed as present. The data for this cohort is sourced from the TARGET - GDC database."
L2,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under the INRGSS staging system and are specifically at Stage L2.
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit the presence of MYCN Amplification as a molecular abnormality."
GMKF - 20 subjects,"{""value"": {""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ALTE05N1""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""GMKF""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""GMKF""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ALTE05N1""]}}], ""path"": ""studies""}}]}","The cohort includes participants from the study identified by the study ID ""ALTE05N1"" and who have external references associated with the external resource name ""GMKF"". Both criteria must be met for inclusion in the cohort."
MYCN,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis showing the presence of MYCN Amplification.
Group A,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Abdomen""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Abdomen""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have tumors located in the abdomen. Both criteria must be met for inclusion in the study.
1p or 11q del,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit either a 1p deletion or an 11q deletion, with the presence of these molecular abnormalities confirmed."
F and Native HI,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Native Hawaiian or Other Pacific Islander""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Native Hawaiian or Other Pacific Islander""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female and identify as Native Hawaiian or Other Pacific Islander.
1990-2002 Stage 4 known metastatic site,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 1990 and 2002. The tumor sites for these patients include the bone, bone marrow, central nervous system, lung, liver, skin, other sites, and lymph nodes. Patients with an unknown tumor state are excluded from this cohort."
11q deletion less than 5 yrs,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years).
1p del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also have a molecular analysis showing the presence of an 11q deletion.
L1,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified under the INRGSS staging system at Stage L1.
11q deletion <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years). All criteria must be met for inclusion in the cohort.
1p deletion less than 5 yrs,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""survival_characteristics.age_at_lkss"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_lkss"": 1}}, {""LTE"": {""age_at_lkss"": 1824}}]}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. Participants are selected based on their age at the last known survival status, which must be between 1 day and 1824 days (approximately 5 years). Additionally, these individuals must have a molecular analysis showing the presence of a 1p deletion abnormality."
ANR-SIOPEN-RX,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN HR-NBL1""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""SIOPEN HR-NBL1""]}}, {""IN"": {""treatment_arm"": [""R2""]}}], ""path"": ""studies""}}]}",The cohort consists of participants from the INRG consortium who are part of the SIOPEN HR-NBL1 study and are in the R2 treatment arm.
1p deletion less than 5 yrs,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""survival_characteristics.age_at_lkss"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_lkss"": 1}}, {""LTE"": {""age_at_lkss"": 1824}}]}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. Participants are selected based on their age at the last known survival status, which must be between 1 day and 1824 days (approximately 5 years). Additionally, these individuals must have a molecular analysis indicating the presence of a 1p deletion abnormality."
2003-2020 Stage 4 known metastatic site,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and have been diagnosed with Stage 4 disease. The diagnosis must have occurred between the years 2003 and 2020. The tumor sites considered include the bone, bone marrow, central nervous system, lung, liver, skin, other sites, and lymph nodes. Additionally, the tumor state must be known, as cases with an unknown tumor state are excluded."
1990-2002 4N,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection criteria include patients with tumors present in the lymph nodes, and those with tumors absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone. Additionally, the patients were diagnosed between the years 1991 and 2002."
ARMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}",,The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS).
ARMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}",,The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS).
Test female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
All NBL,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort includes individuals with the histology type ""Neuroblastoma (Schwannian Stroma-Poor)."" This selection criterion is applied without any exclusions, and all conditions must be met simultaneously."
11q del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a molecular abnormality characterized by the presence of an 11q deletion.
11q deletion <5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years).
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
Brad's patients,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2a"", ""Stage 2b"", ""Stage 3"", ""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2022}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 257, ""upperBound"": 3650}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2022}}]}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 257}}, {""LTE"": {""age_at_tumor_assessment"": 3650}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2a"", ""Stage 2b"", ""Stage 3"", ""Stage 4""]}}], ""path"": ""stagings""}}]}","The cohort consists of female patients who are part of the INRG consortium. These patients have been diagnosed with Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich) and are at stages 2a, 2b, 3, or 4 of the disease. The diagnosis or disease phase occurred between the years 2000 and 2022. Additionally, the age at tumor assessment for these patients ranges from 257 days to 3650 days."
Test female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
epssg,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EpSSG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""EpSSG""]}}]}",The cohort consists of participants whose data was contributed by the EpSSG.
cog,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""COG""]}}]}","The cohort includes participants whose data was contributed by the ""COG"" data contributor."
"Ganglionuroblastoma, Nodular","{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Ganglioneuroblastoma, Nodular (Composite)."
Angiosarcoma of soft tissue,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Angiosarcoma of Soft Tissue (9120/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Angiosarcoma of Soft Tissue (9120/3)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals with a histological diagnosis of Angiosarcoma of Soft Tissue, specifically coded as 9120/3."
Angiosarcoma of soft tissue,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Angiosarcoma of Soft Tissue (9120/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Angiosarcoma of Soft Tissue (9120/3)""]}}], ""path"": ""histologies""}}]}","The cohort includes individuals with a histological diagnosis of Angiosarcoma of Soft Tissue, specifically coded as 9120/3."
No bulky disease,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""No""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of individuals who are part of the NODAL consortium and do not have bulk disease according to their disease characteristics.
ANBL0032+RA,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are enrolled in studies where the treatment arm includes RA combined with anti-GD2 therapy.
1p,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have a molecular analysis indicating the presence of a ""1p deletion"" abnormality. The selection criteria require that this specific molecular abnormality is present in the analysis results."
"Composed: G, Nodular OR Angiosarcoma","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Angiosarcoma of Soft Tissue (9120/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Angiosarcoma of Soft Tissue (9120/3)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of participants who meet either of the following criteria: 

1. They are part of the INRG consortium and have a histology diagnosis of ""Ganglioneuroblastoma, Nodular (Composite).""

2. They have a histology diagnosis of ""Angiosarcoma of Soft Tissue (9120/3)."" 

Participants can meet either one of these criteria to be included in the study."
Hey,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Adult Fibrosarcoma (8810/3)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Adult Fibrosarcoma (8810/3)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase and have been diagnosed with Adult Fibrosarcoma, specifically coded as 8810/3."
NBL-Antibody RX,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the INRG consortium who meet at least one of the following criteria: they are part of studies with the treatment arm ""RA+anti-GD2,"" or they are part of studies with the treatment arm ""R2,"" or they are involved in the study identified by ""ANBL0931."""
Test filter set,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
ANR-COG-ANBL0931,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID ANBL0931. Both criteria must be met for inclusion in the cohort.
MYCN AMPLIFICATION present,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who were at the initial diagnosis phase of their disease. Specifically, these individuals have a molecular abnormality characterized by MYCN amplification, and this abnormality is confirmed to be present."
2003-2020 4N,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection includes patients with tumors present in the lymph nodes and absent in the lungs, other sites, skin, liver, central nervous system, bone marrow, and bone. Additionally, the patients were diagnosed between the years 2003 and 2020."
Bulky disease,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been identified with bulk disease.
MYCN Amplification,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium and have a molecular analysis showing the presence of MYCN amplification.
MYCN non-AMPLIFIed,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who were at the initial diagnosis phase of their disease. Specifically, these individuals underwent molecular analysis, which revealed the presence of MYCN amplification as a molecular abnormality. However, the result of this molecular abnormality was absent."
Test1,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L1""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). These patients were staged using the INRGSS system and classified as Stage L1. Additionally, they exhibited a molecular abnormality characterized by MYCN Amplification."
Fox01Pax3 Less Than 5 Years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1865}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1865}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the FOXO1-PAX3 fusion. Additionally, the age at tumor assessment for these individuals ranges from 3 days to 1865 days."
1990-2002 Stage 4 Liver Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these patients have a tumor present in the liver."
1990-2002 Stage 4 skin present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these individuals have a tumor present at the skin site."
test3,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}]}]}], ""path"": ""stagings""}}]}",The cohort consists of patients who were at the initial diagnosis phase and had a diagnosis of Stage 3 Neuroblastoma (Schwannian Stroma-Poor) with MYCN Amplification.
ANR-COG-ANBL0032+RX,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium who were part of the study identified as ANBL0032. Within this study, the participants were specifically those who were assigned to the treatment arm labeled RA+anti-GD2."
Any_met_new,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. These patients have tumors that are present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, or Skin."
"NRSTS (excluding ""Other"" histology)","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell"", ""Other""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""histology"": ""Alveolar rhabdomyosarcoma (ARMS)""}}, {""!="": {""histology"": ""Botryoid rhabdomyosarcoma (BRMS)""}}, {""!="": {""histology"": ""Embryonal rhabdomyosarcoma (ERMS)""}}, {""!="": {""histology"": ""Pleomorphic rhabdomyosarcoma (PRMS)""}}, {""!="": {""histology"": ""Rhabdomyosarcoma (RMS), not classifiable""}}, {""!="": {""histology"": ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""}}, {""!="": {""histology"": ""Spindle cell""}}, {""!="": {""histology"": ""Other""}}]}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INSTRuCT consortium. The selection criteria exclude individuals with the following histologies: Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, spindle cell, and other unspecified types."
test2,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). These patients were staged using the INRGSS system and classified as Stage L2. Additionally, they exhibited a molecular abnormality characterized by MYCN Amplification."
Fox01Pax3 Less Than 5 Years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1865}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1865}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the FOXO1-PAX3 fusion. The age at tumor assessment for these individuals ranges from 3 days to 1865 days.
Fox01Pax7 Less than 5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the presence of the FOXO1-PAX7 fusion. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
Fox01Pax3 Less Than 5 Years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1865}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1865}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the FOXO1-PAX3 fusion. Additionally, these individuals were assessed for their tumor between the ages of 3 days and 1865 days (approximately 5 years)."
StJude,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SJCRH""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""SJCRH""]}}]}","The cohort consists of participants whose data was contributed by the institution identified by the data contributor ID ""SJCRH""."
Composed ARMS OR ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort includes individuals with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS) histologies. Participants are selected if they have a diagnosis of either ARMS or ERMS, as specified in their histological records."
Composed ARMS OR ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}",The cohort consists of individuals diagnosed with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS). Participants were selected if they had a histology report indicating the presence of either ARMS or ERMS.
Any met non lymph node,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Other""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. These patients have tumors that are present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Skin, or Other. Each patient meets all these criteria, with the presence of the tumor at the specified sites being a key inclusion factor."
test filter,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INSTRuCT Known Survival,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of participants who are part of the INSTRuCT consortium and have known values for the obfuscated survival characteristic labeled as ""lkss_obfuscated."" Both criteria must be met for inclusion in the study."
all_unknown_mets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Liver""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Skin""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. The tumor assessments for these patients indicate that the tumor site was one of the following: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, or Skin. Additionally, the tumor state for all these cases was recorded as Unknown."
Any_met_new,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. These patients have tumors present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, or Skin."
"GDC Large F, AA","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TARGET - GDC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""TARGET - GDC""]}}], ""path"": ""external_references""}}]}","The cohort consists of individuals who are female and identify as Black or African American. Additionally, these individuals have data that is referenced in the ""TARGET - GDC"" external resource."
DSH-PAX3-FOXO1-ARMS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and exhibit the FOXO1-PAX3 fusion molecular abnormality, which is confirmed to be present."
DSH-FOXO1--other-ARMS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-Other fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and exhibit a molecular abnormality characterized by the presence of a FOXO1-Other fusion.
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
NOS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, NOS. Both criteria must be met for inclusion in the study."
alveolar m1 other fusion,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.tnm_finding"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastases, M1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-Other fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-Other fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and have a TNM staging of Metastases, M1. Additionally, they exhibit a molecular abnormality characterized by a FOXO1-Other fusion."
FOXO1PAX3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.tnm_finding"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastases, M1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and have a TNM staging of Metastases, M1. Additionally, they exhibit a molecular abnormality characterized by the FOXO1-PAX3 fusion. All these criteria must be met for inclusion in the cohort."
embryonal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.tnm_finding"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastases, M1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with embryonal rhabdomyosarcoma (ERMS) and have a TNM staging indicating the presence of metastases, classified as M1. All these criteria must be met for inclusion in the cohort."
"RMS (excluding ""Other"" histology)","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with specific types of rhabdomyosarcoma. These types include Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) that is not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, and Spindle cell rhabdomyosarcoma."
1p del,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with this abnormality confirmed as present."
11q and 1p absent,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular characteristics. Specifically, the patients either have an 11q deletion that is absent or a 1p deletion that is absent. Both conditions must be met for inclusion in the study."
11q,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who have a molecular analysis showing the presence of an 11q deletion.
1p and 11q,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit either a 1p deletion or an 11q deletion, with both molecular abnormalities confirmed as present."
DSH-Absent Fusion,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who also have an absent result in their molecular abnormality analysis. Both criteria must be met for inclusion in the study.
PAX7FOXO1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.tnm_finding"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastases, M1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX7 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and exhibit the FOXO1-PAX7 fusion molecular abnormality. Additionally, they have been staged with metastases classified as M1. All these criteria must be met for inclusion in the cohort."
fusion neg alv,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.tnm_finding"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastases, M1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tnm_finding"": [""Metastases, M1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have been diagnosed with alveolar rhabdomyosarcoma (ARMS) and have a TNM staging of Metastases, M1. Additionally, they do not exhibit any molecular abnormalities, as the molecular abnormality result is absent."
Ms,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s"", ""Stage IVs"", ""Stage MS""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Favorable""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_inpc"": [""Favorable""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4s"", ""Stage IVs"", ""Stage MS""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who were at the initial diagnosis phase of their disease. These patients have a histology of ""Neuroblastoma (Schwannian Stroma-Poor)"" with a favorable INPC histology classification. Additionally, they are in one of the following stages: ""Stage 4s,"" ""Stage IVs,"" or ""Stage MS."""
Asian+Pacific Islander,"{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian"", ""Native Hawaiian or Other Pacific Islander""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian"", ""Native Hawaiian or Other Pacific Islander""]}}]}",The cohort includes individuals who identify as either Asian or Native Hawaiian or Other Pacific Islander.
ARMS OR ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of individuals diagnosed with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS). The selection criteria include patients with a histology of ARMS or ERMS, and these conditions are considered separately, allowing for inclusion if either condition is present."
ERMS,"{""__combineMode"": ""AND"", ""histologies.histology"": {""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}",,"The cohort consists of individuals with the histology type ""Embryonal rhabdomyosarcoma (ERMS)."" All selected participants meet this specific criterion."
Another test set,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Not Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}]}",The cohort consists of male participants who are not Hispanic or Latino and are part of the INRG consortium.
"INSTRuCT, AA","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female"", ""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""IN"": {""race"": [""Black or African American""]}}]}",The cohort consists of individuals who are part of the INSTRuCT consortium. The selection includes both female and male participants who identify as Black or African American.
ARMS AND Fox01_Pax3,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS). Additionally, within this group, there is a subset of individuals who have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality."
FOXO1-PAX3,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
1p deletion < 5 years,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1824, ""upperBound"": 10610}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1824}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by a 1p deletion. Additionally, the age of the patients at the time of tumor assessment ranges from 1824 days to 10610 days."
11q deletion < 5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years). All criteria must be met for inclusion in the cohort.
1p deletion < 5 years,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1824, ""upperBound"": 10610}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1824}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by a 1p deletion. Additionally, the age of these patients at the time of tumor assessment ranges from 5 years (1824 days) to approximately 29 years (10610 days)."
Upper arm,"{""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Upper Arm""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Upper Arm""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Primary""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who have a primary tumor that is present in the upper arm.
1p_<5yrs,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These individuals exhibit a 1p deletion molecular abnormality, which is confirmed to be present. The age of the individuals at the time of tumor assessment ranges from 0 to 1825 days (approximately 0 to 5 years)."
1p_<5yrs,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These individuals exhibit a 1p deletion molecular abnormality, which is confirmed to be present. Additionally, the age at tumor assessment for these individuals ranges from 0 to 1825 days."
11q_loss_<5yrs,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a confirmed presence of the 11q deletion molecular abnormality. The age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years).
FLT3-ITD Negative,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have undergone molecular analysis. Specifically, these participants have been tested for the FLT3 internal tandem duplication (ITD) molecular abnormality, and the results show that this abnormality is absent."
mycn_2000-2010,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2010}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 6218}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2010}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 6218}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease. The diagnosis occurred between the years 2000 and 2010. These individuals exhibit MYCN Amplification, which is confirmed to be present. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 6218 days."
Non_amp_>18mo_ >2010dx,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2011, ""upperBound"": 2019}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10480}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2011}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10480}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease. The diagnosis occurred between the years 2011 and 2019. These individuals have a molecular abnormality characterized by MYCN Amplification, but the result of this molecular abnormality is absent. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 10,480 days."
Non_amp_stage4>18mo_2000-2010,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2010}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10480}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2010}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10480}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals from the INRG consortium who were diagnosed with Stage 4 disease between the years 2000 and 2010. These individuals have a molecular abnormality characterized by MYCN Amplification, but the result of this molecular abnormality is absent. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 10,480 days."
non-amp_stage4>18mo-<2000dx,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1984, ""upperBound"": 1999}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10480}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1984}}, {""LTE"": {""year_at_disease_phase"": 1999}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10480}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1984 and 1999. These individuals have a molecular abnormality characterized by MYCN Amplification, with the result of this abnormality being absent. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 10,480 days."
myxoid,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Extraskeletal myxoid chondrosarcoma (9231/3)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Extraskeletal myxoid chondrosarcoma (9231/3)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase and have been diagnosed with extraskeletal myxoid chondrosarcoma, specifically coded as 9231/3."
MYCN_>2010dx,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2011, ""upperBound"": 2019}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 6785}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2011}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 6785}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease. The diagnosis occurred between the years 2011 and 2019. These individuals exhibit MYCN Amplification, which is confirmed to be present. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 6785 days."
INRG Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
Female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
ARMS - fem,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of female participants who have been diagnosed with alveolar rhabdomyosarcoma (ARMS).
MYCN_amp<2000dx,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1984, ""upperBound"": 1999}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 5019}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1984}}, {""LTE"": {""year_at_disease_phase"": 1999}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 5019}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1984 and 1999. These individuals have a molecular abnormality characterized by MYCN Amplification, which is present in their molecular analysis results. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 5019 days."
Composed3,"{""value"": [{""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""selectedValues"": [""Adrenal Gland""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Adrenal Gland""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of individuals with two specific tumor assessment criteria. The first group includes those with metastatic tumors present in the bone marrow. The second group includes individuals with primary tumors present in the adrenal gland. Both groups require the tumor state to be present.
"Male, Asian, Black, Native","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian"", ""Black or African American"", ""Native Hawaiian or Other Pacific Islander""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American"", ""Native Hawaiian or Other Pacific Islander""]}}, {""IN"": {""sex"": [""Male""]}}]}","The cohort consists of male individuals who identify as either Asian, Black or African American, or Native Hawaiian or Other Pacific Islander."
surgery<=5cm,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""tumor_assessments.tumor_size"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""<=5 cm""]}, ""biopsy_surgical_procedures.procedure_type"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Surgery""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""procedure_type"": [""Surgery""]}}], ""path"": ""biopsy_surgical_procedures""}}, {""nested"": {""AND"": [{""IN"": {""tumor_size"": [""<=5 cm""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have undergone surgical procedures and have tumor sizes that are 5 cm or smaller. All criteria must be met for inclusion in the cohort.
all_unknown_mets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Liver""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Skin""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. The tumor assessments for these patients indicate that the tumor site was one of the following: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, or Skin. Additionally, the tumor state for all these cases was recorded as Unknown."
Real known mets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. These patients have tumors present at one or more of the following sites: Bone, Bone Marrow, Liver, Central Nervous System, Lung, Lymph Nodes, or Skin."
Composed - ARMS or ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}]}",The cohort includes individuals diagnosed with either Embryonal rhabdomyosarcoma (ERMS) or Alveolar rhabdomyosarcoma (ARMS).
Paratesticular,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Paratesticular""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Paratesticular""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a primary tumor located in the paratesticular region, and the tumor is currently present."
Real unkown mets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. At the time of initial diagnosis, these patients had tumors with an unknown state located in one of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, or Skin."
Ganglio,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase and have a histology of ""Ganglioneuroblastoma, Nodular (Composite)""."
Composed1,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Asian""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Asian"", ""Black or African American""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""race"": [""Asian""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of male participants who are either Asian or Black or African American. Specifically, within this group, there is a subset of Asian males who were at the initial diagnosis phase of their disease, with their tumors classified as primary."
Luca admin filter,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""CWS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""CWS""]}}]}","The cohort consists of individuals whose data was contributed by the data contributor identified as ""CWS""."
Composed - ARMS or ERMS,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}]}",The cohort includes individuals with either Embryonal rhabdomyosarcoma (ERMS) or Alveolar rhabdomyosarcoma (ARMS) histologies. Participants are selected if they have one of these two specific types of rhabdomyosarcoma.
Male high risk,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of male participants who are part of the INRG consortium. These individuals were at the initial diagnosis phase of their disease, specifically diagnosed with Stage 4 according to the INSS staging system. They exhibit MYCN amplification, which is present as a molecular abnormality. The age at tumor assessment for these participants ranges from 1.5 years (547 days) to 30 years (10,983 days)."
male high risk,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 1.5 years (547 days) to 30 years (10,983 days)."
Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}]}",The cohort consists of individuals who are male.
INRG Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
meta,"{""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals whose tumor assessments classify their tumors as ""Metastatic."""
HR_male_NA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject is censored (i.e. has had no event(s))"", ""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""censor_status"": [""Subject is censored (i.e. has had no event(s))"", ""Subject has had one or more events""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male subjects who are part of the INRG consortium. These subjects have either been censored, meaning they have had no events, or have experienced one or more events. They are specifically at Stage 4 of their condition. The subjects have a MYCN amplification molecular abnormality, but the result of this molecular abnormality is absent. Additionally, the age of the subjects at the time of tumor assessment ranges from 547 days to 10,610 days."
1p present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion"", ""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion"", ""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular abnormalities. These abnormalities include the presence of either a 1p deletion or an 11q deletion, as confirmed by molecular analysis. All selected cases must meet these criteria."
FOX01-PAX3,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who also exhibit the FOXO1-PAX3 fusion molecular abnormality. Both criteria must be met for inclusion in the study.
FOX01-PAX7,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the presence of the FOXO1-PAX7 fusion. The age at tumor assessment for these individuals ranges from 92 days to 1824 days.
Ganglio,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, {""IN"": {""histology_grade"": [""Differentiating""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of ""Ganglioneuroblastoma, Nodular (Composite)"" with a histology grade of ""Differentiating."""
test1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
ANBL0032 2009 and later,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2009, ""upperBound"": 2014}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2009}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically from the study identified as ANBL0032. The data contributors are from the COG group. The participants were included if their disease phase occurred between the years 2009 and 2014, inclusive. All these criteria were combined using an ""AND"" logic, meaning each participant had to meet all the specified conditions to be included in the cohort."
HR_female_NA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events"", ""Subject is censored (i.e. has had no event(s))""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10480}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events"", ""Subject is censored (i.e. has had no event(s))""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10480}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium. These participants have either experienced one or more events or have been censored, meaning they have had no events. They are diagnosed with either Stage 4 or Stage M cancer and have MYCN amplification, but the molecular abnormality result is absent. The age at tumor assessment for these participants ranges from 547 days to 10,480 days."
HR_female_NA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events"", ""Subject is censored (i.e. has had no event(s))""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10480}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events"", ""Subject is censored (i.e. has had no event(s))""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10480}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium. These participants have either experienced one or more events or have been censored, meaning they have had no events. They are diagnosed with either Stage 4 or Stage M cancer and have MYCN amplification, but the molecular abnormality result is absent. The age at tumor assessment for these participants ranges from 547 days to 10,480 days."
Female high risk,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. The age at tumor assessment for these participants ranged from 547 days to 10,983 days."
ARST0332,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ARST0332""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ARST0332""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INSTRuCT consortium and are involved in the study identified by the study ID ARST0332. Both criteria must be met for inclusion in the cohort.
surgery>5cm,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""tumor_assessments.tumor_size"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": ["">5 cm""]}, ""biopsy_surgical_procedures.procedure_type"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Surgery""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""procedure_type"": [""Surgery""]}}], ""path"": ""biopsy_surgical_procedures""}}, {""nested"": {""AND"": [{""IN"": {""tumor_size"": ["">5 cm""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have undergone surgical procedures and have tumors that are larger than 5 cm in size. All these criteria must be met for inclusion in the cohort.
HR_male_NA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject is censored (i.e. has had no event(s))"", ""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""censor_status"": [""Subject is censored (i.e. has had no event(s))"", ""Subject has had one or more events""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male subjects who are part of the INRG consortium. These subjects have either been censored, meaning they have had no events, or have experienced one or more events. They are specifically at Stage 4 of their condition and have a MYCN amplification that is absent in molecular abnormality results. The age of these subjects at the time of tumor assessment ranges from 547 days to 10,610 days."
male high risk,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
Cohn2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
Cohn1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 1.5 years (547 days) to 30 years (10,983 days)."
FOX01-PAX7,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the presence of the FOXO1-PAX7 fusion. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
Cohn1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG Males,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
1p,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis for the 1p deletion abnormality. The results of this analysis can either be ""Absent"" or ""Present."""
Cohn1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
Cohn1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG HR Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
Cohn1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG Males,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INRG consortium.
Cohn2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
Cohn2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG Known 1P,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis for the 1p deletion abnormality. The results of this analysis can either be ""Absent"" or ""Present."""
INRG HR Female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 1.5 years (547 days) to 30 years (10,983 days)."
test_surv_1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG high-risk F,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 1.5 years (547 days) to 30 years (10,983 days)."
Real unkown mets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Unknown""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. At the time of initial diagnosis, these patients had tumors assessed at various sites, including Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, and Skin, with the tumor state being recorded as Unknown."
"NRSTS (excluding ""Other"" histology)","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell"", ""Other""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""histology"": ""Alveolar rhabdomyosarcoma (ARMS)""}}, {""!="": {""histology"": ""Botryoid rhabdomyosarcoma (BRMS)""}}, {""!="": {""histology"": ""Embryonal rhabdomyosarcoma (ERMS)""}}, {""!="": {""histology"": ""Pleomorphic rhabdomyosarcoma (PRMS)""}}, {""!="": {""histology"": ""Rhabdomyosarcoma (RMS), not classifiable""}}, {""!="": {""histology"": ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""}}, {""!="": {""histology"": ""Spindle cell""}}, {""!="": {""histology"": ""Other""}}]}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INSTRuCT consortium. The selection criteria exclude individuals with the following histologies: Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, spindle cell, and other unspecified types."
MY,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Immature Teratoma"", ""Mature Teratoma"", ""Mixed Germ Cell Tumor"", ""Yolk Sac Tumor""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Immature Teratoma"", ""Mature Teratoma"", ""Mixed Germ Cell Tumor"", ""Yolk Sac Tumor""]}}], ""path"": ""histologies""}}]}","The cohort includes individuals with specific histological diagnoses, namely Immature Teratoma, Mature Teratoma, Mixed Germ Cell Tumor, or Yolk Sac Tumor. These histologies are the criteria for inclusion, and no exclusions are applied based on these categories."
test_2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG hi-risk M,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INRG hi-risk M and F,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male"", ""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male"", ""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals from the INRG consortium, including both males and females. Participants were at the initial diagnosis phase of their disease, specifically diagnosed with Stage 4 according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. The age at tumor assessment for these individuals ranged from 547 days to 10,983 days."
INRG test1,"{""value"": {""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Reported"", ""White"", ""Black or African American""]}, ""ethnicity"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Hispanic or Latino"", ""Not Reported""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""ethnicity"": [""Not Hispanic or Latino"", ""Not Reported""]}}, {""IN"": {""race"": [""Not Reported"", ""White"", ""Black or African American""]}}, {""IN"": {""consortium"": [""INRG""]}}]}","The cohort consists of individuals who are part of the INRG consortium. Participants are either of ""Not Reported,"" ""White,"" or ""Black or African American"" race. Additionally, their ethnicity is either ""Not Hispanic or Latino"" or ""Not Reported."" All these criteria must be met for inclusion in the study."
Composed - junk,"{""value"": [{""value"": {""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Reported"", ""White"", ""Black or African American""]}, ""ethnicity"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Hispanic or Latino"", ""Not Reported""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""ethnicity"": [""Not Hispanic or Latino"", ""Not Reported""]}}, {""IN"": {""race"": [""Not Reported"", ""White"", ""Black or African American""]}}, {""IN"": {""consortium"": [""INRG""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of two groups based on the following criteria: 

1. The first group includes individuals who are part of the INRG consortium and have either not reported their race or are identified as White or Black or African American. Additionally, their ethnicity is either not reported or identified as Not Hispanic or Latino.

2. The second group includes male individuals who are part of the INSTRuCT consortium and are identified as Not Hispanic or Latino. 

Participants must meet all criteria within their respective group, and individuals can belong to either group."
INRG test1,"{""value"": {""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Reported"", ""White"", ""Black or African American""]}, ""ethnicity"": {""__type"": ""OPTION"", ""selectedValues"": [""Not Hispanic or Latino"", ""Not Reported""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""ethnicity"": [""Not Hispanic or Latino"", ""Not Reported""]}}, {""IN"": {""race"": [""Not Reported"", ""White"", ""Black or African American""]}}, {""IN"": {""consortium"": [""INRG""]}}]}","The cohort consists of individuals who are part of the INRG consortium. Participants are either of ""Not Reported,"" ""White,"" or ""Black or African American"" race. Additionally, their ethnicity is either ""Not Hispanic or Latino"" or ""Not Reported."" All these criteria must be met for inclusion in the cohort."
1p and 11q,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion"", ""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion"", ""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit specific molecular abnormalities. The selection criteria include two groups: the first group includes patients with a 1p deletion that is present, and the second group includes patients with either a 1p deletion or an 11q deletion, both of which must be present. All patients must meet these criteria to be included in the study."
1p deletion present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
Regional nodes,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Regional""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Regional""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have a regional tumor classification. The tumors are specifically located in the lymph nodes and are currently present.
ANBL0931,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically from the study identified as ANBL0931, with data contributed by the COG. All these criteria must be met for inclusion in the cohort."
Disallowed,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""0896""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""0896""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in study ID 0896. Both criteria must be met for inclusion in the cohort.
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Ganglioneuroblastoma, Nodular (Composite). Both criteria must be met for inclusion in the study."
1p absent ,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular analysis showing a 1p deletion that is absent.
test1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}]}",The cohort consists of participants who are part of the MaGIC consortium.
RMS Met Lung,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have metastatic tumors present in the lung.
HRNBL1 R2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN HR-NBL1""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""SIOPEN""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}, {""IN"": {""study_id"": [""SIOPEN HR-NBL1""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically contributed by SIOPEN. These participants are part of the study identified as SIOPEN HR-NBL1 and are within the treatment arm labeled R2. All criteria must be met for inclusion in the cohort."
1P PRESENT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were at the initial diagnosis phase of their disease and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, they exhibited a molecular abnormality characterized by a 1p deletion, which was confirmed to be present."
1p deletion absent #2,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit a 1p deletion molecular abnormality, and the result of this abnormality is absent."
1p del present and 11q del present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, they exhibit either a 1p deletion or an 11q deletion, both of which are present as molecular abnormalities."
2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
1p or 11q,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion"", ""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion"", ""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients with Neuroblastoma (Schwannian Stroma-Poor) who meet one of the following criteria: either they have a 1p deletion that is present, or they have either a 1p deletion or an 11q deletion, both of which are present."
ANBL0032 Anti-GD2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, contributed by the COG data contributor. The participants are specifically from the study identified as ANBL0032 and are part of the treatment arm labeled RA+anti-GD2. All these criteria must be met for inclusion in the cohort."
ANBL0931,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically from the study identified as ANBL0931. The data contributors for this cohort are from the COG. All these criteria must be met for inclusion in the cohort."
ANBL0032 Anti-GD2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically from the study identified as ANBL0032. The data contributors are from the COG group, and the participants are those who were part of the treatment arm labeled RA+anti-GD2. All these criteria must be met for inclusion in the cohort."
HRNBL1 R2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN HR-NBL1""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""SIOPEN""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}, {""IN"": {""study_id"": [""SIOPEN HR-NBL1""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically contributed by SIOPEN. These participants are part of the study identified as SIOPEN HR-NBL1 and are within the treatment arm labeled R2. All criteria must be met for inclusion in the cohort."
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
1P ABSENT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, they have undergone molecular analysis which shows a 1p deletion, but the result of this molecular abnormality is absent."
prim,"{""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort includes individuals whose tumor assessments classify the tumor as ""Primary."""
ANBL0032 2009 and later,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2009, ""upperBound"": 2014}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2009}}, {""LTE"": {""year_at_disease_phase"": 2014}}]}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically from the study identified as ANBL0032. The data contributors are from the COG group. The participants were included if their year at the disease phase was between 2009 and 2014, inclusive. All these criteria were combined using an AND logic, meaning each participant had to meet all the specified conditions to be included in the cohort."
INRG stage MS,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage MS""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver"", ""Skin"", ""Bone Marrow""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage MS""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage"": [""Stage MS""]}}, {""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage MS""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver"", ""Skin"", ""Bone Marrow""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who have been diagnosed with Stage MS cancer according to the INRGSS staging system. These patients are at the initial diagnosis phase and have metastatic tumors. The tumors are located in the liver, skin, or bone marrow."
1p del present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by the presence of a 1p deletion.
Stage MS Quality Check,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage MS""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage MS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and are classified under the INRGSS staging system as Stage MS. Additionally, their tumor assessments indicate that the tumor is present and classified as metastatic."
1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
11Q PRESENT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by the presence of an 11q deletion.
1p del absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were at the initial diagnosis phase. These individuals have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, they have undergone molecular analysis which shows a 1p deletion, but the result of this molecular abnormality is absent."
1P OR 11Q,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). The cohort is divided into two groups based on molecular abnormalities: one group has a present 11q deletion, and the other group has a present 1p deletion."
1P AND 11Q,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, they exhibit either a 1p deletion or an 11q deletion, both of which are present as molecular abnormalities."
1p deletion absent #2,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit a 1p deletion molecular abnormality, but the result of this abnormality is absent."
11q deletion present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by the presence of an 11q deletion.
1p deletion absent,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, these patients underwent molecular analysis that revealed a 1p deletion, but the result of this molecular abnormality was absent."
11q deletion present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by the presence of an 11q deletion.
Real known mets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. At the time of initial diagnosis, these patients had tumors present in one or more of the following sites: Bone, Bone Marrow, Liver, Central Nervous System, Lung, Lymph Nodes, or Skin."
1p absent,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit a 1p deletion molecular abnormality, but the result of this abnormality is absent."
1pp del OR 11q del,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}]}",The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). The cohort includes two groups based on molecular abnormalities: one group with a 1p deletion present and another group with an 11q deletion present.
1p deletion absent #2,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have undergone molecular analysis. Specifically, these individuals exhibit a 1p deletion molecular abnormality, and the result of this abnormality is absent. All criteria must be met for inclusion in the cohort."
Ip Deletion Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and exhibit a specific molecular profile characterized by the absence of a 1p deletion.
1p deletion present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit a 1p deletion molecular abnormality, with this abnormality confirmed as present."
1p deletion present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by a 1p deletion, which is present in their molecular analysis results."
MaGIC (0 - <11yo),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 4014}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 4014}}]}]}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are part of the MaGIC consortium. These individuals were assessed at the initial diagnosis phase of their disease. The age at the time of tumor assessment for these individuals ranges from 0 to 4014 days.
1p present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who have a molecular analysis showing the presence of a 1p deletion.
11q present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also have a molecular abnormality characterized by the presence of an 11q deletion.
Recent_4n,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection criteria include patients with tumors present in the lymph nodes and absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone. Additionally, the patients were diagnosed between the years 2003 and 2020."
1p absent,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, these patients underwent molecular analysis that revealed a 1p deletion, but the result of this molecular abnormality was absent."
1p present,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, these patients exhibited a molecular abnormality characterized by a 1p deletion, which was confirmed to be present."
Any_bone_marrowmets,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2020. At the initial diagnosis, these patients were in Stage 4 of the disease. The cohort includes two groups: one group with tumors present in the bone marrow, and another group with tumors present in the central nervous system."
INSTRuCT - Latino male only,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}]}","The cohort consists of male participants who are Hispanic or Latino and are part of the INSTRuCT consortium. All three criteriasex, ethnicity, and consortium membershipmust be met for inclusion in the study."
1p or 11q,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who exhibit either a 1p deletion or an 11q deletion, with the presence of these molecular abnormalities confirmed."
4N_1990-2002,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Other""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2002. The selection criteria include patients with tumors present in the lymph nodes, and absent in the bone marrow, bone, liver, lung, other sites, skin, and central nervous system."
4N_2003-2020,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Bone""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Other""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease between the years 2003 and 2019. All patients were diagnosed with Stage 4 disease. The cohort includes patients with tumors present in the lymph nodes. Additionally, it includes patients with tumors absent in the following sites: bone, bone marrow, central nervous system, liver, lung, skin, and other sites."
INSTRuCT Latina fem only,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Female""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}]}",The cohort consists of female participants who are Hispanic or Latino and are part of the INSTRuCT consortium.
"INSTRuCT Lantino m, f","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Male""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""sex"": [""Female""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}]}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and are of Hispanic or Latino ethnicity. The selection includes both males and females, meaning participants can be either male or female, as long as they meet the other criteria."
dec2024-instfem,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG"", ""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG"", ""INSTRuCT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of either the INRG or INSTRuCT consortiums.
1p absent,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, these patients underwent molecular analysis that specifically looked for the 1p deletion abnormality, and the results showed that this abnormality was absent."
Ganglio,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase and have been diagnosed with the histology type ""Ganglioneuroblastoma, Nodular (Composite)."""
Test set 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INRG  2022-04 Cohort 3,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}]}]}","The cohort consists of patients associated with the INRG consortium. At the initial diagnosis phase, patients included are those whose age at tumor assessment is between 365 and 546 days. Additionally, patients are selected if they are classified under either the INRGSS staging system as Stage M or the INSS staging system as Stage 4."
INSTRuCT 2023-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Shoulder"", ""Upper Arm"", ""Forearm"", ""Hand"", ""Buttock"", ""Hip"", ""Thigh"", ""Knee"", ""Leg"", ""Lower Leg"", ""Foot"", ""Other Extremity"", ""Limbs, NOS"", ""Lower Arm""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Shoulder"", ""Upper Arm"", ""Forearm"", ""Hand"", ""Buttock"", ""Hip"", ""Thigh"", ""Knee"", ""Leg"", ""Lower Leg"", ""Foot"", ""Other Extremity"", ""Limbs, NOS"", ""Lower Arm""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and were at the initial diagnosis phase of their disease. The tumor sites for these individuals include the shoulder, upper arm, forearm, hand, buttock, hip, thigh, knee, leg, lower leg, foot, other extremity, limbs not otherwise specified (NOS), and lower arm."
spindle cell,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Spindle cell""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Spindle cell""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase of their disease and have a histology type classified as ""Spindle cell."""
F and Native HI,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Native Hawaiian or Other Pacific Islander""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Native Hawaiian or Other Pacific Islander""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female and identify as Native Hawaiian or Other Pacific Islander.
11q OR 1p,"{""value"": [{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}",{},"The cohort consists of patients who were initially diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and have either a 1p deletion or an 11q deletion, both of which must be present as molecular abnormalities."
Other_mets_present_1990-2002,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between 1990 and 2002. These patients have tumors present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, or Skin."
INSTRuCT Latino male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are Hispanic or Latino and are part of the INSTRuCT consortium.
4S 11q normal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4s disease. At the initial diagnosis phase, these individuals exhibit a molecular abnormality characterized by the presence of an 11q deletion, but the result of this molecular abnormality is absent."
4S 11q deletion,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4s disease. At the initial diagnosis phase, these individuals exhibit a molecular abnormality characterized by the presence of an 11q deletion."
sssss,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
spindle cell,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Spindle cell""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Spindle cell""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase of their disease and have a histology type classified as ""Spindle cell."""
INSTRuCT EpSSG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EpSSG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""data_contributor_id"": [""EpSSG""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium and have data contributed by the EpSSG. Both criteria must be met for inclusion in the study.
Stage 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 1""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were at the initial diagnosis phase of their disease. Specifically, these individuals were diagnosed with Stage 1 of the disease."
test_brian_1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of female participants who are part of the INRG consortium. These participants were at the initial diagnosis phase of their disease, specifically diagnosed with Stage 4 cancer according to the INSS staging system. They exhibit MYCN amplification, but the molecular abnormality result is absent. Additionally, the age at tumor assessment for these participants ranges from 547 days to 10,983 days."
AYA Tumor Assessments,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 5479, ""upperBound"": 14245}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 5479}}, {""LTE"": {""age_at_tumor_assessment"": 14245}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who were at the initial diagnosis phase of their disease. The age at tumor assessment for these individuals ranges from 5,479 days to 14,245 days."
MaGIC (11 - <18yo),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 4015, ""upperBound"": 6569}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 4015}}, {""LTE"": {""age_at_tumor_assessment"": 6569}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. Additionally, these individuals have an age at tumor assessment between 4015 and 6569 days."
ANBL0032 Anti-GD2 MYCN known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study. These participants were in the RA+anti-GD2 treatment arm. Additionally, the cohort includes individuals with MYCN Amplification, regardless of whether the molecular abnormality result was absent or present."
ANBL0032 Anti-GD2 1p known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study. These participants were in the RA+anti-GD2 treatment arm. Additionally, they were analyzed for the 1p deletion molecular abnormality, with results indicating either the presence or absence of this abnormality."
ANBL0931 11q known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. These participants have been analyzed for the molecular abnormality known as ""11q deletion,"" and the results of this analysis can be either ""Absent"" or ""Present."""
INTERACT - male only,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
MaGIC init dx testis,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}, {""IN"": {""tumor_site"": [""Testis""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. These individuals were at the initial diagnosis phase of their disease, with tumors classified as primary and located in the testis."
test_brian_2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants from the INRG consortium who were at the initial diagnosis phase of their disease. These participants were diagnosed with Stage 4 cancer according to the INSS staging system. They exhibited MYCN amplification, but the molecular abnormality result was absent. Additionally, the age at tumor assessment for these participants ranged from 547 days to 10,983 days."
INSTRuCT Known Survival,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of participants who are part of the INSTRuCT consortium and have known values for the obfuscated survival characteristic labeled as ""lkss."" Both criteria must be met for inclusion in the study."
ANBL0032 Anti-GD2 11q known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study. These participants were in the RA+anti-GD2 treatment arm. Additionally, they were analyzed for the 11q deletion molecular abnormality, with results indicating either the presence or absence of this abnormality."
ANBL0032 Anti-GD2 1p known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study. These participants were in the RA+anti-GD2 treatment arm. Additionally, they were analyzed for the 1p deletion molecular abnormality, with results indicating either the presence or absence of this abnormality."
ANBL0931 11q known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. These participants have undergone molecular analysis for the 11q deletion abnormality, and the results of this analysis can be either absent or present."
MaGIC (>18yo),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 6570, ""upperBound"": 8589}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 6570}}, {""LTE"": {""age_at_tumor_assessment"": 8589}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. These individuals were at the initial diagnosis phase of their disease, and their age at the time of tumor assessment was between 18 and 23.5 years."
Cohort A,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Asian""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Alveolar soft-part sarcoma (9581/3)"", ""Angiosarcoma of Soft Tissue (9120/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""!="": {""race"": ""Asian""}}]}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Alveolar soft-part sarcoma (9581/3)"", ""Angiosarcoma of Soft Tissue (9120/3)""]}}], ""path"": ""histologies""}}]}","The cohort consists of male individuals who are not of Asian race. These individuals have been diagnosed with one of the following histologies: Alveolar rhabdomyosarcoma (ARMS), Alveolar soft-part sarcoma (9581/3), or Angiosarcoma of Soft Tissue (9120/3). All criteria must be met for inclusion in the cohort."
ANBL0931 1p known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. These participants have undergone molecular analysis for the 1p deletion abnormality, and the results of this analysis can be either ""Absent"" or ""Present."""
ANBL0032 Anti-GD2 MYCN known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study. These participants were in the RA+anti-GD2 treatment arm. Additionally, the molecular analysis of these participants included the MYCN Amplification abnormality, with results indicating either the presence or absence of this abnormality."
ANBL0931 1p known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. These participants have undergone molecular analysis for the 1p deletion abnormality, with results indicating either the presence or absence of this abnormality."
other_mets_2003-2020,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase of their disease between the years 2003 and 2020. All patients included in the study were diagnosed with Stage 4 disease. The cohort is further divided based on the presence of tumors in specific sites: bone, bone marrow, central nervous system, liver, lung, or skin. Each subgroup includes patients with tumors present at the specified site. The data for the bone site is limited to diagnoses made between 2003 and 2019, while the other sites include diagnoses up to 2020."
"4S, 11q normal bis 2002","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1989, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1989}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4s disease between the years 1989 and 2002. At the initial diagnosis phase, these individuals did not exhibit the 11q deletion molecular abnormality."
NODAL stage I,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage I""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage I cancer. Both criteria must be met for inclusion in the study.
"4s, 11q deletion, bis 2002","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1989, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1989}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4s disease between the years 1989 and 2002. At the initial diagnosis phase, these individuals exhibited a molecular abnormality characterized by the presence of an 11q deletion."
ANBL0931 MYCN known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. These participants have undergone molecular analysis for MYCN Amplification, and the results of this analysis can be either absent or present."
"ANBL0931 11q, 1p, and MYCN known","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. The selection criteria include individuals with either an 11q deletion, a 1p deletion, or MYCN amplification, with the molecular abnormality result being either absent or present. Each participant must meet all these conditions."
"ANBL0032 Anti-GD2 11q, 1p, and MYCN known","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study and received the RA+anti-GD2 treatment arm. The participants were selected based on the presence or absence of specific molecular abnormalities, including 11q deletion, 1p deletion, and MYCN amplification. Each of these molecular abnormalities could either be present or absent in the participants."
Some filter I made,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""medical_histories.medical_history"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neurofibromatosis Type 1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""nested"": {""AND"": [{""IN"": {""medical_history"": [""Neurofibromatosis Type 1""]}}], ""path"": ""medical_histories""}}]}",The cohort consists of male subjects who have experienced one or more events and have a medical history of Neurofibromatosis Type 1.
Some filter I made,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""medical_histories.medical_history"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neurofibromatosis Type 1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""nested"": {""AND"": [{""IN"": {""medical_history"": [""Neurofibromatosis Type 1""]}}], ""path"": ""medical_histories""}}]}",The cohort consists of male subjects who have experienced one or more events and have a medical history of Neurofibromatosis Type 1.
MaGIC Mature and Immature Teratoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mature Teratoma"", ""Immature Teratoma""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mature Teratoma"", ""Immature Teratoma""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants from the MaGIC consortium who have been diagnosed with either Mature Teratoma or Immature Teratoma histologies.
ANBL0032 Anti-GD2 11q known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study. These participants were in the RA+anti-GD2 treatment arm. Additionally, they were analyzed for the 11q deletion molecular abnormality, with results indicating either the presence or absence of this abnormality."
"ANBL0032 Anti-GD2 11q, 1p, and MYCN known","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the INRG consortium who were part of the ANBL0032 study and received the RA+anti-GD2 treatment arm. The participants were selected based on the presence or absence of specific molecular abnormalities, including 11q deletion, 1p deletion, and MYCN amplification. Each of these molecular abnormalities could be either present or absent in the participants."
FOXO1-pax 7 less than 5 years,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""FOXO1-PAX7 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 92, ""upperBound"": 1824}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 92}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS) who have a molecular abnormality characterized by the presence of the FOXO1-PAX7 fusion. The age of these individuals at the time of tumor assessment ranges from 92 days to 1824 days.
FOXO1 fusion less than 5 years,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and have been diagnosed with Alveolar rhabdomyosarcoma (ARMS). These individuals exhibit the FOXO1-PAX3 fusion molecular abnormality. Additionally, the age at tumor assessment for these individuals ranges from 3 days to 1824 days."
GCT COG Stage 1 and 2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I"", ""Stage II""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""COG""]}}, {""IN"": {""stage"": [""Stage I"", ""Stage II""]}}], ""path"": ""stagings""}}]}","The cohort consists of participants from the MaGIC consortium who have been staged using the COG system. Specifically, these participants are classified as either Stage I or Stage II."
1990-2002 Stage 4 no bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1991 and 2002. These patients are all at Stage 4 of their disease. The cohort includes subgroups based on tumor site and state: patients with absent tumors in the bone marrow or bone, and patients with present tumors in the central nervous system, liver, lung, skin, or other sites."
"4S <30days, no MYCN","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s"", ""Stage MS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 30}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 30}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s"", ""Stage MS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with either Stage 4s or Stage MS of the disease. They exhibit MYCN amplification as a molecular abnormality, but the result of this molecular abnormality is absent. Additionally, the age at tumor assessment for these individuals ranges from 0 to 30 days."
ANBL0931 MYCN known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. These participants have undergone molecular analysis for MYCN Amplification, and the results of this analysis can be either ""Absent"" or ""Present."""
"ANBL0931 11q, 1p, and MYCN known","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the INRG consortium who are part of the ANBL0931 study. The selection criteria include individuals with either an 11q deletion, a 1p deletion, or MYCN amplification, with the molecular abnormality result being either absent or present. Each participant must meet all these conditions."
GCT St 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""COG""]}}, {""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the MaGIC consortium and have been classified under the COG staging system as Stage IV.
1990-2002 Stage 4 known metastatic site,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 1990 and 2002. The tumor sites include Bone, Bone Marrow, Central Nervous System, Lung, Liver, Skin, Other, and Lymph Nodes. Patients with an unknown tumor state are excluded from this cohort."
test_1,"{""disease_phase:Relapse"": {""filter"": {""tumor_assessments.tumor_classification"": {""selectedValues"": [""Metastatic""]}}}, ""disease_phase:Initial Diagnosis"": {""filter"": {""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX7 fusion""]}}}}",{},"The cohort consists of two groups of patients. The first group includes patients in the relapse phase of their disease, specifically those whose tumor assessments classify their tumors as metastatic. The second group includes patients at the initial diagnosis phase who have a molecular analysis showing the presence of the FOXO1-PAX7 fusion abnormality."
FOXO1 fusion less than 5 years,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 3, ""upperBound"": 1824}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 3}}, {""LTE"": {""age_at_tumor_assessment"": 1824}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and have been diagnosed with Alveolar rhabdomyosarcoma (ARMS). These individuals exhibit the FOXO1-PAX3 fusion molecular abnormality. Additionally, the age at tumor assessment for these individuals ranges from 3 days to 1824 days (approximately 5 years)."
Eser Data Request,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}], ""path"": ""studies""}}]}]}",The cohort consists of participants from the INRG consortium who meet one of the following criteria: they are part of study ANBL0032 and received the RA+anti-GD2 treatment arm; they are part of study ANBL0931; or they received the R2 treatment arm.
Male Asian - all consortia,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of individuals who are male and identify as Asian. Both criteria must be met for inclusion in the cohort.
"Male, Asian, Black","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian"", ""Black or African American""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male individuals who are either Asian or Black or African American.
"Male, Asian, Black","{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian"", ""Black or African American""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male individuals who are either Asian or Black or African American.
test,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""LDH"", ""Ferritin""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""LDH"", ""Ferritin""]}}], ""path"": ""labs""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone lab tests for LDH and Ferritin. These participants have a known survival status and exhibit a molecular abnormality characterized by MYCN Amplification, with the abnormality result being present."
INRG (all patients),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INSTRuCT (all patients),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
INSTRuCT (all patients),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
ANBL0931,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically from the study identified as ANBL0931. The data for this cohort is contributed by the Children's Oncology Group (COG). All these criteria must be met for inclusion in the cohort."
Eser Data Request,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the INRG consortium who meet one of the following criteria: they are part of study ANBL0032 and received the RA+anti-GD2 treatment arm, or they are part of study ANBL0931, or they received the R2 treatment arm."
INRG (all patients),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
Group A,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2007, ""upperBound"": 2018}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""IN"": {""sex"": [""Male""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2007}}, {""LTE"": {""year_at_disease_phase"": 2018}}]}]}",The cohort consists of male participants who are part of the NODAL consortium. These participants were in a specific disease phase between the years 2007 and 2018.
INSTRuCT extremity ttumors,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Upper Arm"", ""Forearm"", ""Hand"", ""Shoulder"", ""Foot"", ""Buttock"", ""Knee"", ""Lower Leg"", ""Other Extremity"", ""Thigh""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Upper Arm"", ""Forearm"", ""Hand"", ""Shoulder"", ""Foot"", ""Buttock"", ""Knee"", ""Lower Leg"", ""Other Extremity"", ""Thigh""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INSTRuCT consortium who have tumors located in specific sites. These sites include the upper arm, forearm, hand, shoulder, foot, buttock, knee, lower leg, other extremities, and thigh."
STS-Extremity-TL#2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Upper Arm"", ""Forearm"", ""Hand"", ""Shoulder"", ""Buttock"", ""Foot"", ""Lower Leg"", ""Knee"", ""Thigh"", ""Other Extremity"", ""Lower Arm"", ""Leg"", ""Limbs, NOS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Upper Arm"", ""Forearm"", ""Hand"", ""Shoulder"", ""Buttock"", ""Foot"", ""Lower Leg"", ""Knee"", ""Thigh"", ""Other Extremity"", ""Lower Arm"", ""Leg"", ""Limbs, NOS""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals were at the initial diagnosis phase of their disease, and their tumor assessments indicated that the tumor site was located in one of the following areas: Upper Arm, Forearm, Hand, Shoulder, Buttock, Foot, Lower Leg, Knee, Thigh, Other Extremity, Lower Arm, Leg, or Limbs, not otherwise specified (NOS)."
MaGIC (11 - <18yo),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 4015, ""upperBound"": 6569}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 4015}}, {""LTE"": {""age_at_tumor_assessment"": 6569}}]}]}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are part of the MaGIC consortium and were at the initial diagnosis phase of their disease. The age at tumor assessment for these individuals ranges from 4015 to 6569 days.
NODAL stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
2003-2020 non-4n stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2019. At the initial diagnosis, these patients were classified as having Stage 4 disease. Their tumors were metastatic and present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, or Skin."
GNB intermixed,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich). Both criteria must be met for inclusion in the study."
Eser Orhan data request,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}], ""path"": ""studies""}}]}]}",The cohort consists of participants from the INRG consortium who meet one of the following criteria: they are part of study ANBL0032 and received the RA+anti-GD2 treatment arm; they are part of study ANBL0931; or they received the R2 treatment arm.
1990-2002 Stage 4 CNS Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of patients who are part of the INRG consortium. These patients have Stage 4 tumors located in the Central Nervous System, with the tumor being present. Additionally, the patients were diagnosed between the years 1991 and 2002."
Yolk Sac w/ age at dx,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yolk Sac Tumor""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 8589}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 8589}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Yolk Sac Tumor""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the MaGIC consortium and were at the initial diagnosis phase of their disease. These individuals have a histological diagnosis of Yolk Sac Tumor. Additionally, their age at the time of tumor assessment ranges from 1 to 8589 days."
Mixed Germ Cell w/ age at dx,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 8589}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 8589}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor""]}}]}]}], ""path"": ""histologies""}}]}",The cohort consists of individuals who are part of the MaGIC consortium and were at the initial diagnosis phase of their disease. These individuals have a histology of Mixed Germ Cell Tumor and were assessed for tumors at an age between 1 and 8589 days.
test_format_of_filter_set,"{""value"": {""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ABVE-PCx2+IFRT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""ABVE-PCx2+IFRT""]}}], ""path"": ""studies""}}]}","The cohort includes participants who are part of studies where the treatment arm is ""ABVE-PCx2+IFRT""."
Stage 3 and 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage III"", ""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""COG""]}}, {""IN"": {""stage"": [""Stage III"", ""Stage IV""]}}], ""path"": ""stagings""}}]}","The cohort consists of participants from the MaGIC consortium who have been staged using the COG system. Specifically, these participants are classified as either Stage III or Stage IV."
GCT St 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""COG""]}}, {""IN"": {""stage"": [""Stage I""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants from the MaGIC consortium who are classified under the COG staging system and are specifically at Stage I.
MaGIC AFP < 10000,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AFP""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 5, ""upperBound"": 9999}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""lab_result_numeric"": 5}}, {""LTE"": {""lab_result_numeric"": 9999}}]}, {""IN"": {""lab_test"": [""AFP""]}}]}]}], ""path"": ""labs""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. These individuals were at the initial diagnosis phase of their disease. During this phase, they underwent lab tests where the AFP (Alpha-fetoprotein) test was conducted. The numeric results of this AFP test were between 5 and 9999."
MaGIC AFP >= 10000,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AFP""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 10000, ""upperBound"": 867638}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""lab_result_numeric"": 10000}}, {""LTE"": {""lab_result_numeric"": 867638}}]}, {""IN"": {""lab_test"": [""AFP""]}}]}]}], ""path"": ""labs""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. These individuals were at the initial diagnosis phase of their disease. During this phase, they underwent a lab test for AFP, and their lab results showed numeric values ranging from 10,000 to 867,638."
Seminoma / Dysgerminoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Seminoma"", ""Seminoma/Dysgerminoma/Germinoma""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Seminoma"", ""Seminoma/Dysgerminoma/Germinoma""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and have a histology diagnosis of either Seminoma or Seminoma/Dysgerminoma/Germinoma.
Mixed GCT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and have a histology diagnosis of Mixed Germ Cell Tumor. Both criteria must be met for inclusion in the cohort.
MaGIC Demo query,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Dysgerminoma"", ""Embryonal Carcinoma""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Dysgerminoma"", ""Embryonal Carcinoma""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and have a histology diagnosis of either Dysgerminoma or Embryonal Carcinoma. Both criteria must be met for inclusion in the study.
Cohort B,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Not Reported""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""race"": [""Not Reported""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants whose race is not reported and who are part of the INRG consortium. All three criteria must be met for inclusion in the cohort.
inrg,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
MGCT Testis >2000,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2017}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2017}}]}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Testis""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium and have been diagnosed with Mixed Germ Cell Tumor. The diagnosis must have occurred between the years 2000 and 2017. Additionally, the tumor site for these individuals is specifically located in the testis."
MGCT testis <2000,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1989, ""upperBound"": 2000}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1989}}, {""LTE"": {""year_at_disease_phase"": 2000}}]}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Testis""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium and have been diagnosed with Mixed Germ Cell Tumor. The diagnosis occurred between the years 1989 and 2000. Additionally, the tumor site for these individuals is specifically located in the testis."
Non-seminomatous GCT Testis <11 years,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor"", ""Mature Teratoma"", ""Embryonal Carcinoma"", ""Teratoma, NOS"", ""Yolk Sac Tumor""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis"", ""Retroperitoneum Lymph Nodes""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 174, ""upperBound"": 4015}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Testis"", ""Retroperitoneum Lymph Nodes""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 174}}, {""LTE"": {""age_at_tumor_assessment"": 4015}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor"", ""Mature Teratoma"", ""Embryonal Carcinoma"", ""Teratoma, NOS"", ""Yolk Sac Tumor""]}}], ""path"": ""histologies""}}]}","The cohort consists of male participants who are part of the MaGIC consortium. These individuals have been diagnosed with one of the following histologies: Mixed Germ Cell Tumor, Mature Teratoma, Embryonal Carcinoma, Teratoma (not otherwise specified), or Yolk Sac Tumor. The tumor sites are either the testis or retroperitoneum lymph nodes. The age at tumor assessment for these participants ranges from 174 days to 4015 days."
Non-seminomatous GCT Testis 11-18 years,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor"", ""Mature Teratoma"", ""Embryonal Carcinoma"", ""Teratoma, NOS"", ""Yolk Sac Tumor""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis"", ""Retroperitoneum Lymph Nodes""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 4015, ""upperBound"": 6570}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Testis"", ""Retroperitoneum Lymph Nodes""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 4015}}, {""LTE"": {""age_at_tumor_assessment"": 6570}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor"", ""Mature Teratoma"", ""Embryonal Carcinoma"", ""Teratoma, NOS"", ""Yolk Sac Tumor""]}}], ""path"": ""histologies""}}]}","The cohort consists of male participants from the MaGIC consortium. These individuals have been diagnosed with specific histologies, including Mixed Germ Cell Tumor, Mature Teratoma, Embryonal Carcinoma, Teratoma (not otherwise specified), and Yolk Sac Tumor. The tumor sites are located in the testis or retroperitoneum lymph nodes. Additionally, the age at tumor assessment for these participants ranges from 4015 to 6570 days."
GNB nodular all,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the INRG consortium and have a histology diagnosis of Ganglioneuroblastoma, Nodular (Composite). Both criteria must be met for inclusion in the study."
All Nodal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}]}",The cohort consists of participants who are part of the NODAL consortium.
Non-seminomatous GCT Testis 18-30 years,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor"", ""Mature Teratoma"", ""Embryonal Carcinoma"", ""Teratoma, NOS"", ""Yolk Sac Tumor""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis"", ""Retroperitoneum Lymph Nodes""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 6570, ""upperBound"": 8501}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor"", ""Mature Teratoma"", ""Embryonal Carcinoma"", ""Teratoma, NOS"", ""Yolk Sac Tumor""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 6570}}, {""LTE"": {""age_at_tumor_assessment"": 8501}}]}, {""IN"": {""tumor_site"": [""Testis"", ""Retroperitoneum Lymph Nodes""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants who are part of the MaGIC consortium. These individuals have been diagnosed with specific histologies, including Mixed Germ Cell Tumor, Mature Teratoma, Embryonal Carcinoma, Teratoma (not otherwise specified), or Yolk Sac Tumor. The tumor assessments for these participants indicate that the tumors are located in the testis or retroperitoneum lymph nodes. Additionally, the age at tumor assessment for these individuals ranges from 18 to 23 years."
instruct,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
MaGIC Mixed GCT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mixed Germ Cell Tumor""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Mixed Germ Cell Tumor""]}}]}]}], ""path"": ""histologies""}}]}",The cohort consists of individuals who are part of the MaGIC consortium. These individuals were at the initial diagnosis phase of their disease and were diagnosed with a mixed germ cell tumor.
MaGIC YST,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yolk Sac Tumor""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Yolk Sac Tumor""]}}]}]}], ""path"": ""histologies""}}]}",The cohort consists of individuals who are part of the MaGIC consortium and have been diagnosed with a Yolk Sac Tumor at the initial diagnosis phase.
Choriocarcinoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Choriocarcinoma""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Choriocarcinoma""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and have a histology diagnosis of Choriocarcinoma. Both criteria must be met for inclusion in the study.
HRNBL1 R2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN HR-NBL1""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""R2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""SIOPEN""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""R2""]}}, {""IN"": {""study_id"": [""SIOPEN HR-NBL1""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, specifically contributed by SIOPEN. The study focuses on individuals involved in the SIOPEN HR-NBL1 study, who are part of the R2 treatment arm. All these criteria must be met for inclusion in the cohort."
MRC Patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MRC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""data_contributor_id"": [""MRC""]}}]}",The cohort consists of participants who are part of the MaGIC consortium and have data contributed by the MRC. Both criteria must be met for inclusion in the cohort.
me,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hemoglobin"", ""Platelets"", ""WBC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""Hemoglobin"", ""Platelets"", ""WBC""]}}], ""path"": ""labs""}}]}","The cohort includes individuals who have undergone laboratory tests for Hemoglobin, Platelets, and White Blood Cells (WBC)."
inrg2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
ANBL0032 Anti-GD2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0032""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""RA+anti-GD2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0032""]}}, {""IN"": {""treatment_arm"": [""RA+anti-GD2""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium, contributed by the COG data contributor. The participants are specifically from the study identified as ANBL0032 and are part of the treatment arm labeled RA+anti-GD2. All these criteria must be met for inclusion in the cohort."
MaGIC Mature and Immature Teratoma,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""MaGIC""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mature Teratoma"", ""Immature Teratoma""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Mature Teratoma"", ""Immature Teratoma""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants from the MaGIC consortium who have been diagnosed with either Mature Teratoma or Immature Teratoma histologies.
AIEOP Patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AIEOP""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""data_contributor_id"": [""AIEOP""]}}]}",The cohort consists of participants who are part of the MaGIC consortium and have data contributed by AIEOP. Both criteria must be met for inclusion in the cohort.
Group A,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2007, ""upperBound"": 2018}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""IN"": {""sex"": [""Male""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2007}}, {""LTE"": {""year_at_disease_phase"": 2018}}]}]}","The cohort consists of male participants who are part of the NODAL consortium. These participants were in a specific disease phase between the years 2007 and 2018, inclusive."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit the presence of MYCN Amplification as a molecular abnormality."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit a molecular abnormality characterized by MYCN Amplification, which is confirmed to be present."
instruct2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
INRG  2024-03,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with a disease stage classified as Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, or Stage MS. The diagnosis or relevant disease phase occurred between the years 2000 and 2023."
1p or 11q present,"{""value"": [{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). The selection criteria included two groups: one group with a molecular abnormality of 1p deletion that was present, and another group with a molecular abnormality of 11q deletion that was present."
MYCN non-amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and have undergone molecular analysis. The analysis shows the presence of MYCN Amplification, but the result for this molecular abnormality is absent. All these criteria must be met for inclusion in the cohort."
1990-2002 >18mo Stage 4 Node Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with the disease between 1990 and 2002. At the time of initial diagnosis, these patients were in Stage 4 of the disease. Their tumor assessments indicated the presence of metastatic tumors located in the lymph nodes. The age of the patients at the time of tumor assessment ranged from 547 to 8367 days."
1221_patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL1221""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL1221""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID ANBL1221. Both criteria must be met for inclusion in the cohort.
ARMS+ERMS - delete,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of individuals diagnosed with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS). The selection criteria require that participants have a histology of either ARMS or ERMS, as specified in their medical records."
11q present,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""11q deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). Additionally, these patients exhibited a molecular abnormality characterized by the presence of an 11q deletion."
1p and 11q,"{""value"": [{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). These patients also exhibited either a 1p deletion or an 11q deletion, with the molecular abnormality confirmed as present."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit the presence of MYCN Amplification as a molecular abnormality."
1990-2020 >18mo Non 4N Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between 1990 and 2020. At the time of tumor assessment, these patients had metastatic tumors that were present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, or Skin. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to 30 years (10,983 days)."
b1_patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL00B1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL00B1""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID ANBL00B1. Both criteria must be met for inclusion in the cohort.
GNB nodular non-MYCN,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with Ganglioneuroblastoma, Nodular (Composite). Additionally, these participants have undergone molecular analysis, which shows the presence of MYCN Amplification as a molecular abnormality, but the result of this abnormality is absent."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit a molecular abnormality characterized by MYCN Amplification, which is confirmed to be present."
MYCN amplification,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium. These patients have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and are classified under Stage M according to the INRGSS staging system. Additionally, they exhibit MYCN amplification, which is confirmed to be present through molecular analysis."
MYCN amplification,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit a molecular abnormality characterized by MYCN Amplification, which is confirmed to be present."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These patients are classified under the INRGSS staging system as Stage M. Additionally, they exhibit MYCN Amplification, which is confirmed to be present through molecular analysis."
temp-delete2,"{""value"": {""molecular_analysis.anaplasia"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""molecular_analysis.anaplasia_extent"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Focal""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""anaplasia"": [""Present""]}}, {""AND"": [{""!="": {""anaplasia_extent"": ""Focal""}}]}], ""path"": ""molecular_analysis""}}]}","The cohort includes individuals who have anaplasia present in their molecular analysis. However, those with a focal extent of anaplasia are excluded from the selection."
temp-delete,"{""value"": {""molecular_analysis.anaplasia"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""molecular_analysis.anaplasia_extent"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Focal""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""anaplasia"": [""Present""]}}, {""AND"": [{""!="": {""anaplasia_extent"": ""Focal""}}]}], ""path"": ""molecular_analysis""}}]}","The cohort includes individuals with molecular analysis indicating the presence of anaplasia. However, individuals with focal anaplasia extent are excluded from the cohort."
COG all,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""COG""]}}]}",The cohort includes participants whose data was contributed by the COG (Children's Oncology Group).
ARMS OR ERMS2,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}",The cohort consists of individuals diagnosed with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS). The selection criteria include patients with histologies specifically identified as either ARMS or ERMS.
DSRCT Female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Desmoplastic small round cell tumour (8806/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Desmoplastic small round cell tumour (8806/3)""]}}], ""path"": ""histologies""}}]}","The cohort consists of female participants who have been diagnosed with desmoplastic small round cell tumour, identified by the histology code 8806/3."
2003-2020 >18mo Non-4N Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. At the time of tumor assessment, these patients had metastatic tumors that were present in one or more of the following sites: bone, bone marrow, central nervous system, liver, lung, or skin. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to 30 years (10,983 days)."
Censor Status is Censored - no events,"{""value"": {""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject is censored (i.e. has had no event(s))""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""censor_status"": [""Subject is censored (i.e. has had no event(s))""]}}]}","The cohort includes subjects who are censored, meaning they have not experienced any events."
ARMS OR ERMS2,"{""value"": [{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort includes individuals with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS) histologies. Participants are selected if they have a diagnosis of either ARMS or ERMS, as specified in their histological records."
DSRCT Male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Desmoplastic small round cell tumour (8806/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Desmoplastic small round cell tumour (8806/3)""]}}], ""path"": ""histologies""}}]}","The cohort consists of male participants who have been diagnosed with desmoplastic small round cell tumour, identified by the histology code 8806/3. Both criteria must be met for inclusion in the study."
DSRCT All,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Desmoplastic small round cell tumour (8806/3)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Desmoplastic small round cell tumour (8806/3)""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals diagnosed with Desmoplastic Small Round Cell Tumour, as indicated by the histology code 8806/3."
NS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically Nodular Sclerosis, NOS."
INTERACT - male only,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
INTERACT  - all female subjects,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
NLPHL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically the Nodular Lymphocyte Predominance subtype."
St3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage III""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage III""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage III cancer.
St2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage II""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage II cancer. Both criteria must be met for inclusion in the study.
St4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
St1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage I""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage I cancer.
Bulk,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been identified with bulk disease.
RER,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rapid Early Response (adequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Rapid Early Response (adequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have demonstrated a ""Rapid Early Response (adequate)"" in their interim responses."
Censor Status = one or more events,"{""value"": {""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""censor_status"": [""Subject has had one or more events""]}}]}","The cohort includes subjects who have experienced one or more events, as indicated by their censor status."
ESR<30,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ESR""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 29}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""ESR""]}}, {""AND"": [{""GTE"": {""lab_result_numeric"": 0}}, {""LTE"": {""lab_result_numeric"": 29}}]}], ""path"": ""labs""}}]}","The cohort consists of individuals who are part of the NODAL consortium. These individuals have undergone an ESR lab test, and their numeric lab results for this test fall within the range of 0 to 29, inclusive."
NS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically Nodular Sclerosis, NOS."
HL - Stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ann Arbor""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""Ann Arbor""]}}, {""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have been staged using the Ann Arbor system. Specifically, these individuals are classified as Stage IV according to the Ann Arbor staging criteria."
INRG-JUNE25,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
NBL L1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the INRG consortium. These participants are specifically at Stage L1 according to the INRGSS staging system. All criteria must be met for inclusion in the cohort.
1990-2002 >18mo Non-4N Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2002. At the time of tumor assessment, these patients had metastatic tumors that were present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, or Skin. The age of the patients at the time of tumor assessment ranged from 547 to 8367 days."
INSTRuCT Latino fem2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are Hispanic or Latino and are part of the INSTRuCT consortium.
test,"{""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Abdominal Wall""]}, ""tumor_assessments.longest_diam_dim1"": {""__type"": ""RANGE"", ""lowerBound"": 85, ""upperBound"": 250}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Primary"", ""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""OR""}","{""OR"": [{""nested"": {""OR"": [{""AND"": [{""GTE"": {""longest_diam_dim1"": 85}}, {""LTE"": {""longest_diam_dim1"": 250}}]}, {""IN"": {""tumor_site"": [""Abdominal Wall""]}}, {""AND"": [{""!="": {""tumor_classification"": ""Primary""}}, {""!="": {""tumor_classification"": ""Metastatic""}}]}], ""path"": ""tumor_assessments""}}]}","The cohort includes individuals with tumors located in the abdominal wall or with a longest diameter between 85 and 250 units. Tumors classified as either ""Primary"" or ""Metastatic"" are excluded from the selection. The criteria are applied such that any of these conditions can qualify an individual for inclusion."
Stage 4 CNS Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and have been diagnosed with Stage 4 cancer according to the INSS staging system. At the initial diagnosis phase, these patients have metastatic tumors that are present in the central nervous system."
GNB nodular MYCN amp,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have a histological diagnosis of Ganglioneuroblastoma, Nodular (Composite). Additionally, they exhibit a molecular abnormality characterized by MYCN Amplification, and this abnormality is confirmed to be present. All these criteria must be met for inclusion in the cohort."
All Nodal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}]}",The cohort consists of participants who are part of the NODAL consortium.
ESR30+,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ESR""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 30, ""upperBound"": 165}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""ESR""]}}, {""AND"": [{""GTE"": {""lab_result_numeric"": 30}}, {""LTE"": {""lab_result_numeric"": 165}}]}], ""path"": ""labs""}}]}","The cohort consists of individuals who are part of the NODAL consortium. These individuals have undergone an ESR lab test, and their numeric lab results for this test fall within the range of 30 to 165, inclusive."
NLPHL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically the Nodular Lymphocyte Predominance subtype. Both criteria must be met for inclusion in the study."
HL - RER,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rapid Early Response (adequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Rapid Early Response (adequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have demonstrated a ""Rapid Early Response (adequate)"" in their interim responses."
HL-Stage I,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ann Arbor""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""Ann Arbor""]}}, {""IN"": {""stage"": [""Stage I""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants from the NODAL consortium who have been classified under Stage I according to the Ann Arbor staging system.
HL - SER,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Slow Early Response (inadequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Slow Early Response (inadequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have shown a ""Slow Early Response (inadequate)"" in their interim responses. Both criteria must be met for inclusion in the study."
NLPHL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically the Nodular Lymphocyte Predominance subtype."
bhcg,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""-hCG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""-hCG""]}}], ""path"": ""labs""}}]}",The cohort includes individuals who have undergone laboratory testing for -hCG.
Mediastinal Primary,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Mediastinum""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Mediastinum""]}}, {""IN"": {""tumor_classification"": [""Primary""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. These individuals have tumors located in the mediastinum, and the tumors are classified as primary. All these criteria must be met for inclusion in the cohort."
All AML,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
NBL Biology AYA,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL00B1"", ""APEC14B1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 5475, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL00B1"", ""APEC14B1""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 5475}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have participated in either the ANBL00B1 or APEC14B1 studies. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) histology. Additionally, the age at tumor assessment for these individuals ranges from 15 to 30 years."
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have undergone molecular analysis. Specifically, these participants have been tested for the FLT3 internal tandem duplication (ITD) molecular abnormality, and the result of this test is absent."
NODAL - rapid early response ,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rapid Early Response (adequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Rapid Early Response (adequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have demonstrated a ""Rapid Early Response (adequate)"" in their interim responses."
NODAL - slow early response,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Slow Early Response (inadequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Slow Early Response (inadequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have shown a ""Slow Early Response (inadequate)"" in their interim responses. Both criteria must be met for inclusion in the study."
ahod rapid early,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AHOD0031""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rapid Early Response (adequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Rapid Early Response (adequate)""]}}], ""path"": ""subject_responses""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""AHOD0031""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the NODAL consortium who are part of the study identified as AHOD0031. These participants have demonstrated a ""Rapid Early Response (adequate)"" in their interim response assessments."
ahod rapid early,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AHOD0031""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rapid Early Response (adequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Rapid Early Response (adequate)""]}}], ""path"": ""subject_responses""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""AHOD0031""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the NODAL consortium who are part of the study identified as AHOD0031. These participants have demonstrated a ""Rapid Early Response (adequate)"" in their interim response assessments."
Neuroblastoma <5yo,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). Additionally, the age at tumor assessment for these individuals ranges from 0 to 1825 days."
Neuroblastoma <5yo,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). Additionally, the age at tumor assessment for these individuals ranges from 0 to 1825 days."
1990-2002 >18mo Stage 4 CNS Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2002. These patients had tumors classified as metastatic, located in the central nervous system, and present at the time of assessment. The age of patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 22.9 years (8367 days)."
1990-2002 >18mo Stage 4 Liver Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2002. At the time of tumor assessment, these patients had metastatic tumors present in the liver. The age of the patients at the time of tumor assessment ranged from 547 days to 8367 days."
1990-2002 >18mo Stage 4 Lung Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed with their disease between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors present in the lung. The age of the patients at the time of tumor assessment ranged from 547 days to 8367 days."
Neuroblastoma <5yo 1p deletion,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). These individuals exhibit a 1p deletion molecular abnormality, which is confirmed to be present. Additionally, the age at tumor assessment for these individuals ranges from 0 to 1825 days."
ARMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with either Alveolar rhabdomyosarcoma (ARMS) or Embryonal rhabdomyosarcoma (ERMS).
NODAL - all except HLHR13,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""HLHR13""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""HLHR13""}}]}], ""path"": ""studies""}}]}","The cohort consists of participants from the ""NODAL"" consortium. However, individuals from the study with the ID ""HLHR13"" are excluded from this selection."
nodal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}]}",The cohort consists of participants who are part of the NODAL consortium.
arma foxpax3 fusion absent,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who have undergone molecular analysis. Specifically, these individuals do not exhibit the FOXO1-PAX3 fusion abnormality, as the result for this molecular abnormality is absent."
arms foxpax3 fusion present,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX3 fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) who also have a molecular analysis showing the presence of the FOXO1-PAX3 fusion abnormality.
MAGiC - all studies except DFCI registry,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""DFCI Registry""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""DFCI Registry""}}]}], ""path"": ""studies""}}]}","The cohort includes participants from the MaGIC consortium, but excludes those from the DFCI Registry study."
INTERACT - all fem,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
"MaGIC - all studies, ^DFCI, +biopsy","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""DFCI Registry""]}, ""biopsy_surgical_procedures.procedure_type"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Biopsy""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""DFCI Registry""}}]}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""procedure_type"": [""Biopsy""]}}], ""path"": ""biopsy_surgical_procedures""}}]}","The cohort consists of participants who are part of the MaGIC consortium. Individuals from the ""DFCI Registry"" study are excluded. Additionally, participants must have undergone a biopsy procedure."
"Neuroblastoma 11q deletion, <5yo","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by the presence of an 11q deletion. Additionally, the age at tumor assessment for these patients ranges from 0 to 1825 days."
GNBnodstg2b3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3"", ""Stage 2b""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3"", ""Stage 2b""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2010 and 2023. At the initial diagnosis phase, these patients have a histology of Ganglioneuroblastoma, Nodular (Composite) and are staged using the INSS system, specifically at Stage 3 or Stage 2b."
"Neuroblastoma 11q deletion, <5yo","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1825}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1825}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. These patients have a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular abnormality characterized by the presence of an 11q deletion. Additionally, the age of the patients at the time of tumor assessment ranges from 0 to 1825 days."
Orbit III EMB BOT SPD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group III""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Spindle cell""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Eyelid"", ""Orbit""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Eyelid"", ""Orbit""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group III""]}}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INSTRuCT consortium. These patients have tumors classified as Group III according to the IRS staging system. The histological types of the tumors include Embryonal rhabdomyosarcoma (ERMS), Botryoid rhabdomyosarcoma (BRMS), or Spindle cell. Additionally, the tumor sites are specifically located in the eyelid or orbit. All these criteria must be met for inclusion in the cohort."
GNb No stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium. These patients were at the initial diagnosis phase and had a histological diagnosis of Ganglioneuroblastoma, Nodular (Composite). Additionally, they were classified as Stage 4 in their disease staging."
Saved 8,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}]}]}",The cohort consists of male participants who are part of the INRG consortium.
Orbit III ALV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group III""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Eyelid"", ""Orbit""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Eyelid"", ""Orbit""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group III""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}","The cohort consists of patients who are part of the INSTRuCT consortium. These patients have been diagnosed with Alveolar rhabdomyosarcoma (ARMS) and are classified under IRS Group III staging. Additionally, their tumors are located in the eyelid or orbit. All these criteria must be met for inclusion in the cohort."
Saved 21,"{""value"": [{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""race"": [""Asian""]}}]}, {""AND"": [{""IN"": {""sex"": [""Female""]}}]}]}",The cohort consists of individuals who are both Asian and female.
INSS Stage 1-3,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3"", ""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3"", ""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who have been staged using the INSS system and are classified as Stage 1, Stage 2a, Stage 2b, or Stage 3."
Ganglio,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are at the initial diagnosis phase of their disease. Specifically, these individuals have a histology of ""Ganglioneuroblastoma, Nodular (Composite)"" and a histology grade of ""Differentiating."""
GNBno,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage 3"", ""Stage 2b""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage 3"", ""Stage 2b""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have a histological diagnosis of Ganglioneuroblastoma, Nodular (Composite) and are classified in one of the following stages: Stage 4, Stage 3, or Stage 2b."
Relapse Patients,"{""value"": {""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic"", ""Primary"", ""Regional""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic"", ""Primary"", ""Regional""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are in the relapse phase of their disease. These individuals have tumor assessments indicating that their tumor classification is either metastatic, primary, or regional."
1990-2002 >18mo Stage 4 Skin Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals from the INRG consortium who were initially diagnosed with the disease between 1990 and 2002. At the time of initial diagnosis, these individuals were classified as Stage 4 and had metastatic tumors present on the skin. The age at tumor assessment for these individuals ranged from 547 to 8367 days."
Oribt III EMB BOT SPL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group III""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Spindle cell"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Botryoid rhabdomyosarcoma (BRMS)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Orbit"", ""Eyelid""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Orbit"", ""Eyelid""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Spindle cell"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Botryoid rhabdomyosarcoma (BRMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""irs_group"": [""Group III""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INSTRuCT consortium and were at the initial diagnosis phase. These patients have tumors located in the orbit or eyelid and are classified under IRS Group III. Additionally, their histology is identified as either spindle cell, embryonal rhabdomyosarcoma (ERMS), or botryoid rhabdomyosarcoma (BRMS)."
GNBNo stage 2b3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 3""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Nodular (Composite)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 3""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were at the initial diagnosis phase. These patients have a histological diagnosis of Ganglioneuroblastoma, Nodular (Composite) and are classified as either Stage 2b or Stage 3."
INTERACT - all male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
SIOPEN INRG 2b3 UH,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 3""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)"", ""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unfavorable""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""SIOPEN""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)"", ""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 3""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium, specifically contributed by SIOPEN. The patients were at the initial diagnosis phase and had either Stage 2b or Stage 3 disease. Their histology was classified as either Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich), Ganglioneuroblastoma, Nodular (Composite), or Neuroblastoma (Schwannian Stroma-Poor), with an unfavorable histology according to the INPC classification."
INSS Stage 4,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are classified as Stage 4 according to the INSS staging system.
INSS Stage 4,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are classified as Stage 4 according to the INSS staging system.
"INSS Stage 4, 4S","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage 4s""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4"", ""Stage 4s""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are classified under the INSS staging system and are specifically in either Stage 4 or Stage 4s.
INSTRuCT 2021-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Orbit"", ""Eyelid""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Orbit"", ""Eyelid""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals were at the initial diagnosis phase of their disease, and their tumor assessments indicated that the tumor site was either the orbit or the eyelid."
Stage 2b 3 COG UH,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""GPOH""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 3""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)"", ""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype"", ""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unfavorable""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""GPOH""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)"", ""Ganglioneuroblastoma, Nodular (Composite)"", ""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype"", ""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_inpc"": [""Unfavorable""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 3""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and have data contributed by GPOH. These patients were at the initial diagnosis phase and had either Stage 2b or Stage 3 disease. Their histology types include Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich), Ganglioneuroblastoma, Nodular (Composite), Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype, or Neuroblastoma (Schwannian Stroma-Poor), with an unfavorable INPC histology classification."
Wendy data request,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INSS Stage 1-3,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort includes individuals who have been staged using the INSS system and are classified as Stage 1, Stage 2a, Stage 2b, or Stage 3."
NB Patients with MYCNamplification,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female"", ""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are either female or male and are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and have been staged using the INSS staging system.
Metastatic Neuroblastoma,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified as Stage 4 according to the INSS staging system. All criteria must be met for inclusion in the study.
Metastatic Neuroblastoma,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are classified as Stage 4 according to the INSS staging system.
NB Patients without MYCN amplification,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female"", ""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are either female or male and are part of the INRG consortium. They have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and are staged using the INSS system. Additionally, these individuals exhibit MYCN Amplification as a molecular abnormality. All these criteria must be met for inclusion in the cohort."
Metastatic Neuroblastoma 2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female"", ""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M"", ""Stage MS""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating"", ""Undifferentiated or Poorly Differentiated""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_grade"": [""Differentiating"", ""Undifferentiated or Poorly Differentiated""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M"", ""Stage MS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of individuals from the INRG consortium, including both females and males. Participants are at the initial diagnosis phase and have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). Their histology grades are either Differentiating or Undifferentiated/Poorly Differentiated. The staging system used is INRGSS, and they are classified as either Stage M or Stage MS. The tumor classification is Primary, and their survival characteristics are known."
Primary Neuroblastoma,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female"", ""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating"", ""Undifferentiated or Poorly Differentiated""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_grade"": [""Differentiating"", ""Undifferentiated or Poorly Differentiated""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals from the INRG consortium, including both females and males. Participants are at the initial diagnosis phase with a known survival status. They have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and exhibit either differentiating or undifferentiated/poorly differentiated histology grades. The tumor classification is primary, and the staging system used is INRGSS."
Neuroblastoma Metastasis,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female"", ""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating"", ""Undifferentiated or Poorly Differentiated""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Female"", ""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_grade"": [""Differentiating"", ""Undifferentiated or Poorly Differentiated""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of individuals from the INRG consortium, including both females and males. Participants are at the initial diagnosis phase with a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). The histology grades are either Differentiating or Undifferentiated/Poorly Differentiated. The staging system used is INRGSS, and the tumor classification is Primary. Additionally, the survival characteristics of the participants are known."
Non-metastatic Neuroblastoma,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who are staged according to the INSS system. The selected stages include Stage 1, Stage 2a, Stage 2b, and Stage 3."
ARMS - fem,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of female participants who have been diagnosed with alveolar rhabdomyosarcoma (ARMS).
ARMS - male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of male individuals diagnosed with alveolar rhabdomyosarcoma (ARMS).
Composed: ARMS Male OR Fem,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS), including both females and males. The selection criteria require that participants have a histological diagnosis of ARMS, and they can be of either sex, female or male."
1-2-mycn,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with neuroblastoma at Stage 1, Stage 2a, or Stage 2b. Additionally, they exhibit a molecular abnormality characterized by MYCN amplification, which is confirmed to be present."
2003-2019 >18mo Stage 4 Node Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2019. At the initial diagnosis, these patients were classified as Stage 4, with metastatic tumors present in the lymph nodes. The age at tumor assessment for these patients ranged from 547 to 8367 days."
2003-2020 >18mo Stage 4 Lung Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. These patients had metastatic tumors located in the lung, and their age at the time of tumor assessment ranged from 1.5 to 23 years. Importantly, the tumor state was not present at the time of assessment."
1990-2002 >18mo Stage 4 Bone Marrow Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with the disease between 1990 and 2002. At the time of initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor assessments indicated that the tumor site was the bone marrow, and the tumor state was absent. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 22.9 years (8367 days)."
1990-2002 >18mo Stage 4 Skin Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals from the INRG consortium who were diagnosed with a disease between the years 1990 and 2002. At the initial diagnosis phase, these individuals were classified as Stage 4. Their tumor assessments indicated that the tumor was metastatic, located in the skin, and absent in state. The age at tumor assessment for these individuals ranged from 547 to 8367 days."
3-mycn,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 3 cancer and exhibit a molecular abnormality characterized by MYCN amplification, which is confirmed to be present."
Male - all consortia,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}]}",The cohort consists of individuals who are male.
MaGIC - except DFCI registry,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""DFCI Registry""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""DFCI Registry""}}]}], ""path"": ""studies""}}]}","The cohort includes participants from the MaGIC consortium, but excludes those from the DFCI Registry study."
Composed - ARMS-F or Male,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of individuals diagnosed with alveolar rhabdomyosarcoma (ARMS), including both females and males. The selection criteria require that participants have a histology of alveolar rhabdomyosarcoma, and they can be of either sex, female or male. The criteria are inclusive of both sexes, with the condition that they have the specified histology."
Composed - ARMS-F or Male,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS), including both females and males. The selection criteria require that participants have a histology of Alveolar rhabdomyosarcoma (ARMS), and they can be of either sex, female or male."
ARMS - male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of male individuals diagnosed with alveolar rhabdomyosarcoma (ARMS).
AML CNS 2/3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""disease_characteristics.CNS_disease_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""CNS2"", ""CNS3""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""CNS_disease_status"": [""CNS2"", ""CNS3""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants from the INTERACT consortium who have a CNS disease status of either CNS2 or CNS3.
AML CNS 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""disease_characteristics.CNS_disease_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""CNS1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""CNS_disease_status"": [""CNS1""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants who are part of the INTERACT consortium and have a CNS disease status classified as CNS1.
Init diagnosis Neuroblastoma <5yo,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 1853}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 1853}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were at the initial diagnosis phase of their disease and were diagnosed with Neuroblastoma (Schwannian Stroma-Poor). Additionally, the age at tumor assessment for these individuals ranged from 0 to 1853 days."
"L2, Favorable, MYCN Positive","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Favorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology_inpc"": [""Favorable""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with Stage L2 neuroblastoma. These participants have a favorable histology according to the INPC classification. Additionally, they exhibit MYCN amplification, which is confirmed to be present through molecular analysis."
"L2, Favorable, MYCN Positive","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Favorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology_inpc"": [""Favorable""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with Stage L2 neuroblastoma. These participants have a favorable histology according to the INPC classification. Additionally, they exhibit MYCN amplification, which is confirmed to be present through molecular analysis."
MYCN amp,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who also exhibit MYCN Amplification. Both criteria must be met for inclusion in the study.
MYCN non-AMP,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""MYCN Amplification""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""molecular_abnormality"": ""MYCN Amplification""}}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) who do not have MYCN Amplification as a molecular abnormality.
males,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}]}",The cohort consists of individuals who are male.
INSTRuCT  2022-05,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group IV""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Spindle cell"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Spindle cell"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group IV""]}}], ""path"": ""stagings""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been classified under IRS Group IV staging. The histological types included in the selection are Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Spindle cell, and Rhabdomyosarcoma (RMS) with Mixed Embryonal and Alveolar Features."
INSTRuCT 2023-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Shoulder"", ""Upper Arm"", ""Forearm"", ""Hand"", ""Buttock"", ""Hip"", ""Thigh"", ""Knee"", ""Leg"", ""Lower Leg"", ""Foot"", ""Other Extremity"", ""Limbs, NOS"", ""Lower Arm""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Shoulder"", ""Upper Arm"", ""Forearm"", ""Hand"", ""Buttock"", ""Hip"", ""Thigh"", ""Knee"", ""Leg"", ""Lower Leg"", ""Foot"", ""Other Extremity"", ""Limbs, NOS"", ""Lower Arm""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals are at the initial diagnosis phase of their disease, and their tumor assessments indicate that the tumor site is located in one of the following areas: Shoulder, Upper Arm, Forearm, Hand, Buttock, Hip, Thigh, Knee, Leg, Lower Leg, Foot, Other Extremity, Limbs (not otherwise specified), or Lower Arm."
INSTRuCT  2022-05,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group IV""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Spindle cell"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Spindle cell"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group IV""]}}], ""path"": ""stagings""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been classified under IRS Group IV staging. The histological types included in the cohort are Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Spindle cell, and Rhabdomyosarcoma (RMS) with Mixed Embryonal and Alveolar Features."
INRG  2022-04 Cohort 3,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}]}]}","The cohort consists of individuals associated with the INRG consortium. At the initial diagnosis phase, participants were selected if their age at tumor assessment was between 365 and 546 days. Additionally, participants were included if they were classified under either of the following staging criteria: Stage M according to the INRGSS staging system or Stage 4 according to the INSS staging system."
g,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""minimal_residual_diseases.mrd_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Negative""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""mrd_result"": [""Negative""]}}]}]}], ""path"": ""minimal_residual_diseases""}}]}","The cohort consists of individuals who are at the initial diagnosis phase of their disease. Additionally, these individuals have been tested for minimal residual disease (MRD), and their MRD results are negative."
1990-2002 >18mo Stage 4 CNS Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumors were located in the central nervous system and were absent at the time of assessment. The age of the patients at the time of tumor assessment ranged from 1.5 to 23 years."
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have a molecular abnormality identified as FLT3 internal tandem duplication (ITD), with the result of this abnormality being present."
MYCN Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium and have a molecular analysis showing the presence of MYCN amplification.
INRG  2022-04 Cohort 3,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}]}]}","The cohort consists of patients from the INRG consortium. At the initial diagnosis phase, patients included are those who had a tumor assessment between the ages of 1 and 1.5 years (365 to 546 days). Additionally, patients are selected if they are classified under either Stage M according to the INRGSS staging system or Stage 4 according to the INSS staging system."
ERMS - male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of male individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
MaGIC - not incl TE20 study,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""TE20""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""TE20""}}]}], ""path"": ""studies""}}]}","The cohort consists of participants who are part of the MaGIC consortium. However, individuals from the study identified by the study_id ""TE20"" are excluded from this cohort."
composed - ERMS fem and male,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}]}","The cohort consists of individuals diagnosed with embryonal rhabdomyosarcoma (ERMS), including both females and males. Specifically, it includes females with ERMS and males with ERMS, with no exclusions based on sex."
ERMS - male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Embryonal rhabdomyosarcoma (ERMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of male individuals diagnosed with embryonal rhabdomyosarcoma (ERMS).
NA_B1,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL00B1""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unfavorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL00B1""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""histology_inpc"": [""Unfavorable""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who were part of the study ANBL00B1 and have been diagnosed with Stage 4 cancer. These patients have an unfavorable histology according to the INPC classification and exhibit MYCN amplification, but the molecular abnormality result is absent. Additionally, the age of the patients at the time of tumor assessment is between 1 and 1.5 years (365 to 547 days)."
MA-1p loss,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis indicating the presence of a 1p deletion abnormality.
AML Males ,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
NA_B1_M_SCA+,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M"", ""Stage 4""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL00B1""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL00B1""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M"", ""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the study identified by ""ANBL00B1"" and have been diagnosed with either Stage M or Stage 4 cancer. These patients exhibit MYCN Amplification as a molecular abnormality, but the result of this molecular abnormality is absent. Additionally, the age of the patients at the time of tumor assessment is between 365 and 547 days."
MA-MYCN-non,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
MA MYNC-non+1ploss,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of individuals who are part of the INRG consortium. The selection criteria include two specific molecular analyses: First, individuals must have a molecular abnormality of MYCN Amplification, which is absent. Second, they must have a molecular abnormality of 1p deletion, which is present. Both conditions must be met for inclusion in the cohort."
MA MYNC-non+1ploss,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of individuals who are part of the INRG consortium. The selection criteria include two specific molecular analyses: First, individuals must have a molecular abnormality of MYCN Amplification, which is absent. Second, they must have a molecular abnormality of 1p deletion, which is present. Both conditions must be met for inclusion in the cohort."
INSTRuCT 2021-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Orbit"", ""Eyelid""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Orbit"", ""Eyelid""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals were at the initial diagnosis phase of their disease, and their tumor assessments indicated that the tumor site was either the orbit or the eyelid."
2003-2020 >18mo Stage 4 Bone Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2003 and 2020. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor assessments indicated that the tumor site was the bone, the tumor state was absent, and the age at tumor assessment ranged from 547 to 8367 days."
2003-2020 >18mo Stage 4 Bone Marrow Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed with their disease between the years 2003 and 2020. At the initial diagnosis, these patients were classified as Stage 4. Their tumor assessments indicated that the tumor was metastatic, located in the bone marrow, and absent in terms of tumor state. The age of the patients at the time of tumor assessment ranged from 547 to 8367 days."
1990-2002 >18mo Stage 4 Lung Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2002. At the time of tumor assessment, these patients had metastatic tumors located in the lung, with the tumor state being absent. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 22.9 years (8367 days)."
1990-2002 >18mo Stage 4 Liver Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4. Their tumor assessments indicated that the tumor was metastatic, located in the liver, and absent in state. The age at tumor assessment ranged from 547 to 8367 days."
NBL stroma rich,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of participants who are part of the INRG consortium, have been diagnosed with Stage 4 disease, and have a histology of Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich). All these criteria must be met for inclusion in the study."
Composed INSTRuCT LatinX2,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and identify as Hispanic or Latino. The selection includes both females and males, meaning participants can be either female or male, as long as they meet the other criteria."
INSTRuCT Latino fem2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are Hispanic or Latino and are part of the INSTRuCT consortium.
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have undergone molecular analysis. Specifically, these participants have been tested for the FLT3 internal tandem duplication (ITD) molecular abnormality, and the results show that this abnormality is absent."
INSTRuCT 2023-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Shoulder"", ""Upper Arm"", ""Forearm"", ""Hand"", ""Buttock"", ""Hip"", ""Thigh"", ""Knee"", ""Leg"", ""Lower Leg"", ""Foot"", ""Other Extremity"", ""Limbs, NOS"", ""Lower Arm""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Shoulder"", ""Upper Arm"", ""Forearm"", ""Hand"", ""Buttock"", ""Hip"", ""Thigh"", ""Knee"", ""Leg"", ""Lower Leg"", ""Foot"", ""Other Extremity"", ""Limbs, NOS"", ""Lower Arm""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals are at the initial diagnosis phase of their disease. The tumor sites for these individuals include the shoulder, upper arm, forearm, hand, buttock, hip, thigh, knee, leg, lower leg, foot, other extremities, limbs not otherwise specified (NOS), and lower arm."
INRG  2022-04,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}]}","The cohort consists of patients associated with the INRG consortium. At the initial diagnosis phase, patients included are those whose age at tumor assessment is between 365 and 546 days. Additionally, patients are selected if they are classified as either Stage M according to the INRGSS staging system or Stage 4 according to the INSS staging system."
INSTRuCT 2021-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Orbit"", ""Eyelid""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Orbit"", ""Eyelid""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals were at the initial diagnosis phase of their disease, and their tumor assessments indicated that the tumor site was either the orbit or the eyelid."
All stage 3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023.
AML Female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
"Stage 3, <18m","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 546}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease. The diagnosis or disease phase occurred between the years 2003 and 2023. Additionally, the age at tumor assessment for these individuals ranges from 1 day to 546 days."
11q deletion,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023. Additionally, these individuals have a molecular abnormality characterized by the presence of an 11q deletion."
11q normal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023. Additionally, these individuals have undergone molecular analysis, which shows that the 11q deletion molecular abnormality is absent."
17q gain,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease. The diagnosis must have occurred between the years 2006 and 2023. Additionally, these individuals exhibit a molecular abnormality characterized by a 17q gain, which is confirmed to be present."
17q normal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023. Additionally, these individuals have a molecular analysis showing a 17q gain abnormality, but the result of this molecular abnormality is absent."
17q normal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023. Additionally, these individuals have a molecular analysis showing a 17q gain abnormality, but the result of this molecular abnormality is absent."
1p normal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023. Additionally, these individuals have a molecular analysis indicating the presence of a 1p deletion, but the result of this molecular abnormality is absent."
1p deletion,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2006, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2006}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease. The diagnosis occurred between the years 2006 and 2023. Additionally, these individuals have a molecular abnormality characterized by a 1p deletion, which is present in their molecular analysis."
2003-2020 >18mo Stage 4 CNS Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2020. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors located in the Central Nervous System. The tumors were assessed to be absent, and the age at tumor assessment ranged from 1.5 to 22.9 years."
2003-2020 >18mo Stage 4 Liver Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. At the time of tumor assessment, these patients had metastatic tumors located in the liver, with the tumor state being absent. The age of the patients at the time of tumor assessment ranged from 547 to 8367 days."
1990-2002 >18mo Stage 4 Bone Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumors were located in the bone and were absent at the time of assessment. The age of patients at the time of tumor assessment ranged from 547 to 8367 days."
MYCN absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
"Fem, Asian, Black, not reported","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Asian"", ""Black or African American"", ""Not Reported""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American"", ""Not Reported""]}}, {""IN"": {""sex"": [""Female""]}}]}","The cohort consists of individuals who are female and belong to one of the following racial categories: Asian, Black or African American, or Not Reported."
MaGIC - not DFCI registry study - temp,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""DFCI Registry""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""DFCI Registry""}}]}], ""path"": ""studies""}}]}","The cohort includes participants from the MaGIC consortium, but excludes those from the DFCI Registry study."
"Composed - M, F, Asian, Black, not reported","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Asian"", ""Black or African American"", ""Not Reported""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""selectedValues"": [""Asian"", ""Black or African American"", ""Not Reported""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American"", ""Not Reported""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""race"": [""Asian"", ""Black or African American"", ""Not Reported""]}}, {""IN"": {""sex"": [""Female""]}}]}]}","The cohort consists of individuals who are either male or female and belong to one of the following racial categories: Asian, Black or African American, or Not Reported. The selection criteria require that participants must meet both the gender and race conditions simultaneously."
Male Asian Black Not Reported,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Black or African American"", ""Not Reported""]}, ""__combineMode"": ""AND""}",,"The cohort consists of male individuals who are either Asian, Black or African American, or whose race is not reported. All specified criteria must be met for inclusion in the cohort."
L2 11qdeletion,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage L2 neuroblastoma according to the INRGSS staging system. The diagnosis must have occurred between the years 2003 and 2023. Additionally, these individuals must have a molecular analysis showing the presence of an 11q deletion."
"L2, 11q normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed between the years 2003 and 2023. These individuals are classified under the INRGSS staging system as Stage L2. Additionally, they have undergone molecular analysis which shows the absence of the 11q deletion abnormality."
"L2, 1p normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed between the years 2003 and 2023. These individuals are classified under the INRGSS staging system as Stage L2. Additionally, they have undergone molecular analysis which shows the absence of the 1p deletion abnormality."
"L2, 1p deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage L2 neuroblastoma according to the INRGSS staging system. The diagnosis must have occurred between the years 2003 and 2023. Additionally, these individuals must have a molecular analysis indicating the presence of a 1p deletion abnormality."
"Stage 3, >18m","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8576}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8576}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease. The diagnosis or disease phase occurred between the years 2003 and 2023. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 8576 days."
"L2, >18m","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 7856}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 7856}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been staged as Stage L2 according to the INRGSS staging system. The data includes individuals whose disease phase occurred between the years 2003 and 2023. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 7856 days."
Saved 2,"{""value"": [{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""American Indian or Alaska Native""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""race"": [""American Indian or Alaska Native""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}]}, null, null, null]}",The cohort consists of individuals who are both American Indian or Alaska Native and male.
Saved 31,"{""value"": [{""value"": {""survival_characteristics.lkss"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alive""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""nested"": {""AND"": [{""IN"": {""lkss"": [""Alive""]}}], ""path"": ""survival_characteristics""}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}]}",The cohort consists of individuals who are alive and are part of the INSTRuCT consortium.
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular analysis showing the presence of the FLT3 internal tandem duplication (ITD) abnormality.
Saved 7,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}, {""AND"": [{""IN"": {""sex"": [""Unknown""]}}]}]}",The cohort consists of individuals who are part of the INSTRuCT consortium and have an unspecified or unknown sex.
"L2, <18m","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 546}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed with a disease phase between the years 2003 and 2023. At the time of tumor assessment, their age ranged from 1 to 546 days. Additionally, their disease was staged using the INRGSS system, specifically classified as Stage L2."
"Stage 3, >18m, 1 p normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 9852}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 9852}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 cancer according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. These individuals have a molecular abnormality characterized by a 1p deletion, but the result of this molecular abnormality is absent. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 9852 days."
"Stage 3, >18m, 1p deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 9852}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 9852}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 cancer according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. These individuals exhibit a 1p deletion molecular abnormality, which is confirmed to be present. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 9852 days."
"4S, Liver positive","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4s cancer. Additionally, they have a tumor present in the liver."
"4S, Liver negative","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who are classified as Stage 4s. Additionally, these participants have tumor assessments indicating the liver as a tumor site, but with the tumor state being absent."
MAGiC GOG0078 study,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""GOG0078""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""GOG0078""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and are involved in the study identified by the study ID GOG0078. Both criteria must be met for inclusion in the cohort.
"L2, >18m, 11q normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 7856}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 7856}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed between the years 2003 and 2023. These individuals are classified under Stage L2 according to the INRGSS staging system. At the time of tumor assessment, their ages range from 1.5 years (547 days) to approximately 21.5 years (7856 days). Additionally, they exhibit a molecular abnormality characterized by the 11q deletion, which is absent in the molecular analysis results."
"L2, >18m, 11q deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 7856}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 7856}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage L2 neuroblastoma according to the INRGSS staging system. The diagnosis occurred between the years 2003 and 2023. These individuals exhibit a molecular abnormality characterized by the presence of an 11q deletion. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 7856 days."
"L2, >18m, 1p normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 7856}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 7856}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage L2 neuroblastoma according to the INRGSS staging system. The diagnosis occurred between the years 2003 and 2023. Participants were assessed for tumors at an age ranging from 1.5 years (547 days) to approximately 21.5 years (7856 days). Additionally, these individuals exhibit a 1p deletion molecular abnormality, which is absent in the molecular analysis results."
"L1, >18m, 1p deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 7856}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 7856}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage L2 neuroblastoma according to the INRGSS staging system. The diagnosis must have occurred between the years 2003 and 2023. Additionally, these individuals have a molecular abnormality characterized by a 1p deletion, which is present. The age at tumor assessment for these individuals ranges from 547 days to 7856 days."
Saved 3,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}]}",The cohort consists of male participants who are part of the INRG consortium.
"L12, 11q normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed between the years 2003 and 2023. These individuals are classified under the INRGSS staging system as Stage L2. Additionally, they have undergone molecular analysis which shows the absence of the 11q deletion abnormality."
"Stage 3, >18m , 11q normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 9852}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 9852}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 cancer according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. These individuals have a molecular abnormality characterized by an 11q deletion, which is absent in the molecular analysis results. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 9852 days."
"Stage 3, 11q normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. Additionally, these individuals have undergone molecular analysis, which shows the absence of the 11q deletion abnormality."
INSS available,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been staged using the INRGSS system. The selected stages include Stage L1, Stage L2, Stage M, and Stage MS. Additionally, the individuals were diagnosed or had a disease phase between the years 2003 and 2023."
1990-2002 >18mo 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 metastatic disease between 1990 and 2002. The patients were assessed for tumors at various sites, including the Central Nervous System, Lung, Liver, Lymph Nodes, Skin, Bone Marrow, and Bone. For most sites, the tumor state was absent, except for the Lymph Nodes where it was present. The age at tumor assessment ranged from 547 to 8367 days."
"L2, 11q deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage L2 neuroblastoma according to the INRGSS staging system. The diagnosis must have occurred between the years 2003 and 2023. Additionally, these individuals must have a molecular analysis showing the presence of an 11q deletion."
"Stage 3, 11q deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. Additionally, these individuals have a molecular abnormality characterized by the presence of an 11q deletion."
"Stage 3, 1p normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. Additionally, these individuals have undergone molecular analysis, which shows the absence of the 1p deletion abnormality."
4,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with a disease stage between 2003 and 2023. Specifically, the cohort includes those at Stage 3, as well as those at Stages L1, L2, M, or MS, all within the same time frame of 2003 to 2023."
2003-2020 >18mo Stage 4 Skin Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2003 and 2020. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor assessments indicated that the tumor site was the skin, the tumor state was absent, and the age at tumor assessment ranged from 547 to 8367 days."
"Stage 3, >18m, 11q deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 9852}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 9852}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 cancer according to the INSS staging system. The diagnosis or disease phase occurred between the years 2003 and 2023. These individuals have a molecular abnormality characterized by an 11q deletion, which is confirmed to be present. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 9852 days."
"4S, Liver positive, MYCN amp","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4s cancer. Their tumor assessments indicate the presence of a tumor in the liver. Additionally, molecular analysis reveals the presence of MYCN amplification."
1990-2002 >18mo Stage 4 Bone or Marrow Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as having Stage 4 metastatic tumors. The tumors were present in either the bone or bone marrow. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to 30 years (10,983 days)."
2003-2020 >18mo Stage 4 Extranodal Extraosseous,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. The patients are categorized into three groups based on tumor site and state. The first group includes patients with metastatic tumors located in the bone, with the tumor state being absent, and the age at tumor assessment ranging from 547 to 8367 days. The second group includes patients with metastatic tumors located in the bone marrow, also with the tumor state being absent, and the same age range at tumor assessment. The third group includes patients with metastatic tumors located in the central nervous system, liver, or lung, with the tumor state being present, and the age at tumor assessment also ranging from 547 to 8367 days."
MaGIC - males only,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the MaGIC consortium.
Relapse Patients,"{""value"": {""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic"", ""Primary"", ""Regional""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic"", ""Primary"", ""Regional""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are in the relapse phase of their disease. Within this group, the tumor assessments indicate that the tumor classification is either metastatic, primary, or regional."
"Stage 1, 1p deletion","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. Additionally, these individuals have a molecular abnormality characterized by a 1p deletion, which is confirmed to be present."
"4S, Liver positive, MYCN non-amp","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4s""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4s""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4s cancer, with tumors present in the liver. Additionally, their molecular analysis shows MYCN amplification, but the result of this molecular abnormality is absent."
1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present"", ""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present"", ""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with cancer stages 1, 2a, or 2b according to the INSS staging system. The diagnosis occurred between the years 2003 and 2023. Additionally, the molecular analysis of these individuals shows the presence or absence of the 11q deletion abnormality."
2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with a disease stage classified under the INSS system as Stage 1, Stage 2a, or Stage 2b. The diagnosis occurred between the years 2003 and 2023. Additionally, these individuals have undergone molecular analysis that shows the absence of MYCN Amplification."
3,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present"", ""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present"", ""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. These patients have been staged using the INSS system and are classified as Stage 1, Stage 2a, or Stage 2b. The cohort includes two groups based on molecular abnormalities: one group with the presence or absence of 11q deletion, and another group with the absence of MYCN Amplification."
3,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present"", ""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present"", ""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. These patients have been staged using the INSS system and are classified as Stage 1, Stage 2a, or Stage 2b. The cohort includes two groups based on molecular abnormalities: one group with the presence or absence of 11q deletion, and another group with the absence of MYCN Amplification."
Stage 3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 3 disease. The diagnosis or relevant disease phase occurred between the years 2003 and 2023.
1990-2002 >18mo Stage 4 CNS Liver Lung Skin Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung"", ""Liver"", ""Central Nervous System"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung"", ""Liver"", ""Central Nervous System"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2002. At the time of tumor assessment, these patients had metastatic tumors that were present in the lung, liver, central nervous system, or skin. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to approximately 30 years (10,983 days)."
2003-2020 >18mo 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2020. All patients were at Stage 4 during the initial diagnosis phase and had metastatic tumors. The cohort is divided into several groups based on tumor site and state: 

1. Patients with tumors present in the lymph nodes, assessed between 1.5 and 30 years of age.
2. Patients with tumors in the lung, assessed between 1.5 and 23 years of age, where the tumor state is not present.
3. Patients with tumors in the bone, bone marrow, central nervous system, liver, or skin, assessed between 1.5 and 23 years of age, where the tumor state is absent."
MaGIC female all,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the MaGIC consortium.
INTERACT composed - male OR female,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}]}",The cohort consists of individuals who are part of the INTERACT consortium. The selection includes both female and male participants from this consortium.
4,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients who are part of the INRG consortium and have been diagnosed with neuroblastoma between the years 2003 and 2023. The patients are categorized into two groups based on their disease stage. The first group includes patients with Stage 3 neuroblastoma. The second group includes patients with Stage L1, Stage L2, Stage M, or Stage MS neuroblastoma. All patients in the cohort were diagnosed within the specified time frame."
"Stage 1,2 ","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed with a disease between the years 2003 and 2023. Additionally, their disease was classified as either Stage 1, Stage 2a, or Stage 2b."
"Stage 1,2 no MYCN","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. These individuals have been staged as either Stage 1, Stage 2a, or Stage 2b. Additionally, they have undergone molecular analysis which shows the presence of MYCN Amplification, but the result for this molecular abnormality is absent."
INRG available,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1"", ""Stage L2"", ""Stage M"", ""Stage MS""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been staged using the INRGSS system and are classified as Stage L1, Stage L2, Stage M, or Stage MS. Additionally, the data for these individuals was collected between the years 2003 and 2023."
11q available,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. The disease phase for these individuals occurred between the years 2003 and 2023. Additionally, the molecular analysis of these individuals includes the presence or absence of the 11q deletion abnormality."
17q available,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}, {""IN"": {""molecular_abnormality"": [""17q gain""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed or had a disease phase between the years 2003 and 2023. Additionally, they have undergone molecular analysis for the 17q gain abnormality, with results indicating either the presence or absence of this abnormality."
afp,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AFP""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""AFP""]}}], ""path"": ""labs""}}]}",The cohort consists of individuals who have undergone laboratory tests specifically for Alpha-fetoprotein (AFP).
INTERACT - female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
1p available,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}, {""IN"": {""molecular_abnormality"": [""1p deletion""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have a disease phase that occurred between the years 2003 and 2023. Additionally, they have undergone molecular analysis for the 1p deletion abnormality, with results indicating either the presence or absence of this abnormality."
8,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}]}]}",The cohort consists of individuals who are part of the INRG consortium and have been diagnosed between the years 2003 and 2023. The cohort is divided into two groups based on specific criteria. The first group includes individuals with Stage 3 disease according to the INSS staging system. The second group includes individuals with Stage L1 disease who have a molecular analysis showing MYCN Amplification as absent. Both groups are part of the INRG consortium and fall within the specified year range.
9,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. The selection includes two groups: the first group comprises individuals with Stage L2 disease and no molecular abnormalities detected, while the second group includes individuals with Stage 3 disease classified under the INSS staging system."
GC_kirk_2,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""-hCG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""-hCG""]}}], ""path"": ""labs""}}]}",The cohort includes individuals who have undergone the -hCG lab test.
Some saved combined filter ,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}, {""AND"": [{""IN"": {""sex"": [""Unknown""]}}]}, null]}",The cohort consists of individuals who are part of the INRG consortium and have an unspecified sex.
Saved 5,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}]}]}",The cohort consists of male participants who are part of the INSTRuCT consortium.
"INSTRuCT, male, AA","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male individuals who are Black or African American and are part of the INSTRuCT consortium.
MaGIC TE09 study,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TE09""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""TE09""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and are involved in the study identified by the study ID TE09. Both criteria must be met for inclusion in the cohort.
NODAL - all except HLHR13,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""HLHR13""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""HLHR13""}}]}], ""path"": ""studies""}}]}","The cohort consists of participants from the ""NODAL"" consortium. However, individuals from the study with the ID ""HLHR13"" are excluded from this selection."
MYCN available,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent"", ""Present""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. These individuals have undergone molecular analysis specifically for MYCN Amplification, and the results of this analysis are either ""Absent"" or ""Present."""
6,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. These patients have a molecular analysis showing MYCN Amplification, but the result of this abnormality is absent. The cohort includes two groups based on staging criteria: the first group includes patients with stages 1, 2a, or 2b according to the INSS staging system, and the second group includes patients with stage L2."
8,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between 2003 and 2023. The selection criteria include two groups: the first group includes individuals with Stage 3 disease according to the INSS staging system, and the second group includes individuals with Stage L1 disease who have an absent molecular abnormality result. Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
INRG L1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed with a disease phase between the years 2003 and 2023. Additionally, they are classified under Stage L1 according to the INRGSS staging system."
INRG L2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed with a disease phase between the years 2003 and 2023. Additionally, they are classified under Stage L2 according to the INRGSS staging system."
"Composed MaGIC m, f","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Female""]}}]}]}","The cohort consists of individuals who are either male or female and are part of the MaGIC consortium. The selection criteria include both males and females, but all participants must be associated with the MaGIC consortium."
MaGIC female all,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the MaGIC consortium.
5,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage MS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage MS. The diagnosis must have occurred between the years 2003 and 2023. Additionally, these individuals have undergone molecular analysis, which shows the presence of MYCN Amplification as a molecular abnormality, but the result of this abnormality is absent."
7,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2b"", ""Stage 2a"", ""Stage 1""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. These patients have a molecular analysis showing MYCN Amplification, but the result of this abnormality is absent. The cohort includes two groups based on staging criteria: one group with Stage L1, and another group with stages 2b, 2a, or 1 according to the INSS staging system."
"Stage 3, no MYCN, L1","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with Stage 3 disease who have a molecular analysis showing MYCN Amplification as absent.

2. The second group includes patients with Stage L1 disease according to the INRGSS staging system. 

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
"Stage 3, no MYCN, L2","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with Stage 3 disease who have a molecular analysis showing MYCN Amplification as absent.

2. The second group includes patients with Stage L2 disease according to the INRGSS staging system. 

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
test,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}}, ""__type"": ""ANCHORED""}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of female participants who have a 17q gain molecular abnormality. Additionally, at the initial diagnosis phase, these participants also exhibit a 1p deletion molecular abnormality."
INRG 2023-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2021}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2021}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium and have data contributed by COG. These patients were diagnosed between the years 2003 and 2021. At the initial diagnosis phase, they were staged using the INSS system and classified as Stage 1, Stage 2a, or Stage 2b. Additionally, these patients have a molecular abnormality of MYCN Amplification, which is present."
8,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed between the years 2003 and 2023. The selection includes two groups: the first group comprises individuals at Stage L1, and the second group includes those at Stage 3 according to the INSS staging system. Both groups are part of the INRG consortium and fall within the specified year range."
9,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. The selection includes two groups: the first group comprises individuals staged as Stage 3 according to the INSS staging system, and the second group includes those staged as Stage L2. Both groups are selected based on the same consortium and time frame criteria."
"Stage 1,2 , no MYCN, L1","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with stages 2a, 2b, or 1 of the disease, who have a molecular analysis showing MYCN Amplification as absent.

2. The second group includes patients with stage L1 of the disease, classified under the INRGSS staging system. 

Both groups are combined using an ""AND"" logic, meaning patients must meet all criteria within at least one of the groups to be included in the cohort."
A combined filterset,"{""value"": [{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Multiracial""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""race"": [""Multiracial""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}]}, null]}",The cohort consists of individuals who are multiracial males.
"Stage 1, 2, no MYCN, L2","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 2a"", ""Stage 2b"", ""Stage 1""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 2003 and 2023. The selection includes two groups: 

1. The first group includes patients with stages 2a, 2b, or 1, who have a molecular analysis showing MYCN Amplification as absent.

2. The second group includes patients with stage L2 according to the INRGSS staging system. 

Both groups are combined using an AND logic, meaning patients must meet all criteria within their respective group to be included in the cohort."
Sample,"{""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic"", ""Primary"", ""Regional"", ""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic"", ""Primary"", ""Regional"", ""Unknown""]}}], ""path"": ""tumor_assessments""}}]}","The cohort includes individuals whose tumor assessments classify the tumor as either Metastatic, Primary, Regional, or Unknown."
NODAL AnnArbor Stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
"Stage 3, MYCN normal","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Absent""]}}, {""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 3 disease between the years 2003 and 2023. Additionally, these individuals have undergone molecular analysis showing the absence of MYCN Amplification."
"Stage 1-3, no MYCN","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with a disease stage of either Stage 1, Stage 2a, Stage 2b, or Stage 3. The diagnosis occurred between the years 2003 and 2023. Additionally, these individuals have undergone molecular analysis, which shows that MYCN amplification is absent."
"Stage 1-3, no MYCN, L1","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with stages 1, 2a, 2b, or 3 of the disease, who do not have MYCN amplification present in their molecular analysis.

2. The second group includes patients with stage L2 of the disease, classified under the INRGSS staging system. 

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
Saved 4,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}]}]}",The cohort consists of male participants who are part of the INSTRuCT consortium.
"Stage 1-3, no MYCN,  L1","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with stages 1, 2a, 2b, or 3 of the disease, who do not have MYCN amplification, as the molecular abnormality is absent.

2. The second group includes patients with stage L1 of the disease, classified under the INRGSS staging system. 

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
"Stage 3, L2","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. The selection includes two groups: the first group comprises individuals with Stage 3 disease, and the second group includes those with Stage L2 disease according to the INRGSS staging system."
"Stage 1-3, no MYCN, L2","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with stages 1, 2a, 2b, or 3 of the disease, who do not have MYCN amplification present in their molecular analysis.

2. The second group includes patients with stage L2 of the disease, classified under the INRGSS staging system. 

Both groups are part of the same consortium and share the same time frame for diagnosis."
"Stage 3, L1","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. The selection includes two groups: one group with individuals at Stage 3, and another group with individuals at Stage L1 according to the INRGSS staging system."
Saved 6,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}]}]}",The cohort consists of male participants who are part of the INSTRuCT consortium.
INRG  2023-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2021}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""COG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2021}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and have data contributed by COG. These patients were initially diagnosed between the years 2003 and 2021. At the time of initial diagnosis, they were in either Stage 1, Stage 2a, or Stage 2b according to the INSS staging system. Additionally, these patients had a molecular analysis showing the presence of MYCN Amplification."
1990-2002 >18mo Stage 4 Extranodal Extraosseous,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung"", ""Liver"", ""Central Nervous System"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung"", ""Liver"", ""Central Nervous System"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed between 1990 and 2002. All patients were at Stage 4 of the disease at initial diagnosis. The cohort is divided into three groups based on tumor site and state at the time of tumor assessment. The first group includes patients with metastatic tumors in the bone marrow, where the tumor state is absent, and the age at tumor assessment ranges from 547 to 8367 days. The second group includes patients with metastatic tumors present in the lung, liver, central nervous system, or skin, with an age at tumor assessment ranging from 547 to 10983 days. The third group includes patients with metastatic tumors in the bone, where the tumor state is absent, and the age at tumor assessment ranges from 547 to 8367 days."
Hodgkin Stage 1 or 2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I"", ""Stage II""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage I"", ""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with either Stage I or Stage II cancer.
Hodgkin Stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
2003-2020 >18mo Stage 4 Node Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2020. At the initial diagnosis phase, these patients were classified as Stage 4 and had metastatic tumors present in the lymph nodes. The age at tumor assessment for these patients ranged from 547 days to 10,983 days."
Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium and were at the initial diagnosis phase of their disease. Specifically, these individuals were diagnosed with Stage 4 of the disease."
t(8;21) any MRD,"{""value"": {""disease_characteristics.who_aml"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""minimal_residual_diseases.mrd_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Positive"", ""Negative"", ""Not available""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""who_aml"": [""AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1""]}}], ""path"": ""disease_characteristics""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""mrd_result"": [""Positive"", ""Negative"", ""Not available""]}}]}]}], ""path"": ""minimal_residual_diseases""}}]}","The cohort consists of patients diagnosed with Acute Myeloid Leukemia (AML) characterized by the specific genetic abnormality t(8;21)(q22;q22.1), also known as RUNX1-RUNX1T1. These patients are at the initial diagnosis phase of their disease. Additionally, the cohort includes patients with varying minimal residual disease (MRD) results, which can be positive, negative, or not available."
Set1,"{""value"": {""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2017}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10480}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2017}}]}, {""IN"": {""ethnicity"": [""Unknown""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10480}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have an unknown ethnicity. These individuals were diagnosed with their disease between the years 2010 and 2017. At the initial diagnosis phase, they were classified as Stage 4 according to the INSS staging system and had metastatic tumors. Additionally, the age at tumor assessment for these individuals ranged from 547 days to 10,480 days."
MaGIC DFCI Registry - all,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""DFCI Registry""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""DFCI Registry""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the MaGIC consortium and are specifically involved in the DFCI Registry study. Both criteria must be met for inclusion in the cohort.
Composed - INTERACT M OR F,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}]}",The cohort consists of individuals who are part of the INTERACT consortium. It includes both male and female participants.
test,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}]}]}], ""path"": ""molecular_analysis""}}]}",The cohort consists of female participants who were at the initial diagnosis phase of their disease. These participants also exhibited a molecular abnormality characterized by a 17q gain.
INTERACT - female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
INRG - all subjects,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INSTRuCT - all subjects,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}]}",The cohort consists of participants who are part of the INSTRuCT consortium.
MaGIC - All subjects,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}]}",The cohort consists of participants who are part of the MaGIC consortium.
NODAL - all subjects,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}]}",The cohort consists of participants who are part of the NODAL consortium.
INRG - all subjects,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INTERACT - Race = Unk,"{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""race"": [""Unknown""]}}]}","The cohort consists of participants who are part of the INTERACT consortium and whose race is recorded as ""Unknown."""
1531,"{""value"": {""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL1531""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL1531""]}}], ""path"": ""studies""}}]}","The cohort includes participants from the study identified by the study ID ""ANBL1531"". There are no exclusion criteria specified, and the selection is based solely on inclusion in this particular study."
MYCN_3973,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""A3973""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""A3973""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who were part of study A3973. These participants have a molecular analysis showing the presence of MYCN Amplification.
2003-2020 >18mo Stage 4 CNS Liver Lung,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. At the time of tumor assessment, these patients had metastatic tumors that were present in the Central Nervous System, Liver, or Lung. The age of the patients at the time of tumor assessment ranged from 547 to 8367 days."
2003-2020 >18mo Stage 4 Bone or Marrow Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10983}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2020. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumors were present in either the bone or bone marrow. The age of the patients at the time of tumor assessment ranged from 1.5 years (547 days) to 30 years (10,983 days)."
test_build,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""0896""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating"", ""Unknown""]}, ""subject_responses.tx_prior_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Chemoradiotherapy""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 2261, ""upperBound"": 7503}}, ""__type"": ""STANDARD"", ""__combineMode"": ""OR""}","{""OR"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""OR"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}, {""IN"": {""histology_grade"": [""Differentiating"", ""Unknown""]}}], ""path"": ""histologies""}}, {""nested"": {""OR"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 2261}}, {""LTE"": {""age_at_tumor_assessment"": 7503}}]}, {""AND"": [{""!="": {""tumor_classification"": ""Metastatic""}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""OR"": [{""IN"": {""study_id"": [""0896""]}}], ""path"": ""studies""}}, {""nested"": {""OR"": [{""IN"": {""tx_prior_response"": [""Chemoradiotherapy""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the INRG consortium and are involved in study 0896. These participants have a histology of Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich) with a histology grade of either Differentiating or Unknown. They have received Chemoradiotherapy as a prior treatment response. Additionally, the participants are not classified as having metastatic tumors, and their age at tumor assessment ranges from 2261 to 7503 days."
Hodgkin Stage III,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage III""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage III""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage III cancer. Both criteria must be met for inclusion in the study.
NODAL All,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}]}",The cohort consists of participants who are part of the NODAL consortium.
MYCNno_3973,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""A3973""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""A3973""]}}], ""path"": ""studies""}}]}","The cohort consists of participants from the INRG consortium who were part of study A3973. These participants have undergone molecular analysis, specifically for MYCN amplification, and the results of this analysis indicated that MYCN amplification was absent."
FLT3,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)"", ""FLT3-TKD""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)"", ""FLT3-TKD""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a molecular abnormality identified as either FLT3 internal tandem duplication (ITD) or FLT3-TKD, and the result of this molecular abnormality is confirmed to be present."
INTERACT - fem only,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
INTERACT - female,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
nmyc stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unfavorable""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_inpc"": [""Unfavorable""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) with an unfavorable histology. These patients are classified as having metastatic tumors and are in either Stage 4 or Stage M of the disease. Additionally, they exhibit MYCN amplification, which is confirmed to be present."
"Infants <12 months, stage 4/IV/M, MYCN amplified","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 365}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 365}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who were assessed for tumors at an age between 0 and 365 days. These individuals have tumors classified as Stage 4, Stage IV, or Stage M. Additionally, they exhibit a molecular abnormality characterized by MYCN Amplification, and this abnormality is confirmed to be present."
"Infants <12 months, stage 4/IV/M, MYCN amplified","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 365}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 365}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who were assessed for tumors at an age between 0 and 365 days. These individuals have tumors classified as Stage 4, Stage IV, or Stage M. Additionally, they exhibit a molecular abnormality characterized by MYCN amplification, and this abnormality is confirmed to be present."
females,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}]}",The cohort consists of individuals who are female.
bhcg,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""-hCG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""-hCG""]}}], ""path"": ""labs""}}]}",The cohort includes individuals who have undergone laboratory testing for -hCG.
GC_kirk1,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AFP""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""AFP""]}}], ""path"": ""labs""}}]}",The cohort consists of individuals who have undergone laboratory tests specifically for Alpha-fetoprotein (AFP).
Composed - INTERACT M OR F,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}]}","The cohort consists of individuals who are part of the INTERACT consortium. It includes both males and females, with no exclusion based on sex. The selection criteria require that participants must be either male or female, and all must be associated with the INTERACT consortium."
Some saved combined filter,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}, {""AND"": [{""IN"": {""sex"": [""Unknown""]}}]}, null]}",The cohort consists of individuals who are part of the INRG consortium and have an unknown sex.
kikr_1,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AFP""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""AFP""]}}], ""path"": ""labs""}}]}",The cohort consists of individuals who have undergone laboratory tests specifically for Alpha-fetoprotein (AFP).
kirk_2,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""-hCG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""-hCG""]}}], ""path"": ""labs""}}]}",The cohort includes individuals who have undergone the -hCG lab test.
AML Auer Rods Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Auer rods""]}, ""labs.lab_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""disease_characteristics.who_aml"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11"", ""AML with maturation"", ""AML with minimal differentiation"", ""AML with myelodysplasia-related changes"", ""AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1"", ""AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3"", ""AML without maturation"", ""AML, NOS"", ""Acute megakaryoblastic leukemia"", ""Acute monoblastic/monocytic leukemia"", ""Acute myelomonocytic leukemia"", ""Myeloid sarcoma"", ""Not Reported"", ""Pure erythroid leukemia"", ""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are part of the INTERACT consortium. These individuals have undergone lab tests for Auer rods, with results indicating that Auer rods are absent. The cohort includes individuals with various disease characteristics related to acute myeloid leukemia (AML), such as AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, AML with maturation, AML with minimal differentiation, AML with myelodysplasia-related changes, AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3, AML without maturation, AML not otherwise specified (NOS), acute megakaryoblastic leukemia, acute monoblastic/monocytic leukemia, acute myelomonocytic leukemia, myeloid sarcoma, pure erythroid leukemia, as well as cases where the specific type of AML is not reported or unknown. All selection criteria are combined using an AND logic."
MaGIC TE09 AND DFCI registry,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TE09""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""DFCI Registry""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""TE09""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""DFCI Registry""}}]}], ""path"": ""studies""}}]}]}","The cohort consists of participants who are part of the MaGIC consortium. Within this group, participants must either be involved in the study with the ID ""TE09"" or be part of any study except the one with the ID ""DFCI Registry""."
Another saved combined filter,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Not Hispanic or Latino""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}]}]}",The cohort consists of individuals who are male and identify as not Hispanic or Latino.
INRG 2024-01,,{},"The JSON file is empty, so there are no selection criteria or cohort descriptions provided."
Infants < 3 months RMS,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Botryoid rhabdomyosarcoma (BRMS)"", ""Alveolar rhabdomyosarcoma (ARMS)"", ""Spindle cell"", ""Embryonal rhabdomyosarcoma (ERMS)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 90}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 90}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Botryoid rhabdomyosarcoma (BRMS)"", ""Alveolar rhabdomyosarcoma (ARMS)"", ""Spindle cell"", ""Embryonal rhabdomyosarcoma (ERMS)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of either Botryoid rhabdomyosarcoma (BRMS), Alveolar rhabdomyosarcoma (ARMS), Spindle cell, or Embryonal rhabdomyosarcoma (ERMS). Additionally, these patients were assessed for tumors at an age between 0 and 90 days."
MaGIC TE09 AND DFCI registry,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TE09""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""DFCI Registry""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""TE09""]}}], ""path"": ""studies""}}]}, {""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""study_id"": ""DFCI Registry""}}]}], ""path"": ""studies""}}]}]}","The cohort consists of participants from the MaGIC consortium. Within this group, participants are included if they are part of the study with the ID ""TE09."" Additionally, participants from the MaGIC consortium are included if they are not part of the study with the ID ""DFCI Registry."" Both conditions must be satisfied for inclusion in the cohort."
FOX-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""molecular_analysis.gene1"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""gene1"": [""FOXO1""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants who are part of the INSTRuCT consortium and have undergone molecular analysis showing the presence of the gene FOXO1.
test_2,"{""value"": {""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject is censored (i.e. has had no event(s))""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""censor_status"": [""Subject is censored (i.e. has had no event(s))""]}}]}","The cohort consists of subjects who are censored, meaning they have not experienced any events."
DaSH - INTERACT all patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
INSTRuCT FOX-O1 present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""molecular_analysis.gene1"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""gene1"": [""FOXO1""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have undergone molecular analysis, which revealed the presence of the FOXO1 gene, and the molecular abnormality result for this gene is marked as ""Present."""
INSTRuCT FOX-O1 present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""molecular_analysis.gene1"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""gene1"": [""FOXO1""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals have undergone molecular analysis, which revealed the presence of the FOXO1 gene, and the molecular abnormality result for this gene is marked as ""Present."""
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INRG 2022-04 Extension,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Unknown""]}}]}]}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""EVANS""]}}, {""IN"": {""stage"": [""Stage IV""]}}]}]}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. The selection criteria include two groups: 

1. Patients with an unknown stage according to the INSS staging system, who were between 1 and 1.5 years old at the time of tumor assessment.
2. Patients with Stage IV disease according to the EVANS staging system, who were also between 1 and 1.5 years old at the time of tumor assessment. 

Both groups are included in the study, and all criteria must be met for each respective group."
INRG  2022-04 Cohort 3,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS""]}}, {""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}]}]}","The cohort consists of patients from the INRG consortium. At the initial diagnosis phase, patients included are those whose age at tumor assessment is between 365 and 546 days. Additionally, patients are selected if they are classified as Stage M according to the INRGSS staging system or as Stage 4 according to the INSS staging system."
INRG 2022-04 Base OR Extension,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Unknown""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. The selection criteria include two main groups. The first group includes patients with either an unknown stage using the INSS staging system or Stage IV using the EVANS staging system, with an age at tumor assessment between 365 and 547 days. The second group includes patients with an age at tumor assessment between 365 and 546 days, and either Stage M using the INRGSS staging system or Stage 4 using the INSS staging system."
SET 2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Abdomen""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Abdomen""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were at the initial diagnosis phase of their disease and were diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicated that the tumor site was located in the abdomen."
INRG 2022-04 Base OR Extension,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Unknown""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. The selection criteria include two main groups. The first group includes patients with either an unknown stage using the INSS staging system or Stage IV using the EVANS staging system, with an age at tumor assessment between 365 and 547 days. The second group includes patients with an age at tumor assessment between 365 and 546 days, and either Stage M using the INRGSS staging system or Stage 4 using the INSS staging system."
Infant RMS,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Spindle cell""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 365}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 365}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, Embryonal rhabdomyosarcoma (ERMS), Botryoid rhabdomyosarcoma (BRMS), and Spindle cell rhabdomyosarcoma. Additionally, the patients included in the study were assessed for tumors at an age ranging from 0 to 365 days."
Extremity RMS ,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are at the initial diagnosis phase of their disease. These patients have been diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Embryonal rhabdomyosarcoma (ERMS), rhabdomyosarcoma that is not classifiable, rhabdomyosarcoma with mixed embryonal and alveolar features, or spindle cell rhabdomyosarcoma. Additionally, the tumor sites for these patients are located in the buttock, upper arm, thigh, shoulder, other extremities, lower leg, knee, foot, forearm, or hand."
non-US,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AIEOP"", ""BFM-SG"", ""CWS"", ""DCOG"", ""EpSSG"", ""GPLP"", ""GPOH"", ""ICG"", ""JCCG"", ""JPLSG"", ""MMT"", ""MRC"", ""NOPHO"", ""PPLLSG"", ""SIOPEN""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""AIEOP"", ""BFM-SG"", ""CWS"", ""DCOG"", ""EpSSG"", ""GPLP"", ""GPOH"", ""ICG"", ""JCCG"", ""JPLSG"", ""MMT"", ""MRC"", ""NOPHO"", ""PPLLSG"", ""SIOPEN""]}}]}","The cohort includes participants whose data was contributed by any of the following organizations: AIEOP, BFM-SG, CWS, DCOG, EpSSG, GPLP, GPOH, ICG, JCCG, JPLSG, MMT, MRC, NOPHO, PPLLSG, and SIOPEN."
INTERACT - femme,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
INRG 2022-04 Base OR Extension,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Unknown""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. The selection criteria include two main groups. The first group includes patients with an unknown stage according to the INSS staging system, and their age at tumor assessment is between 365 and 547 days. Alternatively, this group also includes patients with Stage IV according to the EVANS staging system, with the same age range at tumor assessment. The second group includes patients with an age at tumor assessment between 365 and 546 days. Within this group, patients are either classified as Stage M according to the INRGSS staging system or as Stage 4 according to the INSS staging system."
NBL Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease. Both criteria must be met for inclusion in the cohort.
INRG2022-04_20240725,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 547}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 546}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Unknown""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 546}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}]}]}","The cohort consists of patients from the INRG consortium who were at the initial diagnosis phase. The selection criteria include two main groups. The first group includes patients with either an unknown stage using the INSS staging system or Stage IV using the EVANS staging system, and who were between 365 and 547 days old at the time of tumor assessment. The second group includes patients who were between 365 and 546 days old at the time of tumor assessment and either had Stage M using the INRGSS staging system or Stage 4 using the INSS staging system."
"INSTRuCT Black, Male","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male individuals who are Black or African American and are part of the INSTRuCT consortium.
"INSTRuCT Black, Female","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are Black or African American and are part of the INSTRuCT consortium.
"Composed INSTRuCT, AA","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and identify as Black or African American. The selection includes both males and females, meaning participants can be either male or female, as long as they meet the other criteria of being Black or African American and part of the INSTRuCT consortium."
"INSTRuCT Black, Male","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male individuals who are Black or African American and are part of the INSTRuCT consortium.
ddoc,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""DCOG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""data_contributor_id"": [""DCOG""]}}]}",The cohort consists of participants who are part of the INTERACT consortium and have data contributed by the DCOG. Both criteria must be met for inclusion in the cohort.
INRG,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
"INSTRuCT Black, female","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are Black or African American and are part of the INSTRuCT consortium.
NODAL AnnArbor Stage I-II,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I"", ""Stage II""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ann Arbor""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""Ann Arbor""]}}, {""IN"": {""stage"": [""Stage I"", ""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium. These individuals have been staged using the Ann Arbor staging system and are classified as either Stage I or Stage II.
INRG Stage 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the INRG consortium and have been classified as Stage 1 in their stagings.
"Composed - INSTRuCT black, M, F","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and identify as Black or African American. The selection includes both males and females, meaning participants can be either male or female, as long as they meet the other criteria."
"INSTRuCT Black, female","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are Black or African American and are part of the INSTRuCT consortium.
NLPHL 2023-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically the Nodular Lymphocyte Predominance subtype."
NLPHL 2023-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically the Nodular Lymphocyte Predominance subtype."
INSTRuCT 2022-06,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, and spindle cell rhabdomyosarcoma. Additionally, these participants exhibit molecular abnormalities characterized by the presence of FOXO1-PAX7 fusion, FOXO1-PAX3 fusion, or FOXO1-Other fusion."
NLPHL 2023-01,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically Nodular Lymphocyte Predominance. Both criteria must be met for inclusion in the study."
non-US,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AIEOP"", ""BFM-SG"", ""CWS"", ""DCOG"", ""EpSSG"", ""GPLP"", ""GPOH"", ""ICG"", ""JCCG"", ""JPLSG"", ""MMT"", ""MRC"", ""NOPHO"", ""PPLLSG"", ""SIOPEN""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""AIEOP"", ""BFM-SG"", ""CWS"", ""DCOG"", ""EpSSG"", ""GPLP"", ""GPOH"", ""ICG"", ""JCCG"", ""JPLSG"", ""MMT"", ""MRC"", ""NOPHO"", ""PPLLSG"", ""SIOPEN""]}}]}","The cohort includes participants whose data is contributed by any of the following organizations: AIEOP, BFM-SG, CWS, DCOG, EpSSG, GPLP, GPOH, ICG, JCCG, JPLSG, MMT, MRC, NOPHO, PPLLSG, and SIOPEN."
1531_Nbl,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL1531""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL1531""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID ANBL1531. Both criteria must be met for inclusion in the cohort.
INRG 1975-1009,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1981, ""upperBound"": 2009}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1981}}, {""LTE"": {""year_at_disease_phase"": 2009}}]}]}","The cohort consists of individuals who are part of the INRG consortium. Additionally, these individuals were diagnosed or had a disease phase occurring between the years 1981 and 2009, inclusive."
INSTRuCT 2022-06,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, and spindle cell rhabdomyosarcoma. Additionally, these participants exhibit molecular abnormalities characterized by the presence of FOXO1-PAX7 fusion, FOXO1-PAX3 fusion, or FOXO1-Other fusion."
"INSTRuCT Blk, Male","{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male individuals who are Black or African American and are part of the INSTRuCT consortium.
INSTRuCT black male and female,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of individuals who are either female or male, identify as Black or African American, and are part of the INSTRuCT consortium."
INSTRuCT black male and female,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""race"": [""Black or African American""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of individuals who are either female or male, identified as Black or African American, and are part of the INSTRuCT consortium. The selection criteria require that participants meet all three conditions: being part of the INSTRuCT consortium, identifying as Black or African American, and being either female or male."
HL Nodular,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically Nodular Sclerosis, NOS."
HL Classical,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Classical, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Classical, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Classical Hodgkin Lymphoma, not otherwise specified (NOS)."
inrg 2025,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
Neuroblastoma Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 disease.
INRG 2023-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2021}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2021}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2021. At the initial diagnosis phase, these patients were identified with MYCN amplification, which was confirmed as present. Additionally, their disease was staged as either Stage 1, Stage 2a, or Stage 2b according to the INSS staging system."
INRG 2023-02,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2021}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2021}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2021. At the initial diagnosis phase, these patients were classified under the INSS staging system as Stage 1, Stage 2a, or Stage 2b. Additionally, they exhibited MYCN amplification, which was confirmed to be present through molecular analysis."
HL Demo,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage II""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage II cancer. Both criteria must be met for inclusion in the study.
Stage III HL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage III""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage III""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage III cancer. Both criteria must be met for inclusion in the study.
Stage IV HL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer. Both criteria must be met for inclusion in the study.
Stage II HL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage II""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been diagnosed with Stage II cancer. Both criteria must be met for inclusion in the study.
HL Mixed cellularity,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Mixed Cellularity, NOS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Mixed Cellularity, NOS""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Hodgkin Lymphoma, Mixed Cellularity, NOS."
inrg 2025,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
FLT3-ITD Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
Hypo_AYA_BALL,"{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""White""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Not Hispanic or Latino""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2013, ""upperBound"": 2023}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}, ""disease_characteristics.who_aml"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""AML, NOS"", ""Acute megakaryoblastic leukemia"", ""Acute monoblastic/monocytic leukemia""]}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""race"": [""White""]}}, {""IN"": {""ethnicity"": [""Not Hispanic or Latino""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2013}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""who_aml"": ""AML, NOS""}}, {""!="": {""who_aml"": ""Acute megakaryoblastic leukemia""}}, {""!="": {""who_aml"": ""Acute monoblastic/monocytic leukemia""}}]}], ""path"": ""disease_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""dna_index"": [""DNA Index <= 1 (Hypodiploid, Diploid)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are White and not Hispanic or Latino. They were diagnosed with the disease between the years 2013 and 2023. The molecular analysis shows a DNA index of less than or equal to 1, indicating hypodiploid or diploid status. The cohort excludes individuals with specific types of acute myeloid leukemia (AML), namely AML, NOS, acute megakaryoblastic leukemia, and acute monoblastic/monocytic leukemia. Additionally, the survival characteristics of the individuals are known."
inrg 4n,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
INRG 4N,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
"No Bone, Marrow, CNS, Lungs, Skin","{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Unknown""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium. The selection criteria include individuals whose tumor assessments indicate the presence of metastatic tumors. The tumor sites considered are the bone, bone marrow, central nervous system, liver, lung, and skin. Additionally, the tumor state must be either absent or unknown. All these conditions must be met for inclusion in the cohort."
11q deletion absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants do not exhibit the 11q deletion molecular abnormality, as the result for this abnormality is absent."
Liver Metastasis Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Liver""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have tumor assessments indicating that the tumor classification is metastatic, the tumor state is absent, and the tumor site is the liver. All these criteria must be met for inclusion in the cohort."
Infants 3-12 months RMS,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Spindle cell"", ""Embryonal rhabdomyosarcoma (ERMS)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 91, ""upperBound"": 365}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Spindle cell"", ""Embryonal rhabdomyosarcoma (ERMS)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 91}}, {""LTE"": {""age_at_tumor_assessment"": 365}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who were at the initial diagnosis phase of their disease. These patients have specific histological types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Rhabdomyosarcoma with mixed embryonal and alveolar features, Rhabdomyosarcoma not classifiable, spindle cell, and embryonal rhabdomyosarcoma (ERMS). Additionally, the age of the patients at the time of tumor assessment is between 91 and 365 days."
INRG MYCN absent - test,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
Metastatic extremity RMS,"{""value"": {""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group IV""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group IV""]}}], ""path"": ""stagings""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had rhabdomyosarcoma, specifically classified as Alveolar rhabdomyosarcoma (ARMS), Embryonal rhabdomyosarcoma (ERMS), Rhabdomyosarcoma (RMS) not classifiable, or Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features. The tumor sites for these patients were located in the buttock, upper arm, thigh, shoulder, other extremities, lower leg, knee, foot, forearm, or hand. Additionally, these patients were categorized in IRS Group IV."
INRG 4N 1981-2001,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1981, ""upperBound"": 2001}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1981}}, {""LTE"": {""year_at_disease_phase"": 2001}}]}, {""nested"": {""AND"": [{""AND"": [{""!="": {""lkss_obfuscated"": ""Unknown""}}]}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""!="": {""histology"": ""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype""}}]}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""!="": {""tumor_site"": ""Bone""}}, {""!="": {""tumor_site"": ""Bone Marrow""}}, {""!="": {""tumor_site"": ""Central Nervous System""}}, {""!="": {""tumor_site"": ""Liver""}}, {""!="": {""tumor_site"": ""Lung""}}, {""!="": {""tumor_site"": ""Skin""}}]}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients associated with the INRG consortium who were diagnosed between 1981 and 2001. At the initial diagnosis phase, patients with the histology subtype ""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype"" are excluded. Additionally, patients with tumors located in the bone, bone marrow, central nervous system, liver, lung, or skin are excluded. The selected patients must have an absent tumor state and a metastatic tumor classification. Furthermore, any patients with unknown survival characteristics are excluded from the cohort."
Testing,"{""value"": {""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""GMKF"", ""TARGET - GDC""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""GMKF"", ""TARGET - GDC""]}}], ""path"": ""external_references""}}]}","The cohort includes individuals who have external references from either ""GMKF"" or ""TARGET - GDC"". These criteria are combined using an ""AND"" condition, meaning that the selection is based on the presence of either of these external resource names."
1990-2020 Stage 4 CNS Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as Stage 4 with metastatic tumors. The tumors were located in the central nervous system, and there was an absence of tumor state."
INTERACT - male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
lymph nodes absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2023}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed between the years 2010 and 2023. They have been staged as either Stage 4 or Stage M. Additionally, their tumor assessments indicate that the tumor site is the lymph nodes, and the tumor state is absent."
INRG  2023-02 - 20240923,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2021}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2021}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}, {""IN"": {""stage_system"": [""INSS""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2021. At the initial diagnosis phase, these patients have a molecular abnormality characterized by MYCN amplification, which is present. Additionally, their disease is staged as either Stage 1, Stage 2a, or Stage 2b according to the INSS staging system."
lymph node present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2023}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and have been diagnosed between the years 2010 and 2023. These patients are in either Stage 4 or Stage M of their disease. Additionally, they have tumors present in the lymph nodes."
mets anywhere else,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2023}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Neck"", ""Other"", ""Pelvis""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Neck"", ""Other"", ""Pelvis""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and have been diagnosed between the years 2010 and 2023. These patients are in either Stage 4 or Stage M of their disease. Additionally, they have tumors that are present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Neck, Pelvis, or other specified locations."
2003-2023 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}]}]}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium, with data collected between 2003 and 2023. At the initial diagnosis phase, the patients included have metastatic tumors. Specifically, the cohort includes patients with tumors located in the bone marrow, bone, central nervous system, liver, lung, or skin, provided the tumor state is neither present nor unknown. Additionally, patients with tumors present in the lymph nodes are included. Furthermore, the cohort encompasses patients diagnosed at Stage 4 or Stage M, according to the EVANS, INRGSS, or INSS staging systems."
INRG 4N 2002-2023,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2002, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2002}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""!="": {""lkss_obfuscated"": ""Unknown""}}]}], ""path"": ""survival_characteristics""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""!="": {""histology"": ""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype""}}]}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""!="": {""tumor_site"": ""Bone""}}, {""!="": {""tumor_site"": ""Bone Marrow""}}, {""!="": {""tumor_site"": ""Central Nervous System""}}, {""!="": {""tumor_site"": ""Liver""}}, {""!="": {""tumor_site"": ""Lung""}}, {""!="": {""tumor_site"": ""Skin""}}]}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between the years 2002 and 2023. At the initial diagnosis phase, patients with the histology subtype ""Ganglioneuroma (Schwannian Stroma-Dominant), Maturing Subtype"" are excluded. Additionally, patients with tumors located in the bone, bone marrow, central nervous system, liver, lung, or skin are excluded. The selected patients must have a tumor state classified as ""Absent"" and a tumor classification of ""Metastatic."" Furthermore, any patients with unknown survival characteristics are excluded from the cohort."
apec_nbl,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""APEC14B1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""APEC14B1""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID APEC14B1. Both criteria must be met for inclusion in the cohort.
MYCN Nonamplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
INRG MYCN present - test,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have undergone molecular analysis, which revealed the presence of MYCN amplification."
MYCN Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium and have a molecular analysis showing the presence of MYCN amplification.
2003-2023 4N,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}, {""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. At the initial diagnosis phase, these patients had tumors present in the lymph nodes. The staging of their disease was classified as either Stage 4 or Stage M, according to the EVANS, INRGSS, or INSS staging systems."
INRG 2010-2023,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}]}","The cohort consists of participants who are part of the INRG consortium. Additionally, the participants must have been in a disease phase between the years 2010 and 2023, inclusive."
2003-2023 4N MNA,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}, {""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. At the initial diagnosis phase, these patients had tumors present in the lymph nodes. Their disease was staged using the EVANS, INRGSS, or INSS systems, and they were classified as either Stage 4 or Stage M. Additionally, these patients exhibited MYCN amplification, which was confirmed to be present through molecular analysis."
2003-2023 4N MYCN-NA,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}, {""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. At the initial diagnosis, these patients had tumors present in the lymph nodes. Their disease was classified as either Stage 4 or Stage M according to the EVANS, INRGSS, or INSS staging systems. Additionally, these patients were tested for MYCN amplification, which was found to be absent."
1990-2020 Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were initially diagnosed with their disease between the years 1990 and 2020. At the time of their initial diagnosis, they were classified as having Stage 4 of the disease."
inv(16)(p13q22) CBFB/MYH11,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
4N 12 months and older,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2002, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2002}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2002 and 2023. At the initial diagnosis phase, these patients were classified as having Stage M disease according to the INRGSS staging system. Additionally, they had metastatic tumors present in the lymph nodes."
Localized extremity RMS,"{""value"": {""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group I"", ""Group IIA"", ""Group IIB"", ""Group IIC"", ""Group III""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group I"", ""Group IIA"", ""Group IIB"", ""Group IIC"", ""Group III""]}}], ""path"": ""stagings""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had histologies classified as Alveolar rhabdomyosarcoma (ARMS), Embryonal rhabdomyosarcoma (ERMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, or spindle cell. The tumor sites for these patients were located in the buttock, upper arm, thigh, shoulder, other extremities, lower leg, knee, foot, forearm, or hand. Additionally, these patients were categorized into IRS groups I, IIA, IIB, IIC, or III."
t(8;21)(q22;q22) RUNX1/ETO,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, identified as the translocation t(8;21)(q22;q22) RUNX1/ETO, which is present in their molecular analysis results."
NODAL AnnArbor Stage I-II,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I"", ""Stage II""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ann Arbor""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""Ann Arbor""]}}, {""IN"": {""stage"": [""Stage I"", ""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants from the NODAL consortium who have been staged using the Ann Arbor staging system. These participants are specifically in Stage I or Stage II of their condition.
NODAL bulky agg,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulky_nodal_aggregate"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulky_nodal_aggregate"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants who are part of the NODAL consortium and have a disease characteristic of having a bulky nodal aggregate.
NODAL -M-B-LowA,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Albumin""]}, ""labs.lab_result_numeric"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 3}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}], ""path"": ""disease_characteristics""}}, {""nested"": {""AND"": [{""IN"": {""lab_test"": [""Albumin""]}}, {""AND"": [{""GTE"": {""lab_result_numeric"": 0}}, {""LTE"": {""lab_result_numeric"": 3}}]}], ""path"": ""labs""}}]}","The cohort consists of male participants who are part of the NODAL consortium. These individuals have a confirmed presence of bulk disease. Additionally, they have undergone lab tests for Albumin, with their lab results falling within the numeric range of 0 to 3."
00B1 4N,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2012, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b"", ""Stage 3"", ""Stage III"", ""Stage II"", ""Stage I"", ""Stage 4s"", ""Stage IVs""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2012}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""!="": {""tumor_site"": ""Bone Marrow""}}, {""!="": {""tumor_site"": ""Bone""}}, {""!="": {""tumor_site"": ""Central Nervous System""}}, {""!="": {""tumor_site"": ""Liver""}}, {""!="": {""tumor_site"": ""Lung""}}]}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""!="": {""stage"": ""Stage 1""}}, {""!="": {""stage"": ""Stage 2a""}}, {""!="": {""stage"": ""Stage 2b""}}, {""!="": {""stage"": ""Stage 3""}}, {""!="": {""stage"": ""Stage III""}}, {""!="": {""stage"": ""Stage II""}}, {""!="": {""stage"": ""Stage I""}}, {""!="": {""stage"": ""Stage 4s""}}, {""!="": {""stage"": ""Stage IVs""}}]}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed between 2012 and 2019. These patients do not have tumors located in the bone marrow, bone, central nervous system, liver, or lung, and their tumor state is neither present nor unknown. Additionally, their tumors are classified as metastatic. The patients are not in stages 1, 2a, 2b, 3, III, II, I, 4s, or IVs at the initial diagnosis."
2002-2023 Stage 4/M,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}, {""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. At the initial diagnosis phase, these patients were classified under stage systems EVANS, INRGSS, or INSS, and were specifically in Stage 4 or Stage M."
2003-2023 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}]}]}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with the disease between 2003 and 2023. The selection criteria include three main groups: 

1. Patients with Stage 4 or Stage M disease, classified under the EVANS, INRGSS, or INSS staging systems.
2. Patients with metastatic tumors present in the lymph nodes.
3. Patients with metastatic tumors in the bone marrow, bone, central nervous system, liver, lung, skin, or lymph nodes, but without the tumor state being present or unknown. 

All patients meet the criteria of being part of the INRG consortium and having their initial diagnosis within the specified years."
apec_nbl,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""APEC14B1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""APEC14B1""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INRG consortium and are involved in the study identified by the study ID APEC14B1. Both criteria must be met for inclusion in the cohort.
1990-2002 Lymph nodes present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}, {""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with a disease phase between the years 1990 and 2002. These patients have metastatic tumors that are present in the lymph nodes. The staging of their disease is classified as Stage 4, Stage IV, or Stage M, according to the EVANS, INRGSS, or INSS staging systems."
2003-2023 4N MNA,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}]}]}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed between 2003 and 2023. The selection criteria include patients with MYCN amplification present at the initial diagnosis. Additionally, patients are included if they were diagnosed at Stage 4 or Stage M according to the EVANS, INRGSS, or INSS staging systems. The cohort also includes patients with metastatic tumors present in the lymph nodes. Furthermore, patients with metastatic tumors in the bone marrow, bone, central nervous system, liver, lung, skin, or lymph nodes are included, provided the tumor state is neither present nor unknown."
NODAL Bulky = yes,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants who are part of the NODAL consortium and have been identified with bulk disease.
NODAL Bulky = no,"{""value"": {""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""No""]}}], ""path"": ""disease_characteristics""}}]}","The cohort includes individuals who do not have bulk disease, as indicated by the selection of ""No"" for the bulk disease characteristic."
INRG Nodal Mets Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are part of the INRG consortium and are at the initial diagnosis phase of their disease. These individuals have metastatic tumors that are present in the lymph nodes.
inrg stage 4/IV/M,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}]}","The cohort consists of participants who are part of the INRG consortium and have been diagnosed with Stage 4, Stage IV, or Stage M cancer."
1990-2020 Lymph Nodes Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as Stage 4 with metastatic tumors. The tumors were present in the lymph nodes."
INRG 1982-2010,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1981, ""upperBound"": 2010}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1981}}, {""LTE"": {""year_at_disease_phase"": 2010}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with the disease between the years 1981 and 2010, inclusive."
INRG 1990-2002,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}","The cohort consists of individuals who are part of the INRG consortium. Additionally, these individuals were diagnosed or had a disease phase occurring between the years 1990 and 2002, inclusive."
2003-2023 MYCN-Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals were diagnosed with their disease between the years 2003 and 2023. At the initial diagnosis phase, they exhibited a molecular abnormality characterized by MYCN amplification, which was confirmed to be present."
1990-2020 Stage 4 Bone Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Bone""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as having Stage 4 metastatic disease. The tumor assessments indicated that the tumor site was the bone, the tumor state was absent, and the tumor classification was metastatic."
1990-2020 Stage 4 Bone Marrow Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as Stage 4 with metastatic tumors. The tumor assessments indicated that the tumor site was the bone marrow, and the tumor state was absent."
INRG No extranodal present or unknown,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Other""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who have metastatic tumors. The tumors are located in one of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Skin, or Other. Importantly, the tumor state must not be ""Present"" or ""Unknown."""
1990-2020 Stage 4 Liver Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as having Stage 4 metastatic disease. Specifically, their tumor assessments indicated that the tumor was metastatic, located in the liver, and the tumor state was recorded as absent."
1990-2020 Stage 4 Skin Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as having Stage 4 metastatic disease. The tumor assessments indicated that the tumor site was the skin, the tumor state was absent, and the tumor classification was metastatic."
All AML,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
All NBL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
NODAL AnnArbor Stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
NODAL NLPHL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Lymphocyte Predominance""]}}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the NODAL consortium and have a histology diagnosis of Hodgkin Lymphoma, specifically the Nodular Lymphocyte Predominance subtype."
1990-2020 Stage 4 Lung Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 1990 and 2020. At the initial diagnosis phase, these patients were classified as having Stage 4 metastatic tumors. The tumors were located in the lung and were absent at the time of assessment."
INRG Patients with Relapse Sites,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who are in the relapse phase of their disease. Additionally, these participants have a tumor state that is currently present, as assessed in their tumor evaluations."
INRG Patients with Relapse Sites,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who are in the relapse phase of their disease. Additionally, these participants have a tumor state that is currently present, as assessed in their tumor evaluations."
Eligibility for INRG Proposal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""SIOPEN"", ""COG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1985, ""upperBound"": 2020}, ""secondary_malignant_neoplasm.smn_yn"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No"", ""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""data_contributor_id"": [""SIOPEN"", ""COG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1985}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""smn_yn"": [""No"", ""Yes""]}}], ""path"": ""secondary_malignant_neoplasm""}}]}","The cohort consists of individuals who are part of the INRG consortium and have data contributed by either SIOPEN or COG. The participants were diagnosed between the years 1985 and 2020. Additionally, the cohort includes individuals regardless of whether they have a secondary malignant neoplasm, as both ""Yes"" and ""No"" responses are included."
2022-06,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Spindle cell""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FOXO1-PAX7 fusion"", ""FOXO1-PAX3 fusion"", ""FOXO1-Other fusion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, and spindle cell rhabdomyosarcoma. Additionally, these participants exhibit molecular abnormalities characterized by the presence of FOXO1-PAX7 fusion, FOXO1-PAX3 fusion, or FOXO1-Other fusion."
NODAL mass=yes,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""BULK_MED_MASS"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have a disease characteristic of having a bulk mediastinal mass.
NODAL mass=yes,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""BULK_MED_MASS"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of participants who are part of the NODAL consortium and have a disease characteristic of having a bulk mediastinal mass.
4n 1990-2002,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Other""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1990 and 2002. At the initial diagnosis, these patients had metastatic tumors present in the lymph nodes. Additionally, they had metastatic tumors in sites such as the bone, bone marrow, central nervous system, liver, lung, skin, or other locations, but these tumors were not present or their presence was unknown. Furthermore, the patients were classified as having Stage 4, Stage IV, or Stage M disease."
11q deletion present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""11q deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium and have a molecular analysis showing the presence of an 11q deletion abnormality.
1990-2020 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 metastatic disease between 1990 and 2020. The selection criteria include patients with tumors assessed at various sites. Specifically, patients with tumors present in the lymph nodes are included, while those with tumors absent in the bone, bone marrow, central nervous system, liver, lung, and skin are also part of the cohort. Each patient must meet these criteria at the initial diagnosis phase."
DaSH - INTERACT FLT3 ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
NODAL AnnArbor Stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
NODAL AnnArbor Stage E,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.E"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""N""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""E"": [""N""]}}], ""path"": ""stagings""}}]}","The cohort consists of participants who are part of the NODAL consortium and have a staging classification of ""E"" equal to ""N""."
NODAL AnnArbor Stage E=yes,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.E"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Y""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""E"": [""Y""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the NODAL consortium and have a staging classification where the 'E' category is marked as 'Y'.
photon,"{""value"": {""radiation_therapies.energy_type"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Photon""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort includes individuals who have received radiation therapies specifically using the energy type ""Photon."""
2003-2023 Lymph nodes not unknown,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. At the initial diagnosis phase, these individuals had tumors located in the lymph nodes, and the tumor state was known, explicitly excluding cases where the tumor state was marked as ""Unknown."""
2003-2023 no extranodal mets present or unknown,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with the disease between the years 2003 and 2023. At the initial diagnosis phase, these individuals had metastatic tumors located in the bone marrow, bone, central nervous system, liver, lung, or skin. Importantly, the tumor state at this phase was neither present nor unknown."
2003-2020 4N,"{""value"": [{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Unknown""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients whose disease phase occurred between 2003 and 2020. All patients are part of the INRG consortium and have metastatic tumors. The cohort includes patients with tumors present in the lymph nodes. Additionally, it includes patients with tumors classified as absent or unknown in the skin, absent in the liver, absent in the bone marrow, and absent in the bone."
2003-2020,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}","The cohort includes individuals whose year at the disease phase falls between 2003 and 2020, inclusive."
1990-2002,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}","The cohort includes individuals whose year at the disease phase falls between 1990 and 2002, inclusive."
CNS Metastasis Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who have metastatic tumors located in the Central Nervous System, with the tumor state being absent."
2003-2023 Nodal mets present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. At the initial diagnosis phase, these patients had metastatic tumors that were present in the lymph nodes."
Lymph Node Metastasis Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}",The cohort consists of individuals who are part of the INRG consortium. These individuals have tumor assessments indicating the presence of metastatic tumors specifically located in the lymph nodes.
17q gain absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of the 17q gain molecular abnormality."
17q gain present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INRG consortium. These individuals have a molecular analysis showing the presence of a 17q gain abnormality.
1p deletion absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of the 1p deletion molecular abnormality."
1p deletion present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INRG consortium who have a molecular analysis showing the presence of a 1p deletion abnormality.
Bone Metastasis Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who have metastatic tumors. Specifically, these tumors are located in the bone and are in an absent state according to tumor assessments."
proton,"{""value"": {""radiation_therapies.energy_type"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Proton""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort includes individuals who have received radiation therapies specifically using proton energy type.
Lung Metastasis Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have tumor assessments indicating that the tumor site is the lung, the tumor state is absent, and the tumor classification is metastatic. All these criteria must be met for inclusion in the cohort."
1990-2002 4n,"{""value"": [{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M"", ""Stage 4"", ""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M"", ""Stage 4"", ""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients whose disease phase occurred between 1990 and 2002. All patients are part of the INRG consortium. They have been staged as either Stage M, Stage 4, or Stage IV, according to the EVANS, INRGSS, or INSS staging systems. The patients have metastatic tumors, with specific tumor site and state conditions: tumors are present in the lymph nodes, absent in the liver, bone marrow, and bone."
INRG 4/IV/M,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M"", ""Stage 4"", ""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M"", ""Stage 4"", ""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been staged using one of the following systems: EVANS, INRGSS, or INSS. Additionally, they have been classified as having Stage M, Stage 4, or Stage IV disease. All these criteria must be met for inclusion in the cohort."
1990-2002 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 metastatic disease between 1990 and 2002. The selection criteria include patients with tumors classified as metastatic, with specific tumor site and state conditions. For lymph nodes, the tumor must be present, while for bone, bone marrow, central nervous system, liver, lung, and skin, the tumor must be absent."
2003-2020 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2019. All patients were at Stage 4 during the initial diagnosis phase and had metastatic tumors. The cohort is divided based on the tumor site and state: patients with tumors present in the lymph nodes, and patients with tumors absent in the bone, bone marrow, central nervous system, liver, lung, and skin."
1990-2002 Non-4N Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were initially diagnosed with the disease between 1990 and 2002. At the initial diagnosis, these patients were classified as having metastatic tumors that were present in one or more of the following sites: bone, bone marrow, central nervous system, liver, lung, or skin. Additionally, these patients were diagnosed at Stage 4 of the disease."
test1,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Female""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""TCGM2004""]}, ""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AIEOP""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""AIEOP""]}}, {""AND"": [{""!="": {""sex"": ""Female""}}]}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""TCGM2004""]}}], ""path"": ""studies""}}]}","The cohort consists of participants who are not female, are part of the study identified as ""TCGM2004,"" and have data contributed by ""AIEOP."""
INSTRuCT Latinx,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Female""]}}]}]}","The cohort consists of individuals who are either male or female, identify as Hispanic or Latino, and are part of the INSTRuCT consortium. The selection criteria include both males and females, but all participants must be Hispanic or Latino and affiliated with the INSTRuCT consortium."
cogtest,"{""value"": {""data_contributor_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""data_contributor_id"": [""COG""]}}]}",The cohort consists of participants whose data was contributed by the COG (Children's Oncology Group).
INSTRuCT Latino male,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are Hispanic or Latino and are part of the INSTRuCT consortium.
INSTRuCT Latino male2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""ethnicity"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hispanic or Latino""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""ethnicity"": [""Hispanic or Latino""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are Hispanic or Latino and are part of the INSTRuCT consortium.
Diagnosis 2010-2020,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2024}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2024}}]}]}","The cohort includes individuals whose year at the disease phase falls between 2010 and 2024, inclusive."
2010-2016,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2016}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2016}}]}]}","The cohort includes individuals whose year at the disease phase falls between 2010 and 2016, inclusive."
DaSH - INTERACT All,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
2010-2024 4n,"{""value"": [{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2024}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2024}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients whose disease phase occurred between 2010 and 2024. All patients are part of the INRG consortium. The cohort includes patients with metastatic tumors that are absent in the liver, bone, bone marrow, and central nervous system. Additionally, at the initial diagnosis phase, patients have metastatic tumors present in the lymph nodes. The patients are classified as having Stage 4, Stage IV, or Stage M disease."
4n 2010-2020,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M"", ""Stage 4"", ""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2010, ""upperBound"": 2024}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M"", ""Stage 4"", ""Stage IV""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2010}}, {""LTE"": {""year_at_disease_phase"": 2024}}]}]}]}","The cohort consists of patients from the INRG consortium who meet specific criteria. These patients have metastatic tumors and are assessed for tumor presence in various sites. Specifically, the cohort includes patients with tumors present in the lymph nodes, and those with tumors absent in the liver, bone marrow, and bone. Additionally, the cohort includes patients staged as Stage M, Stage 4, or Stage IV according to the EVANS, INRGSS, or INSS staging systems. All patients were diagnosed or treated between the years 2010 and 2024."
INSRuCT 2022's,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Adult Fibrosarcoma (8810/3)"", ""Alveolar soft-part sarcoma (9581/3)"", ""Angiosarcoma of Soft Tissue (9120/3)"", ""Clear cell sarcoma of soft tissue (9044/3)"", ""Ectomesenchymoma (8921/3)"", ""Epithelioid Malignant peripheral nerve sheath tumor (9542/3)"", ""Epithelioid sarcoma (8804/3)"", ""Extraskeletal Mesenchymal Chondrosarcoma (9240/3)"", ""Extraskeletal myxoid chondrosarcoma (9231/3)"", ""Leiomyosarcoma (Excluding Skin) (8890/3)"", ""Liposarcoma, NOS (8850/3)"", ""Low-Grade Fibromyxoid Sarcoma (8840/3)"", ""Low-grade myofibroblastic sarcoma (8825/3)"", ""Malignant peripheral nerve sheath tumor (9540/3)"", ""Myoepithelioma carcinoma (8982/3)"", ""Myxoid Liposarcoma (8852/3)"", ""PEComa NOS, malignant (8714/3)"", ""Synovial sarcoma NOS (9040/3)"", ""Synovial sarcoma, biphasic (9043/3)"", ""Synovial sarcoma, spindle cell (9041/3)"", ""Undifferentiated pleomorphic sarcoma (8802/3)"", ""Undifferentiated round cell sarcoma (8803/3)"", ""Undifferentiated sarcoma NOS (8805/3)"", ""Undifferentiated spindle cell sarcoma (8801/3)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 8035}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 8035}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Adult Fibrosarcoma (8810/3)"", ""Alveolar soft-part sarcoma (9581/3)"", ""Angiosarcoma of Soft Tissue (9120/3)"", ""Clear cell sarcoma of soft tissue (9044/3)"", ""Ectomesenchymoma (8921/3)"", ""Epithelioid Malignant peripheral nerve sheath tumor (9542/3)"", ""Epithelioid sarcoma (8804/3)"", ""Extraskeletal Mesenchymal Chondrosarcoma (9240/3)"", ""Extraskeletal myxoid chondrosarcoma (9231/3)"", ""Leiomyosarcoma (Excluding Skin) (8890/3)"", ""Liposarcoma, NOS (8850/3)"", ""Low-Grade Fibromyxoid Sarcoma (8840/3)"", ""Low-grade myofibroblastic sarcoma (8825/3)"", ""Malignant peripheral nerve sheath tumor (9540/3)"", ""Myoepithelioma carcinoma (8982/3)"", ""Myxoid Liposarcoma (8852/3)"", ""PEComa NOS, malignant (8714/3)"", ""Synovial sarcoma NOS (9040/3)"", ""Synovial sarcoma, biphasic (9043/3)"", ""Synovial sarcoma, spindle cell (9041/3)"", ""Undifferentiated pleomorphic sarcoma (8802/3)"", ""Undifferentiated round cell sarcoma (8803/3)"", ""Undifferentiated sarcoma NOS (8805/3)"", ""Undifferentiated spindle cell sarcoma (8801/3)""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are part of the INSTRuCT consortium and were at the initial diagnosis phase of their disease. The participants have a histological diagnosis of one of the following sarcomas: Adult Fibrosarcoma, Alveolar soft-part sarcoma, Angiosarcoma of Soft Tissue, Clear cell sarcoma of soft tissue, Ectomesenchymoma, Epithelioid Malignant peripheral nerve sheath tumor, Epithelioid sarcoma, Extraskeletal Mesenchymal Chondrosarcoma, Extraskeletal myxoid chondrosarcoma, Leiomyosarcoma (excluding skin), Liposarcoma, NOS, Low-Grade Fibromyxoid Sarcoma, Low-grade myofibroblastic sarcoma, Malignant peripheral nerve sheath tumor, Myoepithelioma carcinoma, Myxoid Liposarcoma, PEComa NOS, malignant, Synovial sarcoma NOS, Synovial sarcoma, biphasic, Synovial sarcoma, spindle cell, Undifferentiated pleomorphic sarcoma, Undifferentiated round cell sarcoma, Undifferentiated sarcoma NOS, or Undifferentiated spindle cell sarcoma. The age at tumor assessment for these individuals ranges from 1 to 8035 days."
2017-2021,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2017, ""upperBound"": 2021}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2017}}, {""LTE"": {""year_at_disease_phase"": 2021}}]}]}","The cohort includes individuals whose year at the disease phase falls between 2017 and 2021, inclusive."
2003-2009,"{""value"": {""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2009}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2009}}]}]}","The cohort includes individuals whose year at the disease phase falls between 2003 and 2009, inclusive."
2003-2023 MYCN-NA,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2023. At the initial diagnosis phase, these individuals underwent molecular analysis which showed the presence of MYCN Amplification, but the result of this molecular abnormality was absent."
DaSH - INRG MYCN Not Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
DaSH - INRG All,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
1975-2009 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}}, ""__type"": ""ANCHORED""}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1981, ""upperBound"": 2009}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1981}}, {""LTE"": {""year_at_disease_phase"": 2009}}]}]}]}]}","The cohort consists of patients from the INRG consortium who meet the following criteria: They have been diagnosed with Stage 4, Stage IV, or Stage M cancer. At the initial diagnosis, their tumors are classified as metastatic. For these patients, tumors are located in the bone, bone marrow, central nervous system, liver, lung, skin, or other sites, but the tumor state is neither present nor unknown. Additionally, patients with metastatic tumors in the lymph nodes must have the tumor state marked as present. All patients were diagnosed between the years 1981 and 2009."
Stage 4 bone marrow absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the bone marrow, and the tumor state is absent."
Stage 4 Lung Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_site"": [""Lung""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with cancer at an advanced stage, specifically Stage 4, Stage IV, or Stage M. Additionally, their tumor assessments indicate that there is no tumor present in the lung."
Stage 4 bone marrow absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the bone marrow, and the tumor state is absent. All these criteria must be met for inclusion in the cohort."
All 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are all at Stage 4 of their condition. The selection criteria include patients with tumors present in the lymph nodes. Additionally, patients with tumors absent in the following sites are included: lung, other sites, skin, liver, central nervous system, bone marrow, and bone."
All INTERACT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
Stage 4 skin absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the skin, and the tumor state is absent. All these criteria must be met for inclusion in the cohort."
DaSH - INTERACT t(8;21)(q22;q22) RUNX1/ETO,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the translocation t(8;21)(q22;q22) RUNX1/ETO, and this abnormality is present in their molecular analysis results."
1990-2020 Stage 4 Bone Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as having Stage 4 metastatic disease with tumors located in the bone. Additionally, the tumor state is known, as cases with an unknown tumor state were excluded."
metastatic negative lymph node unknown,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are classified as having Stage 4, Stage IV, or Stage M cancer. These patients have no tumors present in specific sites, including the bone, bone marrow, central nervous system, liver, skin, lung, and other sites."
Stage 4 bone absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the bone, and the tumor state is absent. All these criteria must be met for inclusion in the cohort."
Stage 4 bone absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the bone, and the tumor state is absent. All these criteria must be met for inclusion in the cohort."
Stage 4 CNS absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the Central Nervous System, and the tumor state is recorded as absent. All these criteria must be met for inclusion in the cohort."
NODAL mass=no,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""BULK_MED_MASS"": [""No""]}}], ""path"": ""disease_characteristics""}}]}",The cohort consists of individuals who are part of the NODAL consortium and do not have a bulk mediastinal mass as a disease characteristic.
Stage 4 liver absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the liver is a site of interest, but no tumor is present there. All these criteria must be met for inclusion in the cohort."
Stage 4 skin absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who are at Stage 4. Additionally, these participants have tumor assessments indicating that the tumor site is the skin, and the tumor state is absent."
Stage 4 lymph node present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor is present in the lymph nodes."
4n overall,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are at Stage 4 of their condition. The selection criteria include patients with tumors assessed at various sites with specific states: tumors must be absent in the bone, bone marrow, central nervous system, skin, and lung, while tumors must be present in the lymph nodes."
1990-2020 Stage 4 Skin Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis phase, these patients were classified as having Stage 4 metastatic tumors located on the skin. Additionally, the tumor state is known, as cases with an unknown tumor state were excluded."
DaSH - INRG MYCN Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have undergone molecular analysis, which revealed the presence of MYCN amplification."
Stage 4 other absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who are classified as Stage 4. Additionally, these participants have tumor assessments indicating that the tumor site is categorized as ""Other"" and the tumor state is ""Absent."" All these criteria must be met for inclusion in the cohort."
INSS Stage 4 1990-2002,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between the years 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4 according to the INSS staging system."
INSS Stage 4 w/ complete metastatic site data,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present"", ""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present"", ""Absent""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Liver""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Lung""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Other""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}, {""IN"": {""tumor_site"": [""Skin""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are at Stage 4 according to the INSS staging system. At the initial diagnosis phase, these patients have metastatic tumors. The tumor sites include lymph nodes, bone, bone marrow, central nervous system, liver, lung, skin, and other locations. The tumor state at these sites can be either present or absent."
INSTRuCT_2022-08,,{},"The JSON file is empty, so there are no selection criteria or cohort descriptions provided."
INSTRuCT_2022-09,,{},"The JSON file is empty, indicating that there are no specific selection criteria or filters applied to the cohort."
test auto load,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are all at Stage 4 of their condition. The selection criteria include patients with tumors present in the lymph nodes. Additionally, patients with tumors absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone are included. Each patient meets all these criteria simultaneously."
1990-2020 Stage 4 Nodes Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis phase, these patients were classified as having Stage 4 disease. Their tumors were metastatic and located in the lymph nodes, with the tumor state explicitly known and not marked as unknown."
Other_mets,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the liver is a site of interest, but no tumor is present there. All these criteria must be met for inclusion in the cohort."
Bone-marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are at Stage 4 of their condition. The selection criteria include two groups: one group where the tumor site is the bone and the tumor state is absent, and another group where the tumor site is the bone marrow and the tumor state is absent. Each patient must meet all conditions within their respective group, and patients can belong to either group."
Bone-marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of patients from the INRG consortium who have been diagnosed with Stage 4 cancer. The selection criteria include patients with tumors present in either the bone or bone marrow.
Bone-marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of patients who are part of the INRG consortium and have been diagnosed with Stage 4 cancer. The selection criteria include patients with tumors present either in the bone or in the bone marrow.
Other-met_sites,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin"", ""Neck"", ""Lung"", ""Liver"", ""Central Nervous System"", ""Bone Marrow"", ""Bone"", ""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin"", ""Neck"", ""Lung"", ""Liver"", ""Central Nervous System"", ""Bone Marrow"", ""Bone"", ""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 cancer. The tumor assessments indicate that the tumors are present and located in one or more of the following sites: Skin, Neck, Lung, Liver, Central Nervous System, Bone Marrow, Bone, or other specified locations. All these criteria must be met for inclusion in the cohort."
1990-2020 Stage 4 Lung Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as having Stage 4 metastatic tumors located in the lung. Additionally, any cases where the tumor state was unknown were excluded from the selection."
2003-2020 Extranodal,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Bone"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Bone"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with their disease between the years 2003 and 2020. At the initial diagnosis phase, these patients had metastatic tumors that were present in one or more of the following sites: Bone Marrow, Central Nervous System, Liver, Lung, Bone, or Skin."
Other-mets,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}]}","The cohort consists of patients from the INRG consortium who are at Stage 4 of their condition. The selection criteria are divided into two main groups. The first group includes patients with tumors assessed as absent in the bone, bone marrow, or lymph nodes. The second group includes patients with tumors assessed as present in the liver, other sites, lung, skin, or central nervous system. For the lung site, patients may be at Stage 4, Stage IV, or Stage M."
Other_mets-present_,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are at Stage 4 of their disease. The patients have tumors present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Skin, Lung, Liver, or other unspecified sites. For the Lung site, the stage may also be referred to as Stage IV or Stage M."
INRG (all patients),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
Bone Marrow Metastasis Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who have metastatic tumors. Specifically, these tumors are located in the bone marrow and are classified as absent in terms of tumor state."
Stage 4 Any site,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 cancer. These individuals have tumors that are present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Lung, Liver, or Skin."
1990-2002 Stage 4 CNS Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1990 and 2002. Additionally, these patients have no tumors present in the Central Nervous System."
1990-2002 Stage 4 Other Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, the tumor assessments for these individuals indicate that the tumor site is classified as ""Other"" and the tumor state is ""Absent."""
DaSH - INTERACT FLT3 ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
1990-2002 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Unknown""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who meet specific criteria. Firstly, patients are included if they have been staged as Stage 4, Stage IV, or Stage M. Additionally, patients with metastatic tumors located in the bone, bone marrow, central nervous system, liver, lung, or skin are included if the tumor state is either absent or unknown. Furthermore, the cohort includes patients diagnosed between the years 1990 and 2002. Lastly, patients with metastatic tumors present in the lymph nodes are also part of the cohort. All these criteria must be met for inclusion in the study."
1990-2020 Stage 4 Liver Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as having Stage 4 metastatic tumors located in the liver. Additionally, the tumor state is known, as cases with an unknown tumor state were excluded."
1990-2020 Stage 4 Bone Marrow Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2020. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor site was specifically in the bone marrow, and any cases where the tumor state was unknown were excluded."
1990-2002 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between 1990 and 2002. The selection criteria include patients with tumors present in the lymph nodes. Additionally, patients with tumors absent in the skin, other sites, lung, liver, central nervous system, bone marrow, and bone are included."
1990-2020 Stage 4 CNS Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 1990 and 2020. These patients have metastatic tumors located in the Central Nervous System, and their tumor state is known, excluding those with an unknown tumor state."
Dash - INTERACT inv(16)(p13q22),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a molecular abnormality characterized by the inversion inv(16)(p13q22), and this abnormality is confirmed to be present in their molecular analysis results."
DaSH - INRG MYCN Not Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INRG consortium who have undergone molecular analysis. Specifically, these participants exhibit an absence of MYCN Amplification as a molecular abnormality."
NODAL bulky+mass,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}, {""IN"": {""BULK_MED_MASS"": [""No""]}}], ""path"": ""disease_characteristics""}}]}","The cohort consists of individuals who are part of the NODAL consortium. These individuals have a disease characterized by the presence of bulk disease, but they do not have a medium mass associated with the bulk disease."
1990-2002 Stage 4 Any site,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 1990 and 2002. Additionally, these individuals are at Stage 4 of their disease, with tumors present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Lung, Liver, or Skin."
DaSH - INTERACT all patients,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
DaSH - INTERACT inv(16)(p13q22),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
2003-2023 4N MYCN-NA,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""EVANS"", ""INRGSS"", ""INSS""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""disease_phase:Initial Diagnosis"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present"", ""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}]}]}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage M""]}}, {""IN"": {""stage_system"": [""EVANS"", ""INRGSS"", ""INSS""]}}]}]}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow"", ""Bone"", ""Central Nervous System"", ""Liver"", ""Lung"", ""Skin"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}, {""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed between 2003 and 2023. The selection criteria include patients with MYCN Amplification that is absent, those diagnosed at Stage 4 or Stage M according to the EVANS, INRGSS, or INSS staging systems, and those with metastatic tumors. Specifically, the cohort includes patients with metastatic tumors present in the lymph nodes. Additionally, it includes patients with metastatic tumors in sites such as the bone marrow, bone, central nervous system, liver, lung, skin, or lymph nodes, provided the tumor state is neither present nor unknown."
1990-2020 Stage 4 Known Sites,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Skin""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Lung""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Liver""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 metastatic disease between 1990 and 2020. The patients included in the study have tumors located in specific sites, namely the skin, bone, lymph nodes, lung, liver, central nervous system, or bone marrow. Importantly, patients with an unknown tumor state were excluded from the cohort."
1990-2002 Stage 4 CNS Known,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent"", ""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent"", ""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor site was the Central Nervous System, and the tumor state was either absent or present."
NODAL bulky no mass,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}, {""IN"": {""BULK_MED_MASS"": [""No""]}}], ""path"": ""disease_characteristics""}}]}","The cohort consists of individuals who are part of the NODAL consortium. These individuals have a disease characterized by the presence of bulk disease, but they do not have a medium mass associated with the bulk disease."
veri,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female"", ""Male""]}, ""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Black or African American"", ""Not Reported""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FNCLCC, Grade 2"", ""FNCLCC, Grade 3"", ""FNCLCC, Grade GX""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Brain/Leptomeninges"", ""Liver"", ""Lung"", ""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""radiation_therapies.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic"", ""Primary""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female"", ""Male""]}}, {""IN"": {""race"": [""Black or African American"", ""Not Reported""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic"", ""Primary""]}}]}]}], ""path"": ""radiation_therapies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic""]}}, {""IN"": {""tumor_site"": [""Bone"", ""Brain/Leptomeninges"", ""Liver"", ""Lung"", ""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_grade"": [""FNCLCC, Grade 2"", ""FNCLCC, Grade 3"", ""FNCLCC, Grade GX""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are either female or male and identify as Black or African American or have not reported their race. These individuals are at the initial diagnosis phase of their disease. They have tumors classified as either metastatic or primary, as indicated by radiation therapies. Additionally, they have metastatic tumors that are present in specific sites, including the bone, brain/leptomeninges, liver, lung, or bone marrow, as assessed by tumor assessments. Furthermore, their tumors are graded as FNCLCC Grade 2, Grade 3, or Grade GX according to histology evaluations."
INRG 2024-02,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection includes two groups: 

1. Patients with neuroblastoma classified under the INSS staging system as Stage 1, Stage 2a, or Stage 2b, who do not have MYCN amplification present in their molecular analysis.

2. Patients with neuroblastoma classified under the INSS staging system as Stage 3, regardless of MYCN amplification status. 

Both groups are included in the study, and the criteria are combined using an OR condition, meaning patients meeting either set of criteria are part of the cohort."
INRG 2024-02,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 3""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection includes two groups: 

1. Patients with INSS stage 1, 2a, or 2b neuroblastoma who do not have MYCN amplification, as indicated by the absence of this molecular abnormality.
2. Patients with INSS stage 3 neuroblastoma, regardless of MYCN status.

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
INRG 2024-03,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with a disease stage classified as Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, or Stage MS. The diagnosis or relevant disease phase occurred between the years 2000 and 2023."
INRG 2024-03,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with a disease stage classified as Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, or Stage MS. Additionally, the year of diagnosis or disease phase for these individuals falls between 2000 and 2023, inclusive."
DaSH - INRG MYCN Amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have undergone molecular analysis, which revealed the presence of MYCN amplification."
INRG  2024-02,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with Stage 1, Stage 2a, or Stage 2b neuroblastoma according to the INSS staging system, who do not have MYCN amplification.

2. The second group includes patients with Stage 3 neuroblastoma according to the INSS staging system. 

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
"Evaluation of patients with localized (INSS stage 1-3), MYCN non-amplified neuroblastoma: outcome and association with clinical and molecular markers_INRG  2024-02","{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 3""]}}, {""IN"": {""stage_system"": [""INSS""]}}], ""path"": ""stagings""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2023. The selection criteria include two groups: 

1. The first group includes patients with Stage 1, Stage 2a, or Stage 2b neuroblastoma according to the INSS staging system, who do not have MYCN amplification present in their molecular analysis.

2. The second group includes patients with Stage 3 neuroblastoma according to the INSS staging system. 

Both groups are part of the INRG consortium and were diagnosed within the specified time frame."
Metastatic pattern association with molecular features and outcomes of Neuroblastoma_INRG  2024-03,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2000, ""upperBound"": 2023}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2000}}, {""LTE"": {""year_at_disease_phase"": 2023}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS""]}}], ""path"": ""stagings""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with a disease stage classified as Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, or Stage MS. The diagnosis or relevant disease phase occurred between the years 2000 and 2023. All these criteria must be met for inclusion in the cohort."
"Composed - INTERACT M, F","{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}]}","The cohort consists of individuals who are part of the INTERACT consortium. The selection includes both female and male participants, ensuring that all members are from the specified consortium."
GMKF - 8 subjects ANBL0931,"{""value"": {""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ANBL0931""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""GMKF""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""GMKF""]}}], ""path"": ""external_references""}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""ANBL0931""]}}], ""path"": ""studies""}}]}","The cohort consists of participants who are part of the study identified by the study ID ""ANBL0931"" and have external references associated with the resource name ""GMKF"". Both criteria must be met for inclusion in the cohort."
Age>18mo_stage4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INSS""]}}, {""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been classified under the INSS staging system as Stage 4. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 10,610 days."
INRG M,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants who are part of the INRG consortium. These participants have been staged using the INRGSS staging system and are specifically classified as Stage M.
INTERACT - all male subjects,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}",The cohort consists of male participants who are part of the INTERACT consortium.
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of participants from the INTERACT consortium who have a molecular abnormality identified as FLT3 internal tandem duplication (ITD), with the result of this abnormality being present."
t(8;21),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)"", ""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of participants from the INTERACT consortium who have specific molecular abnormalities. These abnormalities include either the inv(16)(p13q22) or the t(8;21)(q22;q22) RUNX1/ETO translocations. Additionally, the molecular abnormality result for these participants must be ""Present."""
FLT3 + CBF,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)"", ""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}",{},"The cohort consists of participants from the INTERACT consortium who have specific molecular abnormalities. These participants must have either a FLT3 internal tandem duplication (ITD) or an inv(16)(p13q22) abnormality, both of which must be present. Additionally, participants can have either an inv(16)(p13q22) or a t(8;21)(q22;q22) RUNX1/ETO abnormality, with the condition that these abnormalities are also present. The selection criteria require that all specified conditions are met."
Core binding factor,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)"", ""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}",{},"The cohort consists of participants from the INTERACT consortium who have specific molecular abnormalities. The selection criteria include two groups: 

1. Participants with the molecular abnormality inv(16)(p13q22) that is present.
2. Participants with either the molecular abnormality inv(16)(p13q22) or t(8;21)(q22;q22) RUNX1/ETO, both of which must be present.

Participants must meet the criteria of at least one of these groups."
inrg schwa,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) histology. Additionally, their molecular analysis shows a 17q gain abnormality, but the result of this molecular abnormality is absent. All these criteria must be met for inclusion in the cohort."
inv(16),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have a molecular abnormality identified as FLT3 internal tandem duplication (ITD), with the result of this abnormality being present."
AML02-AML08,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AML02"", ""AML08""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""AML02"", ""AML08""]}}], ""path"": ""studies""}}]}",The cohort consists of participants who are part of the INTERACT consortium and are involved in studies with the study IDs AML02 or AML08.
inrg schwa,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""17q gain""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""17q gain""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and exhibit a molecular profile where the 17q gain abnormality is present, but the result of this molecular abnormality is absent."
pauls_test_inrg,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
test,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Arm A""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""Arm A""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}",The cohort consists of participants who are part of the INRG consortium. These participants have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor) and are enrolled in treatment Arm A. All criteria must be met for inclusion in the cohort.
"IR: L2, MYCN neg, <18 months, all histology","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 547}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""molecular_abnormality"": ""MYCN Amplification""}}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 547}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients diagnosed with Neuroblastoma (Schwannian Stroma-Poor) at Stage L2. These patients do not have MYCN Amplification as a molecular abnormality. Additionally, the age at tumor assessment for these patients ranges from 1 day to 547 days."
"IR: L2, MYCN neg, 18 mo - 5 yr, FH","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_inpc"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Favorable""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 1826}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_inpc"": [""Favorable""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""molecular_abnormality"": ""MYCN Amplification""}}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 1826}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients diagnosed with Stage L2 neuroblastoma that is Schwannian stroma-poor and classified as favorable according to the International Neuroblastoma Pathology Classification (INPC). These patients do not have MYCN amplification as a molecular abnormality. Additionally, the age of the patients at the time of tumor assessment is between 1.5 and 5 years."
test_composed,"{""value"": [{""value"": {""race"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Asian""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT"", ""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""studies.treatment_arm"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""ABVE-PCx2+IFRT+DECAx2""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INSTRuCT"", ""INTERACT""]}}, {""IN"": {""race"": [""Asian""]}}]}, {""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""treatment_arm"": [""ABVE-PCx2+IFRT+DECAx2""]}}], ""path"": ""studies""}}]}]}","The cohort consists of participants who meet either of the following criteria: 

1. Participants who are of Asian race and are part of the INSTRuCT or INTERACT consortia.

2. Male participants who are in the treatment arm labeled ""ABVE-PCx2+IFRT+DECAx2""."
"IR: L2, MYCN neg, >5 yrs, differentiating","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L2""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1826, ""upperBound"": 7856}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_grade"": [""Differentiating""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""molecular_abnormality"": ""MYCN Amplification""}}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L2""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1826}}, {""LTE"": {""age_at_tumor_assessment"": 7856}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals diagnosed with Neuroblastoma (Schwannian Stroma-Poor) that is differentiating in histology grade. These individuals are at Stage L2 of the disease and do not have MYCN Amplification as a molecular abnormality. Additionally, the age at tumor assessment for these individuals ranges from 5 to 21.5 years."
"IR: M, <12 mos, MYCN neg","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 0, ""upperBound"": 365}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""molecular_abnormality"": ""MYCN Amplification""}}]}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 0}}, {""LTE"": {""age_at_tumor_assessment"": 365}}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}]}",The cohort consists of patients diagnosed with Stage M Neuroblastoma (Schwannian Stroma-Poor) who do not have MYCN Amplification. The age at tumor assessment for these patients is between 0 and 365 days.
"IR: M, 12-18 mos, MYCN neg, all FH (differentiating, DI>1, no SCA)","{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating""]}, ""molecular_analysis.dna_index"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""DNA Index > 1 (Hyperdiploid)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""MYCN Amplification"", ""11q deletion"", ""17q gain"", ""1p deletion""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 365, ""upperBound"": 1826}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, {""IN"": {""histology_grade"": [""Differentiating""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""molecular_abnormality"": ""MYCN Amplification""}}, {""!="": {""molecular_abnormality"": ""11q deletion""}}, {""!="": {""molecular_abnormality"": ""17q gain""}}, {""!="": {""molecular_abnormality"": ""1p deletion""}}]}, {""IN"": {""dna_index"": [""DNA Index > 1 (Hyperdiploid)""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 365}}, {""LTE"": {""age_at_tumor_assessment"": 1826}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients diagnosed with Stage M neuroblastoma that is Schwannian stroma-poor and differentiating. These patients have a DNA index greater than 1, indicating hyperdiploidy, and do not exhibit molecular abnormalities such as MYCN amplification, 11q deletion, 17q gain, or 1p deletion. Additionally, the age at tumor assessment for these patients ranges from 1 to 5 years."
duble_anchor,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""ANCHORED""}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FNCLCC, Grade 1""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology_grade"": [""FNCLCC, Grade 1""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INSTRuCT consortium. At the initial diagnosis phase, these participants have a histology grade of FNCLCC, Grade 1. Additionally, at the relapse phase, their tumor classification is categorized as Primary."
inrg,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""biopsy_surgical_procedures.procedure_type"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Biopsy""]}, ""biopsy_surgical_procedures.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic"", ""Regional nodes""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""!="": {""consortium"": ""INRG""}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_classification"": [""Metastatic"", ""Regional nodes""]}}, {""IN"": {""procedure_type"": [""Biopsy""]}}]}]}], ""path"": ""biopsy_surgical_procedures""}}]}",The cohort consists of individuals who were not part of the INRG consortium. These individuals were at the initial diagnosis phase of their disease and underwent a biopsy procedure. The tumor classification for these individuals was either metastatic or involved regional nodes.
test2,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Relapse"": {""value"": {""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}}, ""__type"": ""ANCHORED""}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich)""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Relapse""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of male participants who are part of the INRG consortium. At the initial diagnosis phase, these participants were diagnosed with Ganglioneuroblastoma, Intermixed (Schwannian Stroma-Rich) histology. Additionally, at the relapse phase, their tumor assessments indicated the presence of tumors at the bone site."
FOXO1-PAX3,"{""__combineMode"": ""AND"", ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion""]}}",{},The cohort consists of individuals who have a molecular abnormality characterized by the presence of the FOXO1-PAX3 fusion.
SteveInstructFirst,"{""sex"": {""selectedValues"": [""Male""]}, ""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND""}",{},The cohort consists of male participants who are part of the INSTRuCT consortium.
NHR Metastatic Relapse,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage L1"", ""Stage L2"", ""Stage 1"", ""Stage 2a"", ""Stage 2b""]}, ""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 547.501, ""upperBound"": 12483}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS"", ""INSS""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""AND"": [{""GTE"": {""age_at_censor_status"": 547.501}}, {""LTE"": {""age_at_censor_status"": 12483}}]}, {""nested"": {""AND"": [{""IN"": {""stage_system"": [""INRGSS"", ""INSS""]}}, {""IN"": {""stage"": [""Stage L1"", ""Stage L2"", ""Stage 1"", ""Stage 2a"", ""Stage 2b""]}}], ""path"": ""stagings""}}]}","The cohort consists of subjects who are part of the INRG consortium and have experienced one or more events. These subjects are staged according to either the INRGSS or INSS staging systems and are classified within stages L1, L2, 1, 2a, or 2b. Additionally, the age of the subjects at the time of censor status ranges from approximately 1.5 years (547.501 days) to 34 years (12483 days)."
NHR Metastatic Relapse,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS"", ""Unknown""]}, ""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 548, ""upperBound"": 12483}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""AND"": [{""GTE"": {""age_at_censor_status"": 548}}, {""LTE"": {""age_at_censor_status"": 12483}}]}, {""nested"": {""AND"": [{""AND"": [{""!="": {""stage"": ""Stage 4""}}, {""!="": {""stage"": ""Stage 4s""}}, {""!="": {""stage"": ""Stage IV""}}, {""!="": {""stage"": ""Stage IVs""}}, {""!="": {""stage"": ""Stage M""}}, {""!="": {""stage"": ""Stage MS""}}, {""!="": {""stage"": ""Unknown""}}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of subjects who are part of the INRG consortium and have experienced one or more events. The subjects included are those with a histology of Neuroblastoma (Schwannian Stroma-Poor) and are between the ages of 548 days and 12,483 days at the time of censor status. Subjects with staging classified as Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, Stage MS, or Unknown are excluded from the cohort."
NHR Metastatic Relapse,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS"", ""Unknown""]}, ""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 548, ""upperBound"": 12483}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""AND"": [{""GTE"": {""age_at_censor_status"": 548}}, {""LTE"": {""age_at_censor_status"": 12483}}]}, {""nested"": {""AND"": [{""AND"": [{""!="": {""stage"": ""Stage 4""}}, {""!="": {""stage"": ""Stage 4s""}}, {""!="": {""stage"": ""Stage IV""}}, {""!="": {""stage"": ""Stage IVs""}}, {""!="": {""stage"": ""Stage M""}}, {""!="": {""stage"": ""Stage MS""}}, {""!="": {""stage"": ""Unknown""}}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of subjects who are part of the INRG consortium and have experienced one or more events. The subjects included are those with a histology of Neuroblastoma (Schwannian Stroma-Poor) and are aged between 548 and 12,483 days at the time of censor status. Subjects with staging classified as Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, Stage MS, or Unknown are excluded from the cohort."
ARMS1,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)""]}}], ""path"": ""histologies""}}]}",The cohort consists of individuals diagnosed with Alveolar rhabdomyosarcoma (ARMS) as their histology type.
InstructFemaileCensorEvent,"{""value"": {""sex"": {""__type"": ""OPTION"", ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INSTRuCT""]}, ""censor_status"": {""__type"": ""OPTION"", ""selectedValues"": [""Subject has had one or more events""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Female""]}}, {""IN"": {""consortium"": [""INSTRuCT""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}]}",The cohort consists of female participants who are part of the INSTRuCT consortium and have experienced one or more events.
Male Asian Primary tumor,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND"", ""disease_phase:Initial Diagnosis"": {""filter"": {""tumor_assessments.tumor_classification"": {""selectedValues"": [""Primary""]}}}}",{},The cohort consists of male individuals who are Asian and have been initially diagnosed with a primary tumor classification.
male asian 3,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are both male and Asian.
prova 2,"{""consortium"": {""selectedValues"": [""INSTRuCT""]}, ""__combineMode"": ""AND"", ""disease_phase:Initial Diagnosis"": {""filter"": {""stagings.irs_group"": {""selectedValues"": [""Group I"", ""Group IIA"", ""Group III"", ""Group IV""]}, ""histologies.histology"": {""selectedValues"": [""Pleomorphic rhabdomyosarcoma (PRMS)""]}}}}",{},"The cohort consists of individuals who are part of the INSTRuCT consortium. These individuals were at the initial diagnosis phase of their disease and were classified under IRS groups I, IIA, III, or IV. Additionally, they have a histological diagnosis of Pleomorphic rhabdomyosarcoma (PRMS)."
NHR Metastatic Relapse,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS"", ""Unknown""]}, ""age_at_censor_status"": {""__type"": ""RANGE"", ""lowerBound"": 548, ""upperBound"": 12483}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""AND"": [{""GTE"": {""age_at_censor_status"": 548}}, {""LTE"": {""age_at_censor_status"": 12483}}]}, {""nested"": {""AND"": [{""AND"": [{""!="": {""stage"": ""Stage 4""}}, {""!="": {""stage"": ""Stage 4s""}}, {""!="": {""stage"": ""Stage IV""}}, {""!="": {""stage"": ""Stage IVs""}}, {""!="": {""stage"": ""Stage M""}}, {""!="": {""stage"": ""Stage MS""}}, {""!="": {""stage"": ""Unknown""}}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}]}","The cohort consists of subjects who are part of the INRG consortium and have experienced one or more events. The subjects included are those with a histology of Neuroblastoma (Schwannian Stroma-Poor) and are not in stages 4, 4s, IV, IVs, M, MS, or unknown. Additionally, the age of the subjects at the time of censor status is between 548 and 12,483 days."
NHR Metastatic Relapse,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""censor_status"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Subject has had one or more events""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Stage 4"", ""Stage 4s"", ""Stage IV"", ""Stage IVs"", ""Stage M"", ""Stage MS"", ""Unknown""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 548, ""upperBound"": 8511}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""IN"": {""censor_status"": [""Subject has had one or more events""]}}, {""nested"": {""AND"": [{""AND"": [{""!="": {""stage"": ""Stage 4""}}, {""!="": {""stage"": ""Stage 4s""}}, {""!="": {""stage"": ""Stage IV""}}, {""!="": {""stage"": ""Stage IVs""}}, {""!="": {""stage"": ""Stage M""}}, {""!="": {""stage"": ""Stage MS""}}, {""!="": {""stage"": ""Unknown""}}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 548}}, {""LTE"": {""age_at_tumor_assessment"": 8511}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of subjects who are part of the INRG consortium and have experienced one or more events. The subjects do not have a staging of Stage 4, Stage 4s, Stage IV, Stage IVs, Stage M, Stage MS, or Unknown. They have a histology of Neuroblastoma (Schwannian Stroma-Poor). Additionally, the age at tumor assessment for these subjects is between 548 and 8511 days."
Lucas-Sc-set,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 458, ""upperBound"": 10983}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 458}}, {""LTE"": {""age_at_tumor_assessment"": 10983}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been classified under Stage M according to the INRGSS staging system. Additionally, the age at tumor assessment for these individuals ranges from 458 days to 10,983 days."
High risk + MYCN non amp,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage M""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 10610}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 10610}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage M neuroblastoma according to the INRGSS staging system. These individuals exhibit MYCN amplification as a molecular abnormality, but the result of this molecular abnormality is absent. Additionally, the age at tumor assessment for these individuals ranges from 547 days to 10,610 days."
Stager 4 < 18 m,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 553}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 553}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 cancer. Additionally, these individuals were assessed for tumors at an age between 1 and 553 days."
Stage 4 > 18 m,"{""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 513, ""upperBound"": 17212}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 513}}, {""LTE"": {""age_at_tumor_assessment"": 17212}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are at Stage 4 of their condition. Additionally, these individuals have had a tumor assessment at an age ranging from 513 days to 17,212 days. Both criteria must be met for inclusion in the cohort."
MYCN-no,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit the specific molecular abnormality of ""MYCN Amplification,"" but the result of this abnormality is ""Absent."""
L1+Mycn,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""selectedValues"": [""Stage L1""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""selectedValues"": [""INRGSS""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1988, ""upperBound"": 2017}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1988}}, {""LTE"": {""year_at_disease_phase"": 2017}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage L1""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage L1 neuroblastoma, specifically the Schwannian Stroma-Poor subtype, according to the INRGSS staging system. The diagnosis occurred between the years 1988 and 2017. Additionally, these patients exhibit the presence of MYCN amplification as a molecular abnormality."
test,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}]}",The cohort consists of participants who are part of the INRG consortium.
RMS,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INSTRuCT""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Pleomorphic rhabdomyosarcoma (PRMS)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INSTRuCT""]}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Pleomorphic rhabdomyosarcoma (PRMS)""]}}], ""path"": ""histologies""}}]}","The cohort consists of participants from the INSTRuCT consortium who have been diagnosed with specific types of rhabdomyosarcoma. These types include Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Rhabdomyosarcoma (RMS) that is not classifiable, Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features, and Pleomorphic rhabdomyosarcoma (PRMS)."
MaGIC Stage III/IV w/ known dx age,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage III"", ""Stage IV""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 8589}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage III"", ""Stage IV""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 8589}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of individuals who are part of the MaGIC consortium and were at the initial diagnosis phase of their disease. These individuals were diagnosed with either Stage III or Stage IV cancer. Additionally, their age at the time of tumor assessment ranged from 1 day to 8589 days (approximately 23.5 years). Furthermore, the survival characteristics of these individuals are known."
MaGIC Stage I/II w/ known dx age,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""MaGIC""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I"", ""Stage II""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 1, ""upperBound"": 8589}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage I"", ""Stage II""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""AND"": [{""GTE"": {""age_at_tumor_assessment"": 1}}, {""LTE"": {""age_at_tumor_assessment"": 8589}}]}]}]}], ""path"": ""tumor_assessments""}}, {""nested"": {""AND"": [{""IN"": {""lkss_obfuscated"": [""Known""]}}], ""path"": ""survival_characteristics""}}]}","The cohort consists of individuals who are part of the MaGIC consortium and were at the initial diagnosis phase of their disease. These individuals were diagnosed with either Stage I or Stage II disease. The age at tumor assessment for these individuals ranges from 1 day to 8589 days (approximately 23.5 years). Additionally, the survival characteristics of these individuals are known."
MYCN amplified,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage M""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRGSS""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage M""]}}, {""IN"": {""stage_system"": [""INRGSS""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of patients who are part of the INRG consortium. These patients have been diagnosed with Stage M neuroblastoma according to the INRGSS staging system. The histology of their tumors is classified as Neuroblastoma (Schwannian Stroma-Poor). Additionally, these patients exhibit MYCN amplification, which is confirmed to be present through molecular analysis."
NS 34bulky,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage III"", ""Stage IV""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage III"", ""Stage IV""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""Yes""]}}], ""path"": ""disease_characteristics""}}]}","The cohort consists of individuals who are part of the NODAL consortium. These individuals have been diagnosed with either Stage III or Stage IV cancer. Specifically, they have Hodgkin Lymphoma of the Nodular Sclerosis, NOS subtype. Additionally, these individuals exhibit bulk disease characteristics."
NS stage 1 non bulky,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}, ""disease_characteristics.bulk_disease"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage I""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""histology"": [""Hodgkin Lymphoma, Nodular Sclerosis, NOS""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""bulk_disease"": [""No""]}}], ""path"": ""disease_characteristics""}}]}","The cohort consists of individuals who are part of the NODAL consortium. They have been diagnosed with Stage I Hodgkin Lymphoma, specifically the Nodular Sclerosis, NOS subtype. Additionally, these individuals do not have bulk disease."
1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}, ""stagings.stage_system"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""COG""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}, {""IN"": {""stage_system"": [""COG""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_classification"": [""Primary""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the MaGIC consortium who have been diagnosed with Stage IV cancer according to the COG staging system. Additionally, the tumor classification for these participants is specified as Primary."
1p deletion present,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""1p deletion""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have a molecular analysis showing the presence of a ""1p deletion"" abnormality."
MYCN amplification absent,"{""value"": {""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MYCN Amplification""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""MYCN Amplification""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who have undergone molecular analysis and exhibit the specific molecular abnormality of ""MYCN Amplification,"" with the result of this abnormality being ""Absent."" Both criteria must be met for inclusion in the cohort."
afp,"{""value"": {""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AFP""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""lab_test"": [""AFP""]}}], ""path"": ""labs""}}]}",The cohort consists of individuals who have undergone laboratory testing for Alpha-fetoprotein (AFP).
FLT3-ITD Positive,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
FLT3-ITD Negative,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have undergone molecular analysis. Specifically, these participants have been tested for the FLT3 internal tandem duplication (ITD) molecular abnormality, and the result of this test is absent."
Testicular Primary,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""MaGIC""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Testis""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""MaGIC""]}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Testis""]}}, {""IN"": {""tumor_classification"": [""Primary""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the MaGIC consortium. These individuals have been assessed for tumors located in the testis, and the tumors are classified as primary. All criteria must be met for inclusion in the cohort."
Stage 4 bone absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the bone, and the tumor state is absent. All these criteria must be met for inclusion in the cohort."
Stage 4 CNS absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor site is the Central Nervous System, and the tumor state is recorded as absent. All these criteria must be met for inclusion in the cohort."
Stage 4 liver absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and have been diagnosed with Stage 4 cancer. Additionally, these individuals have undergone tumor assessments indicating that the tumor site is the liver, and the tumor state is absent. All these criteria must be met for inclusion in the cohort."
Stage 4 Lung Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4"", ""Stage IV"", ""Stage M""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4"", ""Stage IV"", ""Stage M""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who have been diagnosed with Stage 4, Stage IV, or Stage M cancer. Additionally, these participants have undergone tumor assessments indicating that the tumor site is the lung, and the tumor state is absent."
Stage 4 other absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of participants from the INRG consortium who are classified as Stage 4. These participants have tumor assessments indicating that the tumor site is categorized as ""Other"" and the tumor state is ""Absent."" All these criteria must be met for inclusion in the cohort."
Stage 4 lymph node present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor is present in the lymph nodes."
All 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are classified as Stage 4. The selection criteria include patients with tumors present in the lymph nodes. Additionally, patients with tumors absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone are included."
Stage 4 Bone Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, they have tumors present at the bone site."
Stage 4 Bone Marrow Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate the presence of a tumor in the bone marrow."
2003-2020 Stage 4 any site,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 2003 and 2020. Additionally, these individuals are at Stage 4 of the disease, with tumors present in one or more of the following sites: Bone, Bone Marrow, Central Nervous System, Lung, Liver, or Skin."
1990-2002 Stage 4 Bone absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these patients had tumor assessments indicating that the tumor site was the bone, and the tumor state was recorded as absent."
1990-2002 Stage 4 Marrow Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1990 and 2002. Additionally, these individuals have tumor assessments indicating that the tumor site is the bone marrow, and the tumor state is absent."
1990-2002 Stage 4 Liver Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1990 and 2002. Additionally, these individuals have tumor assessments indicating that the tumor site is the liver, and the tumor state is absent."
1990-2002 Stage 4 Lung Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1991 and 2002. Additionally, these patients had tumor assessments indicating that the tumor site was the lung and the tumor state was absent."
1990-2002 Stage 4 Lymph Node Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these patients have tumors present in the lymph nodes."
1990-2002 Stage 4 Skin Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these individuals have tumor assessments indicating that the tumor site is the skin and the tumor state is absent."
2003-2020 4N,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection criteria include patients with tumors present in the lymph nodes and absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone. Additionally, the patients were diagnosed between the years 2003 and 2020."
1990-2002 4N,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection criteria include patients with tumors present in the lymph nodes and absent in the lung, other sites, skin, liver, central nervous system, bone marrow, and bone. Additionally, the patients were diagnosed between the years 1991 and 2002."
Stage 4 Bone and Marrow Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of patients who are part of the INRG consortium and have been diagnosed with Stage 4 cancer. These patients have tumor assessments indicating the presence of tumors either in the bone marrow or in the bone.
Stage 4 Liver Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, they have a tumor present in the liver."
Stage 4 Other Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor is located at a site categorized as ""Other"" and that the tumor is currently present. All these criteria must be met for inclusion in the cohort."
Stage 4 Other no bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are all at Stage 4 of their condition. The selection criteria include patients with specific tumor site and state combinations: those with absent tumors in the bone marrow or bone, and those with present tumors in the central nervous system, liver, lung, skin, or other sites."
2003-2020 Stage 4 no bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}, {""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 2003 and 2020. These patients are all at Stage 4 of their disease. The cohort includes subgroups based on tumor assessments: patients with absent tumors in the bone marrow or bone, and patients with present tumors in the central nervous system, liver, lung, skin, or other sites."
2003-2020 Stage 4 bone or marrow present,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. These patients have tumor assessments indicating the presence of tumors either in the bone marrow or in the bone. Additionally, the patients were diagnosed between the years 2003 and 2020."
1990-2002 Stage 4 Bone or Marrow present,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 cancer. These patients have tumors present either in the bone marrow or in the bone. Additionally, the patients were diagnosed between the years 1991 and 2002."
CNS no bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are all at Stage 4 of their condition. The selection criteria include three specific groups: 

1. Patients with tumors present in the Central Nervous System.
2. Patients with tumors absent in the Bone Marrow.
3. Patients with tumors absent in the Bone.

Each patient must meet the criteria of being part of the INRG consortium and having Stage 4 disease, with the tumor site and state conditions as specified for each group."
1990-2002 Stage 4,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 disease. Additionally, their year at the disease phase falls between 1991 and 2002, inclusive."
Liver present no bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are all at Stage 4 of their condition. The selection criteria include three specific groups: one group with tumors absent in the bone marrow, another group with tumors absent in the bone, and a third group with tumors present in the liver. Each group is defined by the presence or absence of tumors at these specific sites."
Stage 4 all other sites,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate that the tumor is present in one or more of the following sites: Central Nervous System, Liver, Lung, Other, or Skin."
Stage 4 all other not bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are classified as Stage 4. The selection criteria include three groups: 

1. Patients with tumors assessed as absent in the bone marrow.
2. Patients with tumors assessed as absent in the bone.
3. Patients with tumors present in the central nervous system, liver, lung, other sites, or skin. 

All patients meet the criteria of being part of the INRG consortium and having Stage 4 classification."
2003-2020 Stage 4 all other not bone or marrow,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection includes three specific groups based on tumor assessments: 1) patients with tumors absent in the bone marrow, 2) patients with tumors absent in the bone, and 3) patients with tumors present in the central nervous system, liver, lung, other sites, or skin. Additionally, all patients were diagnosed between the years 2003 and 2020."
1990-2002 Stage 4 all other not bone or marrow,"{""value"": [{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1991, ""upperBound"": 2002}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System"", ""Liver"", ""Lung"", ""Other"", ""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1991}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease. The selection criteria include patients with tumor assessments showing the tumor site as either Bone Marrow or Bone, with the tumor state being absent. Additionally, patients with tumors present in the Central Nervous System, Liver, Lung, Other, or Skin are included. All patients were diagnosed between the years 1991 and 2002."
All Stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the INRG consortium and have been classified as Stage 4 in their stagings.
2003-2020 Stage 4,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}]}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 disease. Additionally, their disease phase occurred between the years 2003 and 2020. All criteria must be met for inclusion in the cohort."
CNS without bone or marrow,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who are all classified as Stage 4. The selection criteria include three specific conditions: 1) patients with tumors present in the Central Nervous System, 2) patients with no tumors in the Bone Marrow, and 3) patients with no tumors in the Bone. Each patient must meet one of these conditions in addition to being part of the INRG consortium and having Stage 4 classification."
CBFB-MYH11 = inv(16),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is confirmed to be present in their molecular analysis results."
t(8;21) = AML-ETO = RUNX1-ETO,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the translocation t(8;21)(q22;q22) RUNX1/ETO, and this abnormality is confirmed to be present."
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
1990-2002 Bone Marrow Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1990 and 2002. Additionally, these patients have tumor assessments indicating the presence of tumors in the bone marrow."
1990-2002 Bone Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these patients have tumor assessments indicating the presence of tumors at the bone site."
2003-2020 Stage 4 Bone Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 2003 and 2020. Additionally, these patients have tumor assessments indicating the presence of tumors at the bone site."
2003-2020 Bone Marrow Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 2003 and 2020. Additionally, these patients have tumor assessments indicating the presence of tumors in the bone marrow."
2003-2020 Stage 4 known metastatic site,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone"", ""Bone Marrow"", ""Central Nervous System"", ""Lung"", ""Liver"", ""Skin"", ""Other"", ""Lymph Nodes""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. The tumor sites included in the study are Bone, Bone Marrow, Central Nervous System, Lung, Liver, Skin, Other, and Lymph Nodes. Patients with an unknown tumor state are excluded from the cohort."
Stage 4 CNS present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium. These individuals have been diagnosed with Stage 4 cancer. Additionally, their tumor assessments indicate the presence of a tumor located in the Central Nervous System."
1990-2002 Stage 4 Bone or Marrow Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of individuals who are part of the INRG consortium and were diagnosed between the years 1990 and 2002. The selection criteria include patients with tumors present in either the bone or bone marrow.
1990-2002 Stage 4 Bone Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1990 and 2002. Additionally, these individuals have tumor assessments indicating that the tumor site is the bone, and the tumor state is absent."
1990-2002 Stage 4 Bone or Marrow Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 1990 and 2002. The patients included in the study have tumors that are present either in the bone or bone marrow.
2003-2020 Bone or Marrow Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. The patients included in the study have tumors that are present either in the bone or bone marrow.
1990-2002 Stage 4 Lung Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these patients have tumors that are present in the lung."
1990-2002 Stage 4 Other Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Other""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these individuals have tumors that are present and located at sites categorized as ""Other."""
1990-2002 Stage 4 CNS present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with Stage 4 disease. The diagnosis occurred between the years 1990 and 2002. Additionally, these patients have tumors present in the Central Nervous System."
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular analysis showing the presence of the FLT3 internal tandem duplication (ITD) abnormality.
1990-2002 Stage 4 Bone Marrow Absent,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}], ""path"": ""tumor_assessments""}}]}","The cohort consists of individuals who are part of the INRG consortium and were diagnosed with Stage 4 disease between the years 1990 and 2002. Additionally, these individuals have tumor assessments indicating that the tumor site is the bone marrow, and the tumor state is absent."
2003-2002 Stage 4 known metastatic site,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were diagnosed with Stage 4 disease between the years 2003 and 2020. These patients have tumors present in at least one of the following sites: Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, or Skin."
1990-2002 Stage 4 non-node present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other"", ""Lung"", ""Liver"", ""Central Nervous System"", ""Bone Marrow"", ""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Other"", ""Lung"", ""Liver"", ""Central Nervous System"", ""Bone Marrow"", ""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were initially diagnosed with their disease between the years 1990 and 2002. At the time of initial diagnosis, these patients were classified as Stage 4. Additionally, their tumors were present in one or more of the following sites: Other, Lung, Liver, Central Nervous System, Bone Marrow, or Bone. The tumor state was recorded as present."
2003-2020 Stage 4 Non-node present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Other"", ""Lung"", ""Liver"", ""Central Nervous System"", ""Bone Marrow"", ""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Other"", ""Lung"", ""Liver"", ""Central Nervous System"", ""Bone Marrow"", ""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were diagnosed with their disease between the years 2003 and 2020. At the initial diagnosis phase, these patients were classified as Stage 4. Additionally, their tumors were present in one or more of the following sites: Other, Lung, Liver, Central Nervous System, Bone Marrow, or Bone."
2003-2020 Mets known,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Present""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. These patients have tumors present at one or more of the following sites: Bone, Bone Marrow, Liver, Central Nervous System, Lung, Lymph Nodes, or Skin."
2003-2020 Stage 4 mets unknown,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Unknown""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Unknown""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. The tumor assessments at the initial diagnosis phase indicate that the tumor sites include Bone, Bone Marrow, Central Nervous System, Liver, Lung, Lymph Nodes, and Skin, with the tumor state being unknown for all these sites."
1990-2002 >18mo Stage 4 Bone Marrow Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4, with the tumor present in the bone marrow and classified as metastatic. The age at tumor assessment for these patients ranged from 1.5 years (547 days) to approximately 22.9 years (8367 days)."
1990-2002 >18mo Stage 4 Bone Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients from the INRG consortium who were diagnosed between 1990 and 2002. At the initial diagnosis, these patients were classified as Stage 4, with tumors present in the bone. The tumors were metastatic, and the age at tumor assessment ranged from 1.5 years (547 days) to approximately 22.9 years (8367 days)."
1990-2002 >18mo 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between 1990 and 2002. The patients have metastatic tumors, and their age at tumor assessment ranges from 1.5 to 23 years. The cohort includes patients with tumors present in the lymph nodes, while for other sites such as skin, liver, lung, central nervous system, bone, and bone marrow, the tumors are not present."
DASH alveolar and anaplasia,"{""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}, ""molecular_analysis.anaplasia"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""IN"": {""anaplasia"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Pleomorphic rhabdomyosarcoma (PRMS), Rhabdomyosarcoma (RMS) not classifiable, and Rhabdomyosarcoma (RMS) with mixed embryonal and alveolar features. Additionally, these individuals exhibit the presence of anaplasia as determined by molecular analysis. Both criteria must be met for inclusion in the cohort."
2003-2020 >18mo 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Skin""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2019}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 2003, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Skin""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2019}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 2003}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""AND"": [{""!="": {""tumor_state"": ""Present""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between the years 2003 and 2020. The patients included in the study have metastatic tumors with specific characteristics based on the site and state of the tumor. The tumor sites considered are Skin, Liver, Central Nervous System, Bone, Bone Marrow, Lymph Nodes, and Lung. For the Skin, Liver, Central Nervous System, Bone, and Bone Marrow sites, the tumor state is absent. For the Lymph Nodes, the tumor state is present, and for the Lung, the tumor state is not present. The age at tumor assessment for all patients ranges from 547 to 8367 days."
1990-2002 >18mo Stage 4 Bone or Marrow Present,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}, ""tumor_assessments.age_at_tumor_assessment"": {""__type"": ""RANGE"", ""lowerBound"": 547, ""upperBound"": 8367}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}, {""AND"": [{""GTE"": {""age_at_tumor_assessment"": 547}}, {""LTE"": {""age_at_tumor_assessment"": 8367}}]}]}]}], ""path"": ""tumor_assessments""}}]}]}",The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 disease between 1990 and 2002. These patients have metastatic tumors that are present either in the bone or bone marrow. The age at tumor assessment for these patients ranges from 547 to 8367 days.
All extremity RMS patients ,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Foot"", ""Hand"", ""Lower Leg"", ""Knee"", ""Other Extremity"", ""Shoulder"", ""Thigh"", ""Upper Arm"", ""Forearm"", ""Buttock""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Botryoid rhabdomyosarcoma (BRMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features"", ""Pleomorphic rhabdomyosarcoma (PRMS)"", ""Rhabdomyosarcoma (RMS), not classifiable""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Foot"", ""Hand"", ""Lower Leg"", ""Knee"", ""Other Extremity"", ""Shoulder"", ""Thigh"", ""Upper Arm"", ""Forearm"", ""Buttock""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are at the initial diagnosis phase of their disease. These patients have been diagnosed with specific types of rhabdomyosarcoma, including Alveolar rhabdomyosarcoma (ARMS), Botryoid rhabdomyosarcoma (BRMS), Embryonal rhabdomyosarcoma (ERMS), Rhabdomyosarcoma with mixed embryonal and alveolar features, Pleomorphic rhabdomyosarcoma (PRMS), or rhabdomyosarcoma that is not classifiable. Additionally, the tumor sites for these patients are located in specific areas of the body, namely the foot, hand, lower leg, knee, other extremities, shoulder, thigh, upper arm, forearm, or buttock."
localized extremity RMS ,"{""value"": {""stagings.irs_group"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Group I"", ""Group IIA"", ""Group IIB"", ""Group IIC"", ""Group III""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""irs_group"": [""Group I"", ""Group IIA"", ""Group IIB"", ""Group IIC"", ""Group III""]}}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Alveolar rhabdomyosarcoma (ARMS)"", ""Embryonal rhabdomyosarcoma (ERMS)"", ""Rhabdomyosarcoma (RMS), not classifiable"", ""Rhabdomyosarcoma (RMS), with Mixed Embryonal and Alveolar Features""]}}]}]}], ""path"": ""histologies""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Buttock"", ""Upper Arm"", ""Thigh"", ""Shoulder"", ""Other Extremity"", ""Lower Leg"", ""Knee"", ""Foot"", ""Forearm"", ""Hand""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who were at the initial diagnosis phase and had tumors classified under specific histologies, including Alveolar rhabdomyosarcoma (ARMS), Embryonal rhabdomyosarcoma (ERMS), Rhabdomyosarcoma (RMS) not classifiable, and RMS with mixed embryonal and alveolar features. These patients were staged in IRS groups I, IIA, IIB, IIC, or III. Additionally, the tumor sites were located in specific areas such as the buttock, upper arm, thigh, shoulder, other extremities, lower leg, knee, foot, forearm, or hand."
FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have a molecular abnormality identified as FLT3 internal tandem duplication (ITD), with the result of this abnormality being present."
1990-2020 Stage 4 Known Mets,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2020}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung"", ""Central Nervous System"", ""Skin"", ""Lymph Nodes"", ""Bone Marrow"", ""Bone"", ""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": true, ""selectedValues"": [""Unknown""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2020}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lung"", ""Central Nervous System"", ""Skin"", ""Lymph Nodes"", ""Bone Marrow"", ""Bone"", ""Liver""]}}, {""AND"": [{""!="": {""tumor_state"": ""Unknown""}}]}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}","The cohort consists of patients who are part of the INRG consortium and were initially diagnosed with the disease between 1990 and 2020. At the initial diagnosis, these patients were classified as Stage 4 and had metastatic tumors. The tumor sites included the lung, central nervous system, skin, lymph nodes, bone marrow, bone, and liver. Patients with an unknown tumor state were excluded from the cohort."
1990-2002 4N,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lymph Nodes""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Bone Marrow""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Central Nervous System""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Liver""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""year_at_disease_phase"": {""__type"": ""RANGE"", ""lowerBound"": 1990, ""upperBound"": 2002}, ""disease_phase:Initial Diagnosis"": {""value"": {""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Lung""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}, ""tumor_assessments.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Metastatic""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lymph Nodes""]}}, {""IN"": {""tumor_state"": [""Present""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Bone Marrow""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Central Nervous System""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Liver""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}, {""AND"": [{""IN"": {""consortium"": [""INRG""]}}, {""AND"": [{""GTE"": {""year_at_disease_phase"": 1990}}, {""LTE"": {""year_at_disease_phase"": 2002}}]}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""stage"": [""Stage 4""]}}]}]}], ""path"": ""stagings""}}, {""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""tumor_site"": [""Lung""]}}, {""IN"": {""tumor_state"": [""Absent""]}}, {""IN"": {""tumor_classification"": [""Metastatic""]}}]}]}], ""path"": ""tumor_assessments""}}]}]}","The cohort consists of patients from the INRG consortium who were initially diagnosed with Stage 4 metastatic disease between 1990 and 2002. The selection criteria include patients with tumors assessed at various sites: those with present tumors in the lymph nodes, and those with absent tumors in the bone, bone marrow, central nervous system, liver, and lung. All patients have metastatic tumor classification."
DaSH - All AML,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
DaSH - INTERACT FLT3-ITD,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a molecular abnormality characterized by the presence of an FLT3 internal tandem duplication (ITD).
DaSH - INTERACT inv(16)(p13q22),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
DaSH - INTERACT t(8;21)(q22;q22) RUNX1/ETO,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, identified as t(8;21)(q22;q22) RUNX1/ETO, which is confirmed to be present in their molecular analysis results."
DaSH - INTERACT t(8;21)(q22;q22) RUNX1/ETO,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, identified as t(8;21)(q22;q22) RUNX1/ETO, which is confirmed to be present in their molecular analysis results."
GMKF - INRG 9047 males,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""9047""]}, ""external_references.external_resource_name"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""GMKF""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""sex"": [""Male""]}}, {""nested"": {""AND"": [{""IN"": {""study_id"": [""9047""]}}], ""path"": ""studies""}}, {""nested"": {""AND"": [{""IN"": {""external_resource_name"": [""GMKF""]}}], ""path"": ""external_references""}}]}",The cohort consists of male participants who are part of study 9047 and have external references associated with the GMKF resource. All these criteria must be met for inclusion in the cohort.
Hodgkin Stage IV,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage IV""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""stage"": [""Stage IV""]}}], ""path"": ""stagings""}}]}",The cohort consists of individuals who are part of the NODAL consortium and have been diagnosed with Stage IV cancer.
NODAL I/II A,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""stagings.AB"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""A""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage I"", ""Stage II""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""AB"": [""A""]}}, {""IN"": {""stage"": [""Stage I"", ""Stage II""]}}], ""path"": ""stagings""}}]}",The cohort consists of participants from the NODAL consortium. These participants have been staged as either Stage I or Stage II and have an AB classification of A. All these criteria must be met for inclusion in the cohort.
PET-positive,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""imagings.imaging_method"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""PET""]}, ""imagings.imaging_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Positive""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""imaging_method"": [""PET""]}}, {""IN"": {""imaging_result"": [""Positive""]}}], ""path"": ""imagings""}}]}",The cohort consists of participants from the NODAL consortium who have undergone PET imaging. The imaging results for these participants are positive.
SER,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""subject_responses.interim_response"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Slow Early Response (inadequate)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""interim_response"": [""Slow Early Response (inadequate)""]}}], ""path"": ""subject_responses""}}]}","The cohort consists of participants who are part of the NODAL consortium and have shown a ""Slow Early Response (inadequate)"" in their interim responses. Both criteria must be met for inclusion in the study."
PET-negative,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""NODAL""]}, ""imagings.imaging_method"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""PET""]}, ""imagings.imaging_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Negative""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""NODAL""]}}, {""nested"": {""AND"": [{""IN"": {""imaging_method"": [""PET""]}}, {""IN"": {""imaging_result"": [""Negative""]}}], ""path"": ""imagings""}}]}",The cohort consists of participants from the NODAL consortium who have undergone PET imaging. The results of these PET imaging tests are negative.
FLT3-ITD Positive,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}",The cohort consists of participants from the INTERACT consortium who have a molecular analysis showing the presence of the FLT3 internal tandem duplication (ITD) abnormality.
FLT3-ITD Negative,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""FLT3 internal tandem duplication (ITD)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Absent""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""FLT3 internal tandem duplication (ITD)""]}}, {""IN"": {""molecular_abnormality_result"": [""Absent""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have undergone molecular analysis. Specifically, these participants have been tested for the FLT3 internal tandem duplication (ITD) molecular abnormality, and the result of this test is absent."
MLL,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(9;11)(p22;q23) / MLL-MLLT3(AF9)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(9;11)(p22;q23) / MLL-MLLT3(AF9)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of participants from the INTERACT consortium who have a specific molecular abnormality, identified as t(9;11)(p22;q23) / MLL-MLLT3(AF9), and this abnormality is confirmed to be present in their molecular analysis results."
INTERACT,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}]}",The cohort consists of participants who are part of the INTERACT consortium.
age-ranges,"{""sex"": {""selectedValues"": [""Female""]}, ""race"": {""selectedValues"": [""Not Reported""]}, ""ethnicity"": {""selectedValues"": [""Not Reported""]}, ""__combineMode"": ""AND"", ""censor_status"": {""selectedValues"": [""Subject has had one or more events""]}, ""age_at_censor_status"": {""lowerBound"": 1019, ""upperBound"": 3119}, ""survival_characteristics.age_at_lkss"": {""lowerBound"": 5003, ""upperBound"": 9934}}",{},"The cohort consists of female subjects whose race and ethnicity are not reported. These subjects have experienced one or more events. At the time of these events, their ages ranged from 1019 to 3119 days. Additionally, their ages at the last known survival status ranged from 5003 to 9934 days."
Complex Cohort #1,"{""disease_phase:Initial Diagnosis"": {""filter"": {""histologies.histology"": {""selectedValues"": [""Alveolar rhabdomyosarcoma (ARMS)""]}, ""tumor_assessments.invasiveness"": {""selectedValues"": [""T2 Stage Finding""]}, ""tumor_assessments.nodal_clinical"": {""selectedValues"": [""N1 Stage FInding""]}, ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Present""]}}}}",{},"The cohort consists of individuals who were initially diagnosed with alveolar rhabdomyosarcoma (ARMS). These individuals have tumors classified as T2 stage, indicating a certain level of invasiveness. Additionally, they have a clinical nodal stage of N1, suggesting regional lymph node involvement. Molecular analysis of these individuals shows the presence of the FOXO1-PAX3 fusion abnormality."
INSTRuCT Figure 3,"{""tumor_assessments.nodal_clinical"": {""selectedValues"": [""N1 Stage FInding""]}, ""molecular_analysis.molecular_abnormality"": {""selectedValues"": [""FOXO1-PAX3 fusion""]}, ""molecular_analysis.molecular_abnormality_result"": {""selectedValues"": [""Present""]}}",{},"The cohort consists of individuals who have been clinically assessed to have N1 stage nodal findings. Additionally, these individuals have a molecular analysis indicating the presence of a FOXO1-PAX3 fusion abnormality."
test123,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""radiation_therapies.tumor_classification"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Primary""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of male individuals who have undergone radiation therapies for tumors classified as primary.
Composed INTERACT - All M OR F subjects,"{""value"": [{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Male""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Male""]}}]}]}",The cohort consists of individuals who are part of the INTERACT consortium. It includes both female and male participants.
INTERACT  - all female subjects,"{""value"": {""sex"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Female""]}, ""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""IN"": {""sex"": [""Female""]}}]}",The cohort consists of female participants who are part of the INTERACT consortium.
Male Asian Not Reported,"{""sex"": {""selectedValues"": [""Male""]}, ""race"": {""selectedValues"": [""Asian"", ""Not Reported""]}, ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are male and are either Asian or have not reported their race.
11q present,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals at the initial diagnosis phase who have been diagnosed with Neuroblastoma (Schwannian Stroma-Poor). Additionally, these individuals exhibit a molecular abnormality characterized by the presence of an 11q deletion."
2,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Differentiating""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are part of the INRG consortium. These individuals were at the initial diagnosis phase of their disease and have a histology grade classified as ""Differentiating."" Additionally, their survival characteristics are known."
NBL stroma-poor,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of participants who are part of the INRG consortium. They have been diagnosed with Stage 4 Neuroblastoma, specifically the Schwannian Stroma-Poor histology type."
schwanoma poor stage 4,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 3""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Abdomen""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of patients who are part of the INRG consortium. These patients have been diagnosed with Stage 3 Neuroblastoma (Schwannian Stroma-Poor). The tumor is located in the abdomen and is currently present.
Bulky,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Yes""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the NODAL consortium and have a disease characteristic of having a bulk mediastinal mass. Both criteria must be met for inclusion in the cohort.
Non-bulky,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""NODAL""]}, ""disease_characteristics.BULK_MED_MASS"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""No""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the NODAL consortium and do not have a bulk mediastinal mass.
1p present,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who were at the initial diagnosis phase and have a histology of Neuroblastoma (Schwannian Stroma-Poor). Additionally, these individuals exhibit a molecular abnormality characterized by a 1p deletion, which is present."
11q AND 1p,"{""value"": [{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""1p deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""11q deletion""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}",{},"The cohort consists of patients who were at the initial diagnosis phase and had a histological diagnosis of Neuroblastoma (Schwannian Stroma-Poor). These patients also exhibited specific molecular abnormalities: either a 1p deletion or an 11q deletion, both of which were confirmed to be present."
1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""histologies.histology_grade"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Undifferentiated or Poorly Differentiated""]}}, ""__type"": ""ANCHORED""}, ""survival_characteristics.lkss_obfuscated"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Known""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are part of the INRG consortium and were initially diagnosed with Neuroblastoma (Schwannian Stroma-Poor) that is either undifferentiated or poorly differentiated. Additionally, these individuals have known survival characteristics."
AML Auer Rods Present,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""labs.lab_test"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Auer rods""]}, ""labs.lab_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}, ""disease_characteristics.who_aml"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11"", ""AML with maturation"", ""AML with minimal differentiation"", ""AML with myelodysplasia-related changes"", ""AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1"", ""AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3"", ""AML without maturation"", ""AML, NOS"", ""Acute megakaryoblastic leukemia"", ""Acute monoblastic/monocytic leukemia"", ""Acute myelomonocytic leukemia"", ""Myeloid sarcoma"", ""Pure erythroid leukemia"", ""Not Reported"", ""Unknown""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are part of the INTERACT consortium. These individuals have undergone lab tests that detected the presence of Auer rods. Additionally, they have been diagnosed with various subtypes of acute myeloid leukemia (AML), including AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, AML with maturation, AML with minimal differentiation, AML with myelodysplasia-related changes, AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3, AML without maturation, AML, NOS, acute megakaryoblastic leukemia, acute monoblastic/monocytic leukemia, acute myelomonocytic leukemia, myeloid sarcoma, pure erythroid leukemia, or cases where the specific subtype is not reported or unknown."
Neuroblastoma Stage 1,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 1""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},The cohort consists of individuals who are part of the INRG consortium and have been classified as Stage 1 in their stagings.
schwanoma poor stage four,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INRG""]}, ""stagings.stage"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Stage 4""]}, ""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Neuroblastoma (Schwannian Stroma-Poor)""]}, ""tumor_assessments.tumor_site"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Abdomen""]}, ""tumor_assessments.tumor_state"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}",{},"The cohort consists of individuals who are part of the INRG consortium. They have been diagnosed with Stage 4 Neuroblastoma (Schwannian Stroma-Poor), with the tumor located in the abdomen and currently present."
inv(16),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
inv(16),"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, inv(16)(p13q22), which is present in their molecular analysis results."
RUNX1/ETO,"{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality_result"": [""Present""]}}, {""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}], ""path"": ""molecular_analysis""}}]}","The cohort consists of individuals who are part of the INTERACT consortium. These individuals have a specific molecular abnormality, identified as the translocation t(8;21)(q22;q22) RUNX1/ETO, which is present in their molecular analysis results."
inv16 + RUNX1/ETO,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""AND""}","{""AND"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of individuals who are part of the INTERACT consortium and have specific molecular abnormalities. Specifically, the cohort includes individuals with the molecular abnormality inv(16)(p13q22) that is present, as well as individuals with the molecular abnormality t(8;21)(q22;q22) RUNX1/ETO that is also present. Both conditions must be met for inclusion in the cohort."
CBF,"{""value"": [{""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""inv(16)(p13q22)""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}, {""value"": {""consortium"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""INTERACT""]}, ""molecular_analysis.molecular_abnormality"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""t(8;21)(q22;q22) RUNX1/ETO""]}, ""molecular_analysis.molecular_abnormality_result"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Present""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}], ""__type"": ""COMPOSED"", ""__combineMode"": ""OR""}","{""OR"": [{""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""inv(16)(p13q22)""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}, {""AND"": [{""IN"": {""consortium"": [""INTERACT""]}}, {""nested"": {""AND"": [{""IN"": {""molecular_abnormality"": [""t(8;21)(q22;q22) RUNX1/ETO""]}}, {""IN"": {""molecular_abnormality_result"": [""Present""]}}], ""path"": ""molecular_analysis""}}]}]}","The cohort consists of participants from the INTERACT consortium who exhibit specific molecular abnormalities. Specifically, the cohort includes individuals with either the inv(16)(p13q22) abnormality or the t(8;21)(q22;q22) RUNX1/ETO abnormality, both of which must be present in the molecular analysis results. Participants must meet at least one of these criteria to be included in the study."
Study0901,"{""value"": {""studies.study_id"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""0901""]}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""IN"": {""study_id"": [""0901""]}}], ""path"": ""studies""}}]}",The cohort consists of participants from study ID 0901.
RMS,"{""value"": {""disease_phase:Initial Diagnosis"": {""value"": {""histologies.histology"": {""__type"": ""OPTION"", ""isExclusion"": false, ""selectedValues"": [""Rhabdomyosarcoma (RMS), not classifiable""]}}, ""__type"": ""ANCHORED""}}, ""__type"": ""STANDARD"", ""__combineMode"": ""AND""}","{""AND"": [{""nested"": {""AND"": [{""AND"": [{""IN"": {""disease_phase"": [""Initial Diagnosis""]}}, {""AND"": [{""IN"": {""histology"": [""Rhabdomyosarcoma (RMS), not classifiable""]}}]}]}], ""path"": ""histologies""}}]}","The cohort consists of individuals who are at the initial diagnosis phase and have a histology classification of ""Rhabdomyosarcoma (RMS), not classifiable."""
